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Abstract
Many Nerve Guidance Conduits (NGCs) have been approved by the Food and Drug
Administration (FDA) as an alternative to nerve autografting for guiding peripheral nerve
regeneration. However these materials offer little therapeutic potential for favourable
axon growth environment, and difficulty in balancing the mechanical properties and the
degradation rate of the implanted material is also a contemporary challenge. This project
involved the design of experimental composite NGCs comprising glass particles and
Pluronic FI27 in the copolymer (poly(lactic-co-glycolic acid)) and examined the
composition-structure-property relationships for such materials. Three glasses (0.5Si-(x)
Na-0.2Ca-0.13Zn-(0.17-x) Ce) (0.0.04 > x > 0.14) were produced. Glasses were
characterised using x-ray diffraction (XRD), Differential Thermal Analysis (DTA),
network connectivity calculations, and ^^Si magic angle spinning nuclear magnetic
resonance spectroscopy (MAS-NMR). The degradability (quantified Ca^^and Zn^^ ion
release) and the cytocompatibility of three glasses were investigated over 1, 3, 7, and 30
days incubation periods according to ISO 10993-14 and ISO 10993-5, respectively. The
degradation profile indicated heterogeneous dissolution of glass networks. All three
glasses indicated good biocompatibility.

The PLGA/F127 conduits were synthesised

with increments of FI27 from 0-5wt%, and the wet-state mechanical property of such
conduits was tested in order to examine the effect of the additional FI27 on the
mechanical property of the conduits. No significant difference was found between the
different compositions. Based on Ca^^ and Zn^^ release profiles and the cell variability
results, the glass with the highest Na:Ce ratio was brought forward for the experimental
design of thirteen PLGA/F 127-Glass NGCs (called CNGC) according to a Box-Behnken
design. The effects of each factor on the responses (initial mechanical property and cell
variability) were found out through response surface methodology (RSM) techniques and
a desirable design was predicted via optimization technology. The wet-state mechanical
properties and the cytocompatibility of six of the thirteen CNGCs were investigated over
1, 3, 7, and 28 day incubation periods. The results show a superior cytocompatibility
when compared with the published literature for the clinically used nerve guidance
conduit Neurolac®, and a comparable mechanical property was obtained for CNGC-I and
V

CNGC-J. All the ions released from CNGC which contain the CNG glass (6 CNGCs)
were examined over 1, 3, 7, and 28 day incubation periods. The Si"^^, Na^, Ca^^ Zn^^
release from CNGCs in this study were ranged from 0.22 - 6.477ppm, 2.307 -3.277ppm,
40 -119ppm, and 45-51 ppm, respectively. The Ce^^ concentrations were under the
minimum detection limits of the ICP standard and instrument utilized for each CNGC.
The Ca^^ and Zn^^ release results indicated that all examined CNGC containing Zn and
Ca may have potential therapeutic effect with respect to the peripheral nerve regeneration.
In general, the results from the viability assay indicated that the experimental NGC
showed comparable mechanical properties and cell viabilities when compared to the
commercial control Neurolac®, demonstrating the equivalent or even enhanced in vitro
compatibility of these CNGCs in relation to a current state of the art material. As such
this project has resulted in the development a new approach to nerve repair and has new
materials

which

show

excellent

potential

VI

as

NGCs

have

been

synthesized.
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1.1

Nervous System

1.1.1 Overview of the Nervous System
The nervous system is the mechanism concerned with the correlation and integration of various
bodily processes and the reactions and adjustments of the organism to its environment [1]. The
two main comportments of the nervous system comprise of (i) the Central Nervous System (CNS)
and (ii) the Peripheral Nervous System (PNS). The CNS consists of the brain and spinal cord
which occupy the dorsal cavity (Fig 1.1)

Figure 1.1: The nervous system: the CNS is shown in light blue and PNS in dark blue [2].
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The PNS consists of a series of nerves, which connect the CNS to the various tissues of the body.
The PNS may be subdivided further into (i) the Somatic Nervous System (SNS) and (ii) the
Autonomic Nervous System (ANS) [2]. The SNS comprises both sensory and motor nerve
divisions; the sensory division (also referred to as the afferent division), carries sensory signals
by way of afferent nerve fibers from somatic receptors (in the head, body wall, and limbs) for the
special senses of vision, hearing, taste, and smell to the CNS. The SNS has a single type of motor
neuron (efferent division) which conducts impulses from the CNS to skeletal muscles only [3].
The ANS, in contrast, consists of efferent pathways that communicate between the CNS and the
effecter organs (muscles or glands). Therefore, it regulates the activities of cardiac muscle,
smooth muscle, endocrine glands, and exocrine glands. The ANS functions involuntarily in an
automatic manner without conscious control. Accordingly, the ANS is the mediator of visceral
reflex arcs [1,4]. The ANS is composed of three branches (or subsystems) [5], such as:
(i) The sympathetic nervous system,
(ii) The parasympathetic nervous system, and
(iii) The enteric system.
In contrast to the SNS, which always acts to excite muscle groups, the ANS can act to excite or
inhibit innervated tissue. The ANS achieves this ability to excite or inhibit activity via dual
innervations of target tissues and organs. Most target organs and tissues are innervated by neural
fibers from both the parasympathetic and sympathetic systems. The sympathetic system
increases overall body activity during times of stress, excitement, or danger. It also stimulates the
“flight or fight” response that allows the individual to face up to an attacker or make a rapid
departure. These nerves originate in the thoracic and lumbar regions of the spinal cord. Their
ganglia are located near the spinal cord( in the chain that line both the right and left sides of the
vertebral column) from the cervical to the sacral region [2]. The parasympathetic system does
the opposite to the sympathetic system. It tends to slow down body activity when the body is not
under stress leading to a “rest and digest” state. They maintain the normal functions of the
relaxed body and promote housekeeping responses, such as digestion [4]. The system originates
in the brain and the sacral region of the spinal cord, while its ganglia are located within walls of
organs [4, 6].
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The division of the PNS and CNS and its associated subdivisions are summarized in Figure 1.2.
Most organs continuously receive input from both sympathetic and parasympathetic nerves,
usually with opposite effects on the organ.

PNS
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Special senses
Visceral senses
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Figure 1.2: Organization of the nervous system [7].

1.1.2 Microscopic Structure of Neurons
The nervous system contains two principal kinds of cells: (i) neurons and (ii) glial cells (also
known as neuroglia) [5]. The neuron is the functional unit; since it is the integral element of the
human’s five senses and of other numerous physical, regulatory, and mental faculties. Neurons
differ from other cells in the body as neurons are found to communicate with each other through
an electrochemical process [8]. Neurons contain some specialized structures (known as, synapses)
and chemicals (known as neurotransmitters). Glial cells (which constitute 90% of the cells in the
nervous system), provide various types of support to the neurons, including structural and
metabolic support [4]. Figure 1.3 illustrates the microstructure of a typical neuron. The neuron is
comprised of three main components [8]: (i) a cell body and two types of neural processes which
extend from the cell body: (ii) the dendrites and (iii) an axon.
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Figure 1.3: The microstructure of a neuron [9]

1.1.2.1 The Cell Body
The cell body, where metabolic maintenance occurs and biosynthesis machinery is located,
contains the cell nucleus, which is surrounded by cytoplasm (a cell membrane), ribosomes
(responsible for assembling the proteins of the cell), lysosomes, Nissl bodies and other
organelles. Of particular interest are the following organelles;
Lysosomes:

are membrane bound vesicles containing various hydrolytic enzymes

necessary for digesting certain material in a cell. They contain an ionic pump that
maintains a highly acidic pH. Lysosomes have two main roles; the first is to release of the
digestive enzymes required in breaking up unnecessary material. The products diffuse
through the lysosomes' membrane and are distributed throughout the rest of the cell to
serve as building blocks for new materials [10]. The second function involves the
breakdown of non-functioning organelles; digesting all organelles and speeding up the
cells' death via autolysis (self-digestion) [11].
4
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NissI bodies: These are sub cellular structures found in nerve cell bodies and dendrites.
They are composed of rough endoplasmic reticulum and hence facilitate protein synthesis
[7].

1.1.2.2 The Axons
Each neuronal cell body gives rise to a single axon: an axon propagates information signals
(nerve impulses) towards another neuron, a muscle fibre or a gland cell (through the neuropil or
through a peripheral nerve). In most neurons, nerve impulses arise from the cone-shaped
elevation called the axon hillock, which then travel along the axon to their destination [6]. The
axon contains cytoplasm, microtubules and neurofilaments, without any Nissl substance. There is
therefore little ability to synthesise protein in the axon. Instead the requirement for proteins must
be met by axoplasmic transport from the cell body itself. At the end of the axon, the axon
terminus (also referred to as the “secretory region”), the neurotransmitters are released into the
synapse.
Figure 1.4(A) shows an illustration of an axon enclosed by an epineurium. Nerve fibres organise
into fibre bundles known as fascicles. The epineurium contains the vessels, and extends between
the fascicles, with each fascicle surrounded by the perineurium. The perineurium (fine, smooth,
transparent membrane), may be easily separated, in the form of a tube. The perineurium is
composed of connective tissue, exhibiting a lamellar arrangement. Figure 1.4(B) illustrates the
components between the individual nerve fibres, containing an inner layer of endoneurium. It
demonstrates a ground substance in which fine bundles of fibrous connective tissue are
embedded, longitudinally and serves to support capillary vessels, arranged so as to form a
network with elongated meshes.
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Figure 1.4: Microscopic illustration of a nerve cellular structure [12].

Many of the fibers are myelinated. In between the layers of the Schwann cells (substance which
encircles the PNS axons, refer to Figure 1.5) is a waxy substance containing a multilayer of
lipids and proteins known as myelin; insulating the axon. Schwann cells wrap about 1 mm of
single axon’s length by spiralling many times around the axon [13]. Gaps in the myelin sheath
(called nodes of Ranvier) appear at intervals along the axon (see Figure 1.3). Each Schwann cell
wraps one axon segment between two nodes.
are the axons.
myelin sheath, surrounded axon
Nuclei are part of either Schwann cells
Or other cells such as fibroblasts.
is the breadth of one myelinated nerve
fibre
the node of Ranvier,
(The gap between two Schwann cells)

Figure 1.5: Microscopic of schwann cell and myelin sheath in longitudinal section [12].

1.1.2.3 The Dendrites
Dendrites are short arm-like extensions emanating from the cell body (neuron). Dendrites from
neurons located in close proximity to one another are tipped by synapses (transmitters and
receivers for chemical messages between the cells) [14]. Dendrites receive stimuli from receptors
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or other neurons and are capable of performing such functions as a result of chemically
regulated ion gates which respond to stimulation by neurotransmitters [6, 9]. Hence the
dendrites increase the area on which a neuron can be stimulated and together with the rest of the
membrane of the cell body constitute the neuron's receptive region. They usually appear short,
tapered, and highly branched. In many neurons the dendrites form a tree-shaped array of
processes extending from the cell body [14].

Presynop't'ic
'terminals

Figure 1.6: The synapse connects axons to dendrites [15].

The junction between an axon, and the next cell with which it communicates, is called a synapse.
Information proceeds from the cell body uni-directionally over the synapse: first along the axon
and then across the synapse to the next nerve or muscle cell [16]. The part of the synapse that is
on the proximal side of the axon (relative to the synapse) is called the pre-synaptic terminal. The
postsynaptic terminal is associated with the adjacent cell, distal to the signal origin. Between
these terminals, there exists a gap, the synaptic cleft, with a thickness of 10 - 50 nm (Figure 1.6).
The fact that the signal is only permitted to travel in one direction, from the pre-synaptic terminal
to the postsynaptic terminal, is due to the release of a chemical transmitter by the pre-synaptic
cell. When the nerve signal reaches the synapse, it causes the release of chemical messengers
from storage vesicles. These chemical messengers travel across the gap between the cells and
then interact with protein molecules located in the membrane surrounding the signal-receiving
neuron [10, 17].
7
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1.1.3 Function of the Nervous System
The nervous system is responsible for the perception of external and internal conditions and the
body's response to them. The PNS consists of neurons that provide communication between the
CNS and various organs throughout the body. Additionally, the CNS has the capacity to
stimulate smells, produce speech, provide signals that control movement, and regulate the
operation of internal organs. This diverse range of activities, which the nervous system conducts,
may be categorized into three basic functions (Figure 1.7), i.e.: sensory, integrative, and motor.

Sensory

Integrative

Motor

Figure 1.7: The three function impulse pathways of the nerve system [7].

1.1.3.1 Sensory Function
Sensory receptors are optimised to respond to specific types of stimuli. However the minority of
these receptors are found to detect stimuli in the external environment, while the majority, that is,
the visceral receptors, are found to detect stimuli that arise within the body [7]. Visceral
receptors transmit information to the CNS by a class of afferent neurons (known as visceral
afferents). The function of sensory receptors is transduction i.e. to convert one form of energy
into another. In sensory transduction (reception) receptors convert the energy of a sensory
stimulus into changes in membrane potential called receptor potentials [4]. Receptor potentials

8
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resemble postsynaptic potentials, in that, they are graded potentials caused by the opening or
closing of ion channels. Receptors adapt to the stimulus, that is, their response declines with the
passage of time. Receptor adaptation is a decrease over time in the magnitude of the receptor
potential: in the presence of a constant stimulus [4].
1.1.3.2 Integrative Function
The nervous system integrates (processes) sensory; an important integrative function is
perception, the conscious awareness of sensory stimuli. Perception occurs in the brain [10].
1.1.3.3 Motor Function
Once sensory information is integrated, the nervous system may elicit an appropriate motor
response, such as, muscle contraction or gland secretion. The neurons that serve this function are
called motor or efferent neurons. Motor neurons carry information away from brain towards the
spinal cord or out of the brain and spinal cord to effectors, through cranial and spinal nerves [1,4,
18]. The motor division may inhibit or excite smooth muscle, cardiac muscle and glands. It
relaxes gastric and intestinal wall muscles increases sweating, heart rate and blood flow to
skeletal muscles. Contractions of the gastric and intestinal wall muscles decease sweating, heart
rate, blood flow to skeletal muscles and coordinates the activity of muscles and glands of the
gastric and intestinal walls [4]

1.1.4 Nerve Physiology
1.1.4.1 Nerve Impulse
Nerve cells are responsible for sending electrical impulses from one part of the body to another.
By monitoring both the internal and external environment, the nervous system is responsible for
keeping the body in a state of homeostasis (that is, maintaining a relatively constant internal
environment) [17]. Neurons can respond to stimuli and conduct impulses in the form of graded
potentials, (action potentials) that transmit messages via neurotransmitters from one area of the
cell to another. The neurotransmitters conduct nerve impulses from a motor neuron to a muscle
fiber cell across a neuromuscular junction [17].
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The cell body is enclosed by a cell membrane whose thickness is about 7.5 - 10.0 nm [16]. There
is an unequal distribution of ions (charged atoms) on the two sides of the cell membrane, with
one electrode placed inside a neuron and the other outside. The inside of the neuron is slightly
negative relative to the outside (Figure 1.8).
This difference in ionic charge is referred to as the actual Resting Membrane Potential (RMP).
This difference is partly the result of an unequal distribution of potassium ions (K^) and sodium
ions (Na^) located on either side of the membrane. This unequal distribution of ions is the result
of an unequal distribution from a combination of active transport and diffusion of sodium and
potassium ions across the cell membrane, and the ability of large organic anions to pass out of
the cell. A sodium-potassium pump transports sodium ions out of the neuron and potassium ions
in. For every three Na^ ions actively transported out, only two K" ions are actively transported in
[12]. If a nerve cell is stimulated, the transmembrane voltage necessarily changes. The
stimulation may be excitatory or inhibitory [16].

+30
0
S

fo 5 -70
:qq

Resting Potential
Na+

Na+

K+ K+
K+ K+
Na+

Na+

Figure 1.8: The resting membrane potential of a nerve cell [17]

If a very rapid change in membrane potential occurs, then the excitatory stimulus is considered
strong enough for the membrane potential to go from the resting potential to some positive value
in a very short period of time, this phenomena is otherwise referred to as the action potential.
' excitatory (that is, depolarising-, characterised by a change of the potential inside the cell relative to the outside in
the positive direction, and hence making an action potential more likely);
^ Inhibitory (that is, hyperpolarising, characterised by a change in the potential inside the cell relative to the outside
in the negative direction, and hence by making an action potential less likely).
10
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Figure 1.9: The sodium channels are opened [17].

Figure 1.9 illustrates a stimulus causing the sodium channels^ to open. However, due to the
presence of a greater quantity of sodium on the outside than the inside of the membrane, sodium
is found to diffuse rapidly into the nerve cell. All these positively-charged sodium ions rushing in
causes the membrane potential to become positive: resulting in the inside of the membrane
becoming more positive relative to the outside.
The sodium channels open only briefly, and then close again. The potassium channels "*[19]
shape action potentials and set the membrane potential as demonstrated in Figure 1.10. There is
more potassium inside the membrane than outside, as positively charged potassium ions diffuse
outward. As these positive ions are actively transported outwards, the inside of the membrane
once again becomes negative with respect to the outside.

^ Sodium channels: the integral membrane proteins that form ion channels, conducting sodium ions (Na ) through a
cell's plasma membrane.
'* Potassium channel: form potassium-selective pores that span cell membranes, whose permeability to ions is
extremely sensitive to the transmembrane potential difference.
11
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Figure 1.10: The potassium channels are opened [17].

After stimulation, the membrane voltage returns to its original resting value. If the membrane
stimulus is insufficient to enable the transmembrane potential to reach the threshold: the
membrane will not activate. The response of the membrane to this kind of stimulus is essentially
passive. If the excitatory stimulus is strong enough, the transmembrane potential reaches the
threshold, and the membrane produces a characteristic electric impulse, (i.e. the nerve impulse).
This potential response follows a characteristic form regardless of the strength of the trans
threshold stimulus. It is also considered that the action impulse of an activated membrane
follows an “all-or-nothing” law. The electric recording of the nerve impulse is referred to as the
action potential (Figure 1.11). In addition, if the nerve impulse is recorded magnetically; it is
referred to as an action current. This process repeats itself and action potentials move down the
nerve cell membrane. This 'movement' of action potentials is called an impulse [17] .
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Figure 1.11: Nerve impulse [18]

1.1.4.2 Conduction across synapses
Activation in the form of the nerve impulse (that is, action potential) is first seen in the axon
hillock. From there, it propagates along the axon, then transfers as an impulse (as axodendritic
(from axon to dendrites); axosomatic (from axon to cell body); or axoaxonic (from axon to
axon)) to different organs. The neuron sending the signals is referring as the presynaptic neuron
and the neuron receiving the signal is called postsynaptic neuron (Figure 1.12). There are two
types of synapses, (i) chemical synapses, and (ii) electrical synapses.
The presynapses and the postsynapses are separated by the synaptic cleft in the chemical
synapses. When an impulse arrives at a terminal bulb, the terminal bulb membrane becomes
more permeable to calcium [17]. Calcium diffuses into the terminal bulb and activates enzymes
which results in the synaptic vesicles moving towards the synaptic cleft. Some vesicles fuse with
the membrane and release neurotransmitters. The neurotransmitter molecules diffuse across the
cleft and fit into receptor sites in the postsynaptic membrane. When these sites are filled, the
sodium channels open, which results in an inward diffusion of sodium ions. This causes the
membrane potential to become less negative: thus, approaching the threshold potential (as
described in Section 1.1.4.1). If an adequate amount of neurotransmitter is released, coupled with
the required opening of sufficient sodium channels; the result is that, the membrane potential will
reach threshold. Thus, an action potential occurs and spreads along the membrane of the post-
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synaptic neuron, for which, the impulse will be transmitted. If insufficient neurotransmitter is
released, the impulse will not be enabled for transmission.
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Figure 1.12: Nerve impulse across the synapse [20],

At an electrical synapse, action impulses conduct directly between adjacent cells. The conduction
velocity is dependent upon the electrical properties and the geometry of the axon. An important
physical property of the membrane is the change in sodium conductance, due to activation. The
higher the maximum value achieved by the sodium conductance, the higher the gradient of
voltage; increased local currents, faster excitation, and increased conduction velocity [20]. The
capacitance of the membrane per unit length determines the amount of charge required to
achieve a certain potential and therefore affects the time required to reach the threshold, resulting
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in a slower conduction velocity. The velocity also depends on the resistivity of the medium
(inside and outside the membrane), since these also affect the depolarization time constant. The
smaller the resistance: the smaller the time constant and the faster the conduction velocity. The
temperature is known to profoundly affect the time constant of the sodium conductance; with a
decrease in temperature producing a decrease in the conduction velocity [21].
The above effects are reflected in an expression derived by Muler and Markin [16] using an
idealised nonlinear ionic current function. For the velocity of the propagating nerve impulse in
unmyelinated axons, they hypothesise that:

V =

^Na max

Equation 1.1
Where:
V = velocity of the nerve impulse [m/s]
/Namax= maximum sodium current per unit length [A/m]
Fth = threshold voltage [V]
ri =

axial resistance per unit length [Q/m]

Cm =

membrane capacitance per unit length [F/m]

The non-myelinated areas of the axons (the nodes of Ranvier), are illustrated in Figure 1.11.
Since the myelin acts as an insulator, membranes coated with myelin will not conduct impulses.
Therefore, in a myelinated neuron, action potentials only occur along the nodes of Ranvier, while
impulses 'jump' over the areas of myelin going from node to node in a process denoted as
salutatory conduction.
The membrane capacitance per unit length of a myelinated axon is much smaller in comparison
with an unmyelinated axon. Therefore, the myelin sheath increases the conduction velocity
potential. The resistance of the axoplasm per unit length is inversely proportional to the crosssectional area of the axon and thus to the square of the diameter. The membrane capacitance per
unit length is directly proportional to the diameter. Since the time constant formed from the
product controls the nodal transmembrane potential, it is reasonable to assume that the velocity
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would be inversely proportional to the time constant [15]. On this basis, the conduction velocity
of the myelinated axon is considered to be directly proportional to the diameter of the axon [15].
This concurs that the conduction velocity in mammalian myelinated axons is linearly dependent
upon the diameter. The conduction velocity in myelinated axon has the approximate value which
was indicated by (Ludvig Hermann 1872), [16]

v = 6d

Equation 1.2

Where:
V = velocity [m/s]
d= axon diameter [pm]

B

Figure 1.13; Conduction of a nerve impulse in a nerve axon, where (A): Continuous conduction in an unmyelinated
axon and (B): Salutatory conduction in a myelinated axon [22]

1.1.5 Peripheral Nerve Damage
Peripheral Nerve Injury (PNl) can be defined as a defect that results in a disruption of a
peripheral nerve, such that, it can no longer transmit an action potential [23]. PNl is a common
form of trauma, with up to 300,000 cases each year in Europe alone; in the United States,
approximately 200,000 patients are treated surgically each year for such injuries [24]. PNTs
range from minor nerve compression injuries and simple transaction injuries to severe nerve
injury, such as, the laceration and avulsion injuries (including, brachial plexus injuries)

16

Chapter!. Literature Review

developed as a result of sports injuries; road traffic accidents; fractures; bums and iatrogenic
lesions. Most PNI’s affect the upper extremity function and induce severe suffering for patients.
The fact that 5% of all open wounds in the limbs are complicated by peripheral nerve trauma: is
a strong indication for the relevance of developing repair and regeneration therapies.
1.1.5.1 Etiology
Dysfunction of peripheral nerves may result from damage to: (i) neurons, (ii) Schwann cells (iii)
the myelin sheath. The damages to the peripheral nerves are commonly the results of mechanical
effects. Stretch-related injuries are the most frequently reported type [25]. Peripheral nerves are
inherently elastic due to their collagenous endoneurium, but when traction forces exceed the
nerve's capacity to stretch, axons over long segments i.e. nerves are disrupted and injury occurs
[26]. Laceration injuries (comprising 30% of serious injuries) are caused by blunt or penetrating
trauma. The nerves in these injuries are not cleanly sectioned. Instead, they appear to exhibit an
irregular pattern. Compression and ischemia is the third most common type of peripheral nerve
injury. These injuries include palsy due to nerve compression, as well as entrapment
neuropathies. Compression injuries can be induced by: (i) fractures; (ii) hematomas and
compartment syndrome; (iii) proximal venous ligation; (iv) direct trauma to muscle; (v) infection;
(vi) bums and (vii) localized pressure by casts. Motor vehicle accidents and gunshot wounds, on
the other hand, can result in severe tissue destruction. Mechanical deformation is considered to
be the primary mechanism in the more severe cases of compression injury [27]. Nerves undergo
degenerative changes at the edges of the compressed area and not underneath the centre of the
cuff, where ischemia is most severe [23, 25, 26].
1.1.5.2 Pathology
PNI may result in demyelination or axonal degeneration [28]. Clinically, both demyelination and
axonal degeneration result in a disruption of the sensory and/or motor function of the injured
nerve.
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Figure 1.14: The process of Wallerian Degeneration of the peripheral nerve [51]

When a mild stretch or compression injury disrupts or distorts the myelin sheath at the injury
site, focal demyelination occurs, leaving the axons intact [28]. This causes a transient state of
disrupted conduction along the injured segment (conduction slowing or blocked). Since the
axons remain intact, function can be restored by focal remyelination.
When an axon is cut, Wallerian degeneration^ [18] leads to axon degeneration and loss of
conduction by about 4 days post injury. As a result of interruption of the post-ganglionic
sympathetic efferent fibres, motor paralysis is observed, resulting in red and dry skin in the area
innervated by the nerve [29]. Figure 1.14 illustrates the Wallerian degeneration of the peripheral
nerve. The first nerve is in the normal state, the second is compressed and the third shows the
loss of the myelin sheath between neighboring Schwann cells (nodes of Ranvier). Finally, the
fourth is in a state of disconnection and degeneration. After significant injury the connection
with the target muscle is lost.
^ Wallerian Degeneration: When nerve fibres are cut across, the central ends of the fibres degenerate as far as the
first node of Ranvier; but the peripheral ends degenerate simultaneously throughout their whole length. The axons
break up into fragments and become surrounded by drops of fatty substance which are formed from the breaking
down of the medullary sheath. The nuclei of the primitive sheath proliferate, and finally absorption of the axons and
fatty substance occurs.
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1.L5.3 Classification
The clinical appearance of an injured nerve depends on the nerve affected. Injury to a motor
nerve results in a loss of muscle function, whereas injury to a sensory nerve results in a loss of
sensation to the affected nerve's sensory distribution or neuromatous or causalgia pain. The
Seddon [30] classification for nerve injury comprises neurapraxia, axonotmesis and neurotmesis.
In addition, Sunderland [31] proposed five grades of nerve injuries based on the damage
sustained by the nerve components, nerve functionality, and the ability for spontaneous recovery,
as follows:
1. Neurapraxia is a first-degree nerve injury which involves a temporary conduction block with
demyelination of the nerve at the site of injury (without axon disruption and degeneration)
[25]. This is considered to be a biochemical lesion, caused by concussion or shock-like
injuries to the fibre. In this case, neurapraxia occurs due to either compression or relatively
mild, blunt blows, (including some low-velocity missile injuries close to the nerve). There is
a temporary loss of function which is reversible within hours to months of the injury [32].
2. Axonotmesis (second degree injury) accounts for severe trauma or compression (mainly seen
in crush injury). It involves loss of the relative continuity of the axon and it’s covering of
myelin. Since axonal continuity is lost, Wallerian degeneration occurs. Electrically, the nerve
exhibits rapid and complete degeneration, with the subsequent loss of motor neurons.
Regeneration of the motor end plates may occur, once the endoneural tubules are intact.
There may also exist, a level of retrograde proximal degeneration of the axon, and for
regeneration to occur, in this instance, this loss must first be overcome. Additionally, in more
severe traumatic injuries, the proximal degeneration may extend beyond the next node of
Ranvier. This overlaps with second, third, and forth degree injuries[23, 25, 28].
3. Neurotmesis is the most severe lesion with a complete loss of motor, sensory and autonomic
function. Neurotmesis may arise due to severe concussion, stretch, and lacerations.
Neurotmesis nerve injury at the lesion site causes damage with varying degrees to the nerve
trauma as well as the axon and myelin, which degenerate from that point distally. Some of
the encapsulating connective tissue loses its continuity with the most severe neurotmesis
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lesions, resulting in a gross continuity of the nerve being disrupted. This requires surgical
repair, but recovery is unpredictable [25, 28, 32].
Figure 1.15 illustrates the Seddon [30] classification of peripheral injury combined with the
Sunderland’s five grades of PNI, and the relative pathology of the PNI. Neurapraxia is the
mildest form of PNI, comprising only of damage to the myelin sheath. Axonotmesis, however,
covers a range of three grades of (medium to severe) PNl’s: with additional endoneurium and
perineurium tissue damage, respectively. Neurotmesis is the most severe form of PNI.

Tissue Damage

Recovery
None

Incomplete

Full
Sunderland Grade
Seddon Grade

1

2

3

Neurapraxia Axonotmesis

4

5

Neurotmesis

Figure 1.15: Seddon and Sunderland classifications and the resulting relative neuron injury of the peripheral nerve
[54].

1.1.6 Clinical challenge
As discussed, PNI results in either partial or total loss of motor, sensory and autonomic functions
in the involved segments of the body. Significant interest lies in determining how to efficiently
restore motor, sensory and autonomic nerve function following PNI. From perspective of neuron
recovery, reinnervation of denervated targets can be achieved by regeneration of injured axons or
by collateral branching of undamaged axons in the vicinity. The regeneration of axons plays a
predominant role in this instance. Following PNI, in the endoneurium, macrophages are recruited
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and Schwann cells re-differentiate to produce diffusible and cell surface molecules that support
the movement of growth cones. In nerve cell bodies, changes in gene expression lead to
synthesis of growth-associated proteins, which are transported to the growth cone to increase its
motility.
1.1.6.1 Nerve Regeneration
Schwann cells play a key role in nerve regeneration. Schwann cells that lack contact with axons
transiently proliferate, forming a cell strand known as a Schwann cell column, within the basal
lamina tube [33]. The Schwann cell column provides regenerating axons with a favourable
environment for growth. Another role of the Schwann cell is to help remove the degenerated
axonal and myelin debris and then pass it on to macrophages. Macrophages migrate into the
traumatised region, passing through the walls of capillaries, which have become permeable in the
injury zone [34]. Schwann cells and macrophages work together to phagocytose and clear the
site of injury. A single Schwann cell makes up a single segment of an axon's myelin sheath,
while oligodendrocytes (the equivalent cells in the CNS), on the other hand, encase themselves
around numerous axons, at once. Furthermore, to assist in the formation of the myelin sheaths of
PNS axons; the role of the Schwann cell is to essentially guide the re-growth of PNS axons. This
occurs with the Schwann cells arranging themselves in a series of cylinders that serves as a guide
for sprouts of regenerating axons. If one of these sprouts encounters a cylinder, the sprout will
grow through the tube. The Schwann cells also play a neurosupportive role in the regeneration of
a nerve [33].
Endoneurial mast cells also play a pivotal role in the recovery process. They release histamine
and serotonin, which enhance capillary permeability and facilitate macrophage migration [35].
During the initial stages, the endoneurial tubes swell in response to the trauma. However, after
the first 2 weeks they become smaller in diameter. When the degenerative process is complete,
nerve fiber remnants composed of Schwann cells within an endoneurial sheath are all that remain.
In severe injuries, nerve regeneration begins only after Wallerian degeneration has ceased;
conversely, in mild injuries the regenerative and repair processes begin almost immediately. For
neurapraxia and axonotmesis, restoration of function occurs early via two mechanisms: (i)
reversal of conduction blocks and (ii) via axonal regeneration. Functional recovery is complete in
21
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these milder degrees of injury. In more severe nerve injuries, in which endoneurial tubes are
disrupted, regenerating axons are no longer confined to their original sheaths. Consequently, they
meander into surrounding tissue or into inappropriate endoneurial tubes, thus failing to re
innervate as required. Neurological recovery is compromised, generally to a degree proportional
to the severity of the injury [35].
The functional significance of the regeneration is to replace the distal nerve segment lost during
degeneration, thus allowing reinnervation of target organs and the restitution of their
corresponding functions. The main events that occur at the peripheral nerve are summarized in
Figure 1.16.
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Figure 1.16: Nerve regeneration. Where (A): shows the normal nerve fibres (B): Post-injury results in distal
fragmentation of axon and myelin sheaths (C): The Schwann cells lead axon sprouting (D): After the completion of
re-innervation, the axon is connected [36]

In spite of the fact that peripheral axons can regenerate through the injury site towards the distal
stump, reinnervation of target does not always lead to adequate recovery of both motor and
sensory functions. The factors that affect the functional recovery of nerves are listed as follows:
1.

The grade of damage to the neuronal cell body due to axotomy and retrograde degeneration
(excluding the possibility of regeneration);

2.

The inability for axonal growth due to the nerve lesions or to underlying diseases;

3.

The selectivity of axon target reconnection plays an important role in the impairment of
function after nerve injury and regeneration, target organ adequate reinnervation of each
type of end organ by their original axons is far from perfect after nerve transaction;
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4.

The poor specificity of reinnervation by regenerating axons, when target organs become re
innervated by nerve fibers with different function.

Aberrant reinnervation is pronounced during regeneration over long distances. However, this
will aid to limit the effect on disturbed sensory localization or fine motor control post injuries.
1.1.6.2 Clinical Treatment
Functional deficits caused by PNIs can be compensated for by three neural mechanisms: (i) the
reinnervation of denervated targets by regeneration of injured axons; (ii) the reinnervation by
collateral branching of undamaged axons; (iii) and the remodelling of nervous system circuitry
related to the lost functions. Clinically, treatment is tailored to each individual, depending upon
the injury level. In the case of neurotmesis, (with damaged structures) where surgical therapy
may be required, there exist two classes of surgical treatment, as follows:
1. End-to-end closure: If the separated parts of the protective cover can be sewn together (gap
less than 2-3cm), the nerve fibers inside eventually grow back [37], This is preferably done
within one to two weeks post injury. This is also known as primary nerve repair. There are three
main categories of primary repair including epineurial, group fascicular, and fascicular repairs.

inserting
the stay
sutures

a suture
in front

stay
sutures
inversed

Figure 1.17: End-to-end closure nerve repair [60]
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(a)Epineunal repair,

(b) Perineural repair,

(c) Group fascicular repair |381

Figure 1.18: The suturing technologies for end-to-end nerve repair [26]

Epineuriai end-to-end repair suturing technique involves simple suture of the epineurial sheath of
the nerve. Such a repair is suitable for shaping lacerations with no loss of nerve substance and for
partial nerve lacerations when the proper alignment of the nerve is already established [39J. This
is an easier and faster method, and demands less manipulation of the fine internal structure
(including vascular supply), minimizing both the internal disruption of the nerve as well as the
blood supply [38, 40, 41]. However, such repairs achieve less precise alignment of the fascicles
and the possibility of leaving a gap between the two nerve stumps, which can fill with fibrous
scar tissue. In an epineurial repair, the external epineurectomy is performed for up to 0.5 cm on
each side. Thus, by the time the epineurium proliferates and reaches the suture line, that line has
already healed, precluding any interposition of the epineurium between the stumps.
The perineurial end-to-end nerve repair (also called fascicular repair) involves the suturing of the
corresponding nerve fascicles and distal nerve stump in order to gain the optimal level of
alignment [38, 42]. The perineurial repair technique provides better reinnervation. Group
fascicular end-to-end repair comprises micro-sutures, which are placed through the inter
fascicular, and external epineurial tissue, where the sutures are tied using mild to moderate
tension to approximate the fascicular groups. With respect to the perineural and group fascicular
repair, the interfascicular or perineural stitches (for example, 10-0 nylon, and 5-7 cm long thread)
are placed for each fascicle or fascicular group. Adequate alignment of the fascicles or fascicular
groups is achieved by the use of an excessive number of sutures, which can add to the foreign
body response and scaring at the side of the nerve repair [43]. The main disadvantages associated
with primary repair are: (1), only specific types of injury are amenable to immediate surgical
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correction [44]; (2), there is a potential for suture line dehiscence due to delayed necrosis [38];
(3), primary repair is performed on a more friable epineurium [38, 45].
2. Nerve Grafting: Nerve grafting procedures have been performed since 1876 [46]. It has been
evident for years that tension in the suture line when repairing large divided PNs has a negative
impact on the regeneration of nerve [47]. In cases of large gap defects it is not possible to
reattach the nerve by primary means. In such cases where the defect is too large (c. >3cm)
natural grafts (either autograft of allograft) or synthetic/artificial substitutes are used to facilitate
regeneration and restoration of function (Fig 1.19).

Figure 16 - "CaWe graft" - Courtesy Gotti. F.S.’*
A - nerve
D - grafts
C - cabtes link
D - pos»tioning of tbe cabtes
I E - suture of tbe graft
j

Figure 1.19: Nerve grafting and its structures [60].

The following section will examine contemporary clinical approaches and devices for the repair
of large defects. Specific emphasis will be placed on clinically approved devices and approaches
such that a comprehensive examination of the state of the art is possible.
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1.2

FDA Approved Guidance Conduits and Wraps for Peripheral
Nerve Injury: A Review of Materials and Efficacy

1.2.1 Introduction
Insufficient functional recovery after peripheral nerve injury (PNI) continues to be a significant
clinical challenge [48]. Since the mid 1980’s, the FDA have approved several devices based on
natural and synthetic biomaterials to repair nerve defects arising from PNI. PNIs result in over
8.5 million restricted activity days and almost 5 million bed/disability days each year [49, 50];
unfortunately, not all are manageable via surgical intervention. Consequently, over 200,000
peripheral nerve repair procedures are performed annually in the US [51]. Surgical interventions
such as neurorhaphy -direct suture repair without the use of grafted materials -may be deployed
for short (<5 mm) nerve gaps. However, larger defects repaired by neurorhaphy, exhibit
excessive tension over the suture line and offer poor surgical results [52]. There are various
surgical techniques used to perform neurorhaphy, including: (i) conventional group fascicular
repair comprising micro-sutures placed through the inter-fascicular and external epineurial tissue
[41, 53], (ii) perineurial repair involving the suturing of corresponding nerve fascicles and distal
nerve stump for optimum alignment [54], and (iii) epineural repair; usually applied directly to
the transected nerve injury and comprises sutures passed through the epineurial sheath. The latter
being an easier and faster method which minimizes both the internal disruption of the nerve as
well as the disturbance of the blood supply [40, 41]. Neurotisation (nerve transfer) is an
alternative, graft free intervention, which connects the proximal nerve stump directly to the
muscle belly and can be used in only very selected situations. Generally, however, neurotisation
procedures have poorer results than neurorrhapy or nerve grafting [52]. Given these limitations
and the clinical need to repair larger defects, procedures utilizing graft materials are necessary.

1.2.2 The Ideal Nerve Repair Device: Current Concepts
The majority of recent research efforts in the field of peripheral nerve grafting has emphasized
enclosing (entubulating) opposing nerve stumps (of the severed nerve) in a non-neural tube
(Nerve Guidance Conduit or NGC) fabricated from natural or synthetic materials [52, 55-58].
The desired effect of nerve entubulation: is to increase the (i) number; (ii) speed, and (iii) length
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of the regenerating axons [59]. After the nerve stumps are inserted and sutured into the ends of
the tube, a protein-rich (axoplasmic) fluid exudate from the nerve stumps, which contains
growth-promoting substances, is released into the NGC (see Fig. 1.20). A neomatrix of fibrin
will be formed within days providing support for the migration of Schwann cells, as well as
fibroblasts and macrophages. From the perspective of an NGC it is important to note that
Schwann cells have the ability to support their own survival by autocrine circuits, and block
apoptosis when cultured in a high density, thus, enhancing potential for axonal growth from the
proximal end towards the distal stump [60].
To promote axonal regeneration and achieve functional recovery, it is critical to minimize the
period of Wallerian Degeneration which is controlled by four critical factors [51]:
(i) The existence of Schwann cells.
(ii) The secretion of neurotrophic factors (NTFs) after injury and during regeneration.
(iii) The existence of a basal lamina: a specialized type of extracellular (ECM) matrix that acts as
a scaffold for neural cells.
(iv) The components ECM have been shown to promote neurite elongation in vivo
(v) The existence of a distal stump.
(vi) The distal nerve has also been found to be important for peripheral nerve regeneration
because it supplies various neurotrophic factors for axonal regeneration.
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Figure 1.20: Principle of nerve entubulization and the sequence of events leading to the growth of a new nerve
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Heath and Rutkowski [61]
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NGCs are required to mechanically support and direct axonal sprouting between the injured
nerve stumps; whilst preventing fibrous tissue ingrowth into the injury site and retaining
neutrophic and neurotropic factors secreted by the damaged nerve ends [62]. To support these
requirements, the following criterion for idealized NGCs and protectant wrap devices have been
identified [37, 62-71]:
(i)

The biomaterial employed must be biocompatible and provoke no inflammatory response.

(ii)

The biomaterial must be biodegradable whilst maintaining a mechanically stable
architecture during the regeneration process and resist tear from sutures and tissue
inflammation.

(iii) The device must be flexible and soft so as to prevent compression of regenerating axons
and limit tissue inflammation respectively.
(iv) The device should provide a guidance cue {via a tubular 3D structure) for the extending
growth cone to eliminate misdirection.
(v)

The biomaterial must be semi permeable to allow the diffusion/influx of oxygen and
nutrients from interstitial fluid to the surviving nerve tissue through pores in the conduit
wall’^. The need to facilitate this requirement via adjusting the conduit wall porosity is
restricted by the opposing need to prevent the infiltration of inflammatory cells into the
conduit and to minimize the diffusion of growth factors out of the conduit [72]report
preferable pore sizes in the range of about 5 to 30 pm, preferably about 10 to 20 pm. They
propose that a pore size less than about 5 pm inhibits cells and tissue to proliferate, whereas
if the pore size exceeds about 30 pm, entry of inflammatory cells becomes excessive.
Controlling permeability may also affect the formation of the fibrin matrix in the initial
stage of regeneration [70].

(vi) The device should prevent fibrous tissue ingrowth into the injury site and retain secreted
neurotrophic factors secreted by the damaged nerve ends.
(vii) The device must meet technical requirements for further production, sterilization, long
term storage, and surgical handling, such as, suturing (suture retention and tear).
In addition, such biomaterials and their contiguous devices must have the appropriate dimensions
to facilitate bridging the nerve gap defect without tension and the conduit width must also be
able to house securely the two nerve end stumps without any compression [73-75]. The internal
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diameter and wall thickness of NGCs appears to influence the rate of nerve regeneration and, as
such, the tube must be large enough to accommodate any swelling of the nerve without resulting
in any compression of the nerve by swelling during degradation of the tubular construct [62].
The use of artificial NGCs enables the fabrication of a wide specification of conduit sizes to suit
site-specific nerve lesions in mass production and as such offer significant advantages over
autograft and allograft material. In brief, the design specification required: is a biocompatible
and bioresorbable scaffold that supports outgrowing axons (neurite extension) within a
microenvironment known to favor peripheral nerve regeneration, while minimizing the
interactions between the myofibroblasts and axon growth. With these specifications for preparing
optimum NGCs in mind, the FDA have approved the following products (devices) with regards
their safety and efficacy in addressing the requirements to promote complete peripheral nerve
regeneration across inter sump gaps (nerve lesions) and nerve crush injuries post traumatic injury.

1.2.3 Methodology
The

premarket

notifications

(510(k)s)

medical

devices

database

(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/default.htm) on
the FDA website was used to correlate all of the Class II FDA approved peripheral nerve
regeneration devices currently on the market. This database (of releasable 510(k)s) can be
searched by 510(k) number, applicant, device name and/or FDA product code. The regulation
number for these devices is classified by the FDA as 882.5275 (nerve cuff) as subpart F
(Neurological Therapeutic Device) of part 882 for neurological devices. The product
classification code for these devices is coded as JXI. A search on the premarket notifications
database using only the product code (JXI) yielded 11 currently FDA approved devices (refer to
Tables 1.1 and 1.2) from March 22nd, 1999 to August 5th, 2010. Summaries of safety and
effectiveness are available for most recent records since the database is updated on a monthly
basis by the FDA. Each of the devices in Tables 1.1 and 1.2 were investigated further using
scientific databases such as science direct, springerlink and wiley interscience to generate a
history of all of the pre-clinical (refer to Tables 1.3, 1.5 and 1.7) and clinical testing (refer to
Tables 1.4, 1.6 and 1.8) performed to-date. To aid this step, the individual company websites
were also studied. Patents pertaining to each of the devices were also investigated. Subsequently,
the investigation was reduced to three devices (NeuraGen®, Neurotube® and Neurolac® based
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on collagen Type I, PGA and PCL, respectively) on account of the wide availability in preclinical and clinical data in comparison to the other (collagen, porcine SIS and PVA) approved
devices. In summary, the 11 FDA approved devices form the primary basis for the present
review and are discussed in detail with respect to each of their key advantages and limitations.

1.2.4 Current State of the Art
The following section provides the review of current state-of-the-art materials with respect to
approved devices for peripheral nerve regeneration, and in the context of the ideal device
outlined in section 1.2.2. To provide additional context, this section will outline the key features
of autograft and allograft tissue prior to examining FDA approved devices under the following
headings:
(i) Non-resorbable devices.
(ii) Natural resorbable devices.
(iii) Synthetic resorbable devices.
The key advantages and limitations for each of the FDA approved materials/devices will be
outlined at the end of each section.
1.2.4.1 Nerve Autograft
Nerve autografts are considered the ‘gold standard’ technique for repair of peripheral nerve
discontinuities. The autografting technique was first reported between the years 1870 and 1900,
but it was Millessi [76] who worked extensively on the nerve grafting technique demonstrating
its superiority over epineural suturing under tension. To date, nerve autografts have, by far,
offered the best results in nerve regeneration [70]. Donor nerves can include functionally less
important nerves such as sural nerves, superficial cutaneous nerves or lateral and medial
antebrachii cutaneous nerves [52]. However, the key limitations associated with their use include
[55, 67, 77-79]: (i) the requirement for a second surgical procedure in order to harvest graft
tissue; (ii) donor site morbidity and loss of function; (iii) mismatch of donor nerve size with
recipient site due to structural differences; (iv) occurrences of potential painful neuroma
formations; (v) lack of graft material; (vi) increased cost to the healthcare provider and (vii)
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the investigation and development of alternative devices for peripheral nerve repair.
1.2.4.2 Nerve Allograft
An alternative to autografling is the use of cadaveric or donor nerve tissue in the form of
allografts [56, 58, 80-83]. For discontinuities where reconstruction requires a length of graft
exceeding that available by autografting, the use of cadaveric allograft material is an alternative
clinical option. Allograft nerve provides guidance and viable donor Schwann cells, which enable
host axons to pass from the proximal to distal stump and reinnervate target organs. While the use
of nerve allografts can potentially allow functional recovery comparable to that of the nerve
autograft, it requires that patients receive systemic immunosuppression for approximately 18
months [82]. Systemic immunosuppression is maintained to allow the host axons and Schwann
cells to regenerate across the allograft scaffold, but may result in opportunistic infections or even
tumor formation [83]. Furthermore, due to limited supply and the increased risk of cross
contamination and secondary infection [56, 57, 84, 85], this allograft is limited in its ability to
satisfy patients and clinicians. The use of processed nerve allografts; capable of retaining the
scaffold of nerve tissue but made non-immunogenic by processing (e.g. repeated freeze-thaw
cycles; exposure to radiation; extended storage in cold University of Wisconsin solution; and
decellularization with detergents [86] has ameliorated some of the limitations of allograft.
Processed allografts possess the advantage of providing a biological substrate for nerve
regeneration without the requirement of immunosuppression. The key advantage of allografts
over autograft is the lack of donor site morbidity and virtually unlimited length of nerve tissue
available for transplantation. Moreover, the injured nerve in the recipient can be replaced with
the same nerve type from the donor; for example, mixed sensory-motor ulnar nerve can be
replaced with the same mixed type ulnar nerve harvested from the donor providing better motor
recovery compared to sensory only sural nerve graft [87]. Its key limitation, however, may be
attributed to the tendency of the immunogenicity of the nerve allograft to decrease over time as
the process of exchanging Schwann cells from donor origin to host ones proceeds, necessitating
the requirement for immunosuppression. In addition, immunosuppressive agents that decrease
the possibility of rejection carry the inherent risk of infection, decreased wound healing, and
other systemic effects.
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1.2.4.2.1 Acellular Human Nerve Allograft
AxoGen Inc. (Alachua, FL) is the only medical device manufacturing company that offer
acellular human nerve allografts (Avance®" Nerve Graft) in lengths between 15 and 70mm, and
diameters between 1 and 5mm. Avance® is a decellularized and cleansed ECM matrix derived
from donated human peripheral nerve tissue and is processed and distributed in accordance with
FDA requirements for Human Cellular and Tissue-based Products (HCT/P) (21 CFR Part 1271),
requisite state regulations and the guidelines of the American Association of Tissue Banks
(AATB). The cleaning process for this material preserves the inherent and relevant structural
characteristics of the tissue [83]. The graft is produced by processing human nerve tissue with a
combination of detergent decellularization, chondroitinase CSPG (CSPGs are composed of a
protein core and a varying number of covalently attached chondroitin sulfate (CS)
glycosaminoglycans side chains known to affect neural activity and deemed as axon growing
inhibitors [83] degradation, and gamma-irradiation sterilization [88]. The processing technique is
indicated to render the tissue non-immunogenic [86, 89, 90], however processing does impact
performance.
Prior to receiving FDA approval, Avance® nerve allografts were studied in an animal trial using
adult rats; in which eight of nine rats implanted with chondroitinase-treated acellular grafts
showed a positive response {via histology and immunocytochemistry analyses) as compared to
only two of nine rats implanted with untreated acellular grafts [90]. In this study, Neubauer ei al
[90] showed that 40mm frozen-thawed decellularized nerve allografts could support regeneration
along their full length when pretreated with chondroitinase, but significant regeneration did not
progress beyond 20 mm in untreated controls. In separate study (rat sciatic model, Xmm defect)
by Whitlock et. al. [86] the Avance® material was compared with a collagen based device
(NeuraGen®,

discussed

later in

section

1.2.3.4).

Avance® demonstrated comparable

performance with NeuraGen® and autograft. When evaluated in a 14mm sciatic nerve gap model,
autograft were superior to Avance® which was in turn superior to NeuraGen® conduits at six
weeks postoperatively. However, at 12 weeks, these differences were no longer apparent. In a
28mm defect model, autografts again performed better (with respect to electric stimulation) than
processed allografts at both, 6 and 22 weeks: while regeneration through the NeuraGen® conduit
was often insufficient for analysis. Of note, Avance® grafts were associated with regeneration of
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20 times more myelinated axons when compared with NeuraGen® for both 14 and 28mm gaps.
With respect to its clinical performance, between July 2007 and March 2008, seven patients (five
men and two women with a mean age of 44 years (range 23-65) were treated surgically (10
nerve discontinuities) using the Avance®. Eight digital and two dorsal sensory nerves were
repaired. The mean nerve graft length was 2.23 cm (range of 0.5 to 30 mm) with a mean follow
up time of 9 months [91]. Functional recovery was evaluated (in a blinded fashion) by a hand
therapist using moving and static two point discrimination tests. Implantation sites were also
evaluated for any signs of infection, rejection, or graft extrusion. Results showed that Avance®
restored nerve sensation to near normal levels within nine months following treatment with no
cases of infection or rejection. In brief, the recent advancements of tissue reprocessing and
established tissue bank networks have led to the availability of high quality autografts.
Key Advantage:
• Ready availability and elimination of donor site morbidity and reducing operative times.
Key Limitation:
• The key limitation is increased scarring and fibrosis associated with host rejection (likely to
impose a mechanical barrier for reinnervation, in the absence of immunosuppression).
Table 1.1: Available FDA Approved Nerve Guide Conduit Devices

510K

FDA

Product

Approval

Clearance

Name

Material

Degradation

Diameter

Length

(Months)

(mm)

(cm)

3

2.3-8

2-4

Company

Date
K983007

22/03/

Neurotube®

PGA

Synovis® Micro

1999/

Companies

or

Alliance Inc.

1995

www.synovismi
cro.com

KOI 1168

22/06

NeuraGen®

Type 1

36 to 48

1.5-7

2-3

collagen

/2001

Integra Life
Sciences Corp.
www.integrals.
com

K012814

21/09
/2001

Neuroflex™

Type 1

4 to 8

collagen

2-6

2.5

Collagen Matrix
Inc. www.collag
en matrix.com
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K012814

21/09

NeuroMatrix™

Type I

4 to 8

2-6

2.5

/2001

Collagen Matrix
Inc.

collagen

www.collagenm
atrix.com
K031069

SIS

3

1.5-7

10

Cook Biotech

15/05

AxoGuard^”

2003

Nerve

Products

Connector

www.cookbiote
ch.com

K032115/
K050573

10/10

Neurolac®

P(DLLA-

16

1.5-10

3

e-CL)

2003/

Polyganics B.V.
www.polyganic
s.com

04/
2005
K100382

8/05
/2010

SaluTunnel™
Nerve
Protector^'^

PCL
PVA

NonResorbabl

2-10

6.35

Salumedica™
L.C.C.,
www.salumedic

e

Table 1.2: Available FDA Approved Absorbable Nerve Cuff/Protectant Wrap Devices.

510K
FDA
Approval

Product

Material

Clearance Name

Degradation

Diameter

Length

(Months)

(mm)

(cm)

Non
Absorbable

2-10

6.35

Company

Date
(D/M/Y)
K002098

24/11/
2000/

Salubridge^*^

PVA

Salumedica"^
L.C.C.
www.salumedic

or 2001

a.com/
K031069

15/05
2003

AxoGuard^'^

Porcine

Nerve

SIS

3

2-10

2-4

Cook Biotech
Products
www.cookbiote

Protector

ch.com
K012814

16/07
/2004

NeuraWrap™

Type I
collagen

36 to 48

3-10

2-4

Integra Life
Sciences Corp
WWW.integrals.

com
K012814

14/07
/2006

NeuroMend™

Type I

4 to 8

collagen

4-10

2.5-5

Collagen Matrix
Inc.
www.collagenm
atrix.com
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1.2.4.3 Non-Resorbable Devices (Synthetic Origin)
1.2.4.3.1

Polyvinyl Alcohol Hydrogel (Salubridge'“; SaluTunneP“)

The Salubridge™ nerve cuff device is composed of a hydrophilic and non-degradable
biomaterial (called Salubria™) which is thermally crystallized from a repeatedly freeze-thawed
organic polymer solution containing the PVA molecular backbone in 20% w/w (CAS Registry
Number 9002-89-5, -CHjCHCOH)-) and 0.9% sodium chloride [92, 93]. The Salubria^”
hydrogel composition, originally developed by Ku [94] contains water in similar proportions to
human tissue, making it soft and compliant (US Patent no. 6,231,605 B1 [94]). The device is
permanent and its mechanical properties may be influenced by several factors, including: (i) the
weight percentage of the respective components of the hydrogel, (ii) the molecular weight of the
PVA, (iii) the number of freeze/thaw cycles used during synthesis and (iv) the duration of the
freeze cycle. The freeze/thaw cycle promotes mesh entanglement between PVA molecules
conferring mechanical strength [93]. This processing approach differs from traditional crosslinking methods which introduce toxic agents and decrease biocompatibility [95]. In addition,
Salubria™ can be easily molded into customized anatomic shapes because it is gelatinous prior
to the freeze/thaw processing (US Patent no. 5,981,826, [95]). Salubridge™ nerve cuff
(Salumedica LLC (Atlanta, GA) is a nerve protectant wrap based on the Salubria™ biomaterial.
Salubridge^'^'’ is a flexible tubular sheath developed to provide a protective environment for
peripheral nerve repair after injury. This technology remains the only synthetic non-resorbable
NGC with 510k approval received from the FDA (K002098, Table 1.2) in 2000. Salumedica
LCC have also received 510k approval (K100382, see Table 1.1) for the SaluTunnel™ nerve
protector (August 2010); a device of identical composition and structure to the Salubridge™
device, with the only difference being a longitudinal slit to facilitate ease of surgical placement.
SaluTunnel™ is indicated for the management of peripheral nerve injuries in which there has
been no substantial loss of nerve tissue. Salubridge™ and SaluTunnel™ are currently available
in different sizes (2, 5 and 10 mm internal diameter), with each device provided in a standard
length of 6.35 cm. Both devices are provided sterile, hydrated in saline for presentation onto the
operative field, and are single use only. Salubridge^^ is currently available worldwide through a
license and distribution agreement (2008), held by Salumedica LCC with Arthrex Corporation
marketed under the commercial name of Hydrosheath
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have both been approved since 2000 and 2010, respectively, pre-clinical and clinical studies have
not yet been published for either device.
Key advantage:
'puyl

• Salubridge

___

and SaluTunnel

TKyf

combine water in similar proportions to human tissue with

PVA leading to a mechanical stable structure which is easily sterilized.
Key limitations:
• The non-resorbable nature of this material lends itself to issues relating to nerve
compression and tension at the suture lines after nerve regeneration has occurred.
• There are no published clinical studies which have examined the efficacy of this material in
a controlled, randomized and prospective fashion.
1.2.4.4 Resorbable Devices (Natural Origin)
1.2.4.4.1

Type 1 Collagen based devices (NeuraGen®; Neuroflex™; NeuroMatrix™;

NeuraWrap™ and NeuroMend™)
Natural materials offer increased levels of biocompatibility, decreased toxicity and enhanced
migration of support cells when compared with synthetic materials [96, 97]. Collagen is a major
component of ECM and has widespread use as a biological material including peripheral nerve
repair [98-105]. When purified, collagen is only weakly antigenic, and its antigenicity can be
further reduced via enzymatic removal of the non-helical telopeptide regions of the molecule, or
by crosslinking [62]. Diffusion processes through collagen matrices are facilitated by smooth its
microgeometry and transmurale permeability (~100,000D) [104, 105]. A molecular weight cut
off of approximately 50,000D has been reported to facilitate diffusional transportation of
nutrients and other molecules, while preventing cells from entering the conduit structure [61].
The adhesive properties of collagen for different cell types also permit enhanced survival and
proliferation [105].
NeuraGen® (Integra Life Sciences Corporation (Plainsboro, NJ)) was the first semi-permeable
Type I collagen NGC to receive approval from the FDA in 2001 (KOI 1168, Table 1.1). The
NeuraGen® device is available in two different lengths (2 and 3cm) and a varying range of inner
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diameters (1.5 to 7mm). The fibrillar structure of the collagen is maintained throughout the
manufacturing process, permitting the construction of a biocompatible tubular matrix that has
sufficient mechanical strength, defined permeability and a controlled rate of resorption [106,
107]. However, this material is not expected to fully resorb for a period of up to 4 years post
implantation [70]. The manufacturers advise pre-hydration of the tube for pliability and
resilience in order to permit ease of handling provided in the manufacturer’s instructions for use
(IFU).
The pre-clinical cases examining the efficacy of NeuraGen® are summarized in Table 1.3. The
first trials using NeuraGen® were conducted by Mackinnon et al. [108] and showed no
occurrence of compression neuropathy in comparison with other more rigid or nonbiodegradable (silicon) materials. Archibald et al [106] later reported on the intubulation repair
of peripheral nerves with NeuraGen® to be as effective as a standard nerve autograft. This study
compared to NeuraGen® to autograft and direct suturing of transected peripheral nerves in both
rats (sciatic) and nonhuman primates (median nerve of six adult male Macaca fascicularis
monkeys). After 4 weeks, the direct suture repair group demonstrated a significantly greater
muscle action potential (MAP), in comparison to the other surgical repair groups. However, at 12
weeks all four surgical repair groups displayed similar levels of recovery of the motor response.
Statistical analysis of the motor responses in the non-primate model (as judged by the slope of
the recovery curves) indicated a significantly enhanced rate of recovery for the NeuraGen®
group. In contrast, the sensory action potential (SAP) amplitude exhibited no statistical
difference, between groups. This research was substantiated when regeneration across 5 mm
nerve gap defects in 15 (median and 1 ulnar) nerves of eight macaca fasicularis monkeys using:
(i) NeuraGen® NGCs; (ii) nerve autografts and (iii) direct suturing were evaluated over a period
of three and a half years [73]. This research demonstrated that nerve regeneration using
NeuraGen® in the nonhuman primate is similar to that after autograft repair. The final level of
physiological recovery for both repair procedures was comparable to direct suture repair of the
median nerve. In these studies, there was no reported scar tissue or inflammatory response with
complete absorption minimizing the possibility of nerve entrapment [73, 109]. Tyner et al [110]
used NeuraGen® in a rat sciatic nerve model in an effort to stimulate linear neuronal outgrowth
and reduce random axon sprouting. 13% (1 of 8) of animals receiving the conduit developed
autonomy in comparison to 88% (7 of 8) to the control (neurectomy) group, which was
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significantly less (P<0.01). Advanced linear axonal regrowth of the NeuraGen® treated animals
suggested that this material and its contiguous device, has the capacity to alter the regrowth of
transected nerves and reduce the severity of symptoms associated with neuropathic pain. The
positive results of such trials helped translate the technology into the clinic.
The clinical cases published since NeuraGen® received FDA approval are summarized in Table
1.4. Initial clinical experience using NeuraGen® was reported by Taras et al. [75] in a clinical
study on 73 peripheral nerves (including median, ulnar, radial, posterior interosseous common
digital, proper digital, and the superficial radial sensory nerve). Therapeutic observations of the
peripheral nerve repairs utilizing NeuraGen® yielded no rejection and only two cases of scar
sensitivity. Patients tolerated splinting and range of motion (ROM) exercise, and resisted
exercise without negative clinical consequences. A year later, Ashley et al. [Ill] implanted
NeuraGen® in 7 patients with brachial plexus birth injuries, using 5 to 7mm tube lengths for
discontinuities not exceeding 2 cm. An ongoing clinical study has similarly reported similar
results, to date [75] (refer to Table 1.4). Parole et al. [112] described a prospective study of 8
female patients who received a total of 9 NeuraGen® conduits for repair of lingual (6) or inferior
alveolar (3) nerves treated within a 3 to 7 month period following injury. In this study,
NeuraGen® was split longitudinally and encased the injured nerve with at least a 15mm margin.
Four of the patients were observed after 1 year and the remaining 4 were observed after a 30
month period. The results showed that four implants were associated with good improvement,
four with some improvement and 1 with no improvement. In the same year, Bushnell et al. [113]
published results of 14 digital nerve repair procedures with NeuraGen®. Follow-up periods of 12
and 22 months were used for patients. The outcome showed four of the repairs exhibited good
results; four patients achieved good sensibility and one patient demonstrated poor sensibility.
Most recently, Lohmeyer et al. [114] published results 15 digital nerve repairs in the hands of 14
patients; for which the longest nerve gap defect bridged was 18 mm. A follow up period of 1
year allowed measurements to be obtained from 12 patients; for which four of them showed very
good results, five patients achieved good sensibility, one patient poor and two patients no
recovery at all. A clinical study is currently under investigation in Germany, for which Stang [71]
has preliminary reported; the removal of NeuraGen® from some patients, but hypothesized it
was likely due to super-infection, poor tissue coverage or persistent neuroma pain. In October
2010, Integra Life Sciences announced the results of the multi-center human clinical trial
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comparing NeuraGen® with direct suture repair for presentation at the joint meeting of the
American Association for Hand Surgery (AAHS), American Society for Reconstructive
Microsurgery (ASRM), and American Society for Peripheral Nerve (ASPN), 2011. The clinical
trial was a controlled, randomized, blind, parallel group, multi-center study of peripheral nerve
repair comparing NeuraGen® to direct suture in patients who had complete traumatic nerve
injuries to the median and/or ulnar nerves. 32 patients completed the 2 year post-operative
follow-up period, during which they were routinely examined for sensory and motor
electrophysiological function, post-operative pain assessments and overall hand-function. Results
showed that patients who received NeuraGen® had lower post-operative pain than those treated
with direct suture repair. The overall study conclusion was that entubulation nerve repair using
the NeuraGen® is as effective a method of joining severed nerves as direct microsurgical suture
or short gap graft repair.
In the same year that NeuraGen® received FDA approval. Collagen Matrix, Inc. (Franklin Lakes,
NJ) received approval for the use of two (Collagen Type I) NGC devices; NeuroMatrix

and

Neuroflex^*^ (KOI2814, Table 1.1). Neuroflexis a white resorbable, flexible, non-friable,
semi-permeable tubular matrix designed to create a favorable environment for axonal growth
across a nerve gap defect and is kink resistance up to 140° (US Patent No. 6,716,225 [115]). The
device slowly resorbs in vivo over a period of 4 to 8 months whilst its highly purified Type I
collagen fiber structure provides the required mechanical strength at the site of repair.
Neuroflex^"^ is currently the only flexible and kink resistant Type 1 collagen NGC on the market
which has been designed to bridge nerve gap defects not exceeding 2.5 cm [116]. The
NeuroMatrix™ product has the same material composition as Neuroflex™, but without the
flexibility and kink resistant properties of Neuroflex^”^. Both devices are presented as crimped
semi-permeable matrices having a pore size in the range of 0.001 to 0.005 pm to allow for
nutrient transfer [117]. The manufacturers’ claim the devices to be cell occlusive and capable of
preventing fibrogenic cell migration into the wound site and are fully resorbed over 4 to 8
months [116]. Interestingly, although both devices have been approved since 2001, neither
device is the basis for published animal or clinical studies.
In addition to the above devices, NeuraWrap™ (Integra Life Sciences Corporation, Plainsboro,
NJ), a Type I collagen nerve protectant wrap, received approval for human use by the FDA
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(K041620, Table 1.2) in 2004. NeuraWrap has an identical material composition to NeuraGen®.
The purpose of the wrap is to protect injured or crushed nerves during regeneration by
preventing the formation of neuromas. NeuraWrap™ is indicated to provide a non-constricting
encasement for injured peripheral nerves. The wall of the NeuraWrap device has a longitudinal
slit that allows the wrap to be positioned easily over the injured nerve. The manufacturers state
the main advantages of the device include: (i) minimal potential for scar formation,
encapsulation and nerve entrapment; and (ii) Its ability to creating an appropriate environment
for repair. NeuraWrap has a porous outer membrane that mechanically resists compression from
surrounding tissues while excluding scar tissue formation and a semi-permeable inner membrane
that allows for nutrient permeation. NeuraWrap™ is available in inner diameter ranging from 3
to 10 mm of varying lengths: 2 to 4 cm. It remains unclear, due to lack of clinical evidence,
whether sewing a wrap such as NeuraWrap™ shut, is comparable to the use of an NGC devices
with respect to nerve regeneration.
The final device in this category is NeuroMend™ (Collagen Matrix, Inc., Franklin Lakes, N.J.).
This device is also a Type I collagen nerve protectant wrap (K060952, Table 1.2) approved in
2006, and is compositionally identical to the above devices. NeuroMend^*^ has been designed to
wrap a protective environment around an injured (crushed) peripheral nerve in which there has
been no substantial loss of nerve tissue as opposed to addressing a complete peripheral nerve
discontinuity. NeuroMend™, like the other devices in this section, is a resorbable, semipermeable, collagen wrap. However, it is designed to unroll and self curl to best match the
dimensions of the injured nerve [115]. It has the same technological characteristics as
NeuroMatrix^"^; its selective permeability allows nutrient diffusion, while blocking fibroblast
cell migration [107]. It has also been shown to be well received by soft tissue and provokes
limited inflammatory response, while exhibiting full levels of resorbability [115, 118-122].
Although NeuroMend^''^ has been cleared for FDA approval since 2006, there is limited
scientific (animal and clinical) evidence (in the peer reviewed literature) regarding its efficacy.
The material is expected to fully resorb between 4 to 8 months post implantation [107].
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Table 1.3; Experimental data on the collagen based FDA approved peripheral nerve regeneration device
NeuraGen®.
1st
Author

Model

Results

Tyner

Animal

Rats(24 Sprague Dawley)

Moderate to severe autonomy was

-2007

Nerve Location

Distal (sural, peroneal and tibial nerves)

observed in 88% (7 of 8) of the

[110]

Gap size

20mm

control (neurectomy) animals.

Methods

Histology autonomy scoring

13% (1 of 8) of NeuraGen animals

Controls

8 controls

developed autonomy(P < .01).

Group

8 neuraGen®

Follow up

8 wks

Animal

Prospective non human primate

Reinervation of Pacinian corpuscles
and thenar muscles in all cases.

Archibald
1995

Nerve Location

5 median , &15 ulnar

[73]

Gap size

20mm

Methods

MAP,SAP,Histomorphology

Controls
Group

5 Autografts
5NeuraGen®, 15 median ,51 suture,
1 ulnar

Follow up

3.5 yrs

Archibald
1991

Animal

Rat and primate(Macaca

In the rat model: At 4 weeks the

fasciculeearis monkeys

repair group of direct suture

[106]

Nerve Location

Sciatic Median

demonstrated a significantly greater

Gap size

40mm

MAP, compared to the other groups.

Methods

Electrophysio-logical

However, at 12 weeks all groups

evaluation

displayed similar levels of recovery.

Controls

Direct suture autograft

Axonal regeneration and maturation

Group

NeuroGen

over a nerve gap distance of at least

Follow up

4-12 wks

15 mm

Table 1.4: Clinical data on the use of the NeuraGen® devices in clinical trials.

1st Author
Study Design

Model

Results

Retro-spective chart review

40/126 lost to follow-up.

Wangens
teen

Numbers

126 pairs, 96 patients

26/126 quantitative testing: 35% reporting

2009

Patient Age

Ranges 7-79, Mean 33

improvement and 31% requiring revision.

[123]

Nerves Location

Sensory
Ranges 2.5-20 mm. Mean 11.712.8mm

60/126 qualitative testing: with 45%
reporting improvement and 5% requiring

Gap Size
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Methods

Semmes Weinstein testing, 2pD
electromyography

Complications, 2 minor and 1 case of
pulmonary embolism. All postoperative.

Follow up

256 days to last follow up

*, 11 (9%) repairs received revision

Lohmeyer

Study Design

Prospective cohort study

4/12 excellent;

2009

Numbers

15 repairs, 14 patients

5/12 good;

[114]

Patient Age

1/12 poor;
2/12 none.

Nerves Location

Digital

Gap Size

Mean: 12.5 ± 3.7 mm

Methods

2pD, electro-myography

Follow up

12 mths

Bushnell

Study Design

Retrospective human

4/9 excellent;

2008

Numbers

4/9 good;

[113]

Patient Age

12 repairs
Range: 18-50; Mean: 33

Nerves Location

Digital

Gap Size

<20mm
2pD, Semmes- Weinstein mono
filament testing, and Quick DASH

Methods
Follow up
Parole

Study Design

2008

Numbers

['•12]

Patient Age
Nerves Location
Gap Size
Methods

1/9 fair

12-22 mths
Retrospective human
9 repairs

4/9 good;
4/9 some;
1/9 none.

Lingual and inferior alveolar
15mm
2pD, object and texture identifica-tion, and return to work/function

Follow up

12-30 mths

Ashley

Study Design

Retrospective human

4/5 good (1 yr follow up);

2006

Numbers

5 repairs

3/5 excellent (2 yrs follow up).

Patient Age

Range: 2.8-17.3; Mean: 8 ±5

Nerves Location

Brachial plexus

Gap Size

<20mm

Methods

Motor scale composite

Follow up

Range: 18-26; Mean:23.2± 4

Taras

Study Design

Retrospective human

1/5 poor

2005

Numbers

73 repairs

Ongoing clinical study

[75]

Patient Age

[111]

Nerves Location
Gap Size
Methods

Median, ulna, radial, posterior
Interosseouscommon digital.
superficial radial
<20mm
2pD, Semmes- Weinstein mono
filament testing, and Quick DASH

Follow up
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Key advantage:
• Collagen Type I; is abundant, easily isolated and purified and can be made to offer varying
degrees of resorbability.
• Adhesiveness for different cell types allows long-time survival and proliferation, (though
some limitations exist as noted).
• Collagen Type I has an established record of biocompatibility and has been shown to
support and guide tissue regeneration in vivo.
• In prospective and retrospective clinical studies, NeuraGen® has been reported to have
comparable efficacy to the gold standard in defects up to 20mm. In fact, NeuraGen® has
published consistently since 2005 to 2009 on the devices clinical safety and efficacy. In
addition, pre-clinical studies showing efficacy in defects up to 40mm have been reported.
No other FDA device has reported levels of efficacy up to this gap length in the literature.
Key limitations:
• With respect to NeuraGen® the time required for complete biodegradation to occur (48
months) which may lead to nerve compression.
• Neuroflex^"^; NeuroMatrix™; NeuraWrap^”^ and NeuroMend™ in contrast are reported to
fully biodegrade by a time period of 8 months.
• Undesirable immune responses and the requirement to use immunosuppressive drugs, for
certain devices is a disadvantage. Furthermore, though abundant, batch-to-batch variations
can compromise reproducible performance'^^. In addition it also appears as the degeneration
interval is increased, the regenerative supporting ability of the stored nerve is compromised;
hence, nerve storage for repair should not be excessively delayed [55].
1.2.4.4.2

Porcine Small Intestinal Submucosa (Surgisis® Nerve Cuff)

Small intestinal submucosa (SIS) is a strong, pliable, cell-free collagen matrix derived from
porcine small intestine [124]. SIS is a plentiful and commercially available ECM that has been
proven to retain much of the original structure and composition of the natural, intact ECM [125].
SIS is prepared from the mucosa and muscle layers of the small intestine, which are treated with
a hypotonic solution to lyse and wash away cells [126]. The resultant ECM material is composed
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of collagen, fibronectin, growth factors, glycosaminoglycans, proteoglycans, and glycoproteins
[97]. Preliminary studies have shown that SIS may be applied as a neural guidance material in
providing axonal regeneration [127, 128]. The Surgisis® SIS Nerve Cuff, developed using
porcine SIS appears to have the potential to facilitate host tissue regeneration without displaying
any immunologic rejection [129-132]. SIS provides a scaffold for host cells to reconstruct related
tissue supports early with abundant new vessel growth, and appears to foster cellular
differentiation as well as deposition and maturation of the host ECM components - consequently
initiating site-specific tissue remodeling [133]. During the remodeling process of healing, the
mesh provides sufficient mechanical strength for tissue support while acting as a scaffold for
rapid natural tissue incorporation.
The composition of the Surgisis® SIS nerve cuff (Cook Biotech Products, West Lafayette, IN)
approved for human use by the FDA (K031069, Tables 1.1 and 1.2) is also marketed as i)
AxoGuard™ Nerve Connector and ii) AxoGuard^'^ Nerve Protector in the form of a tubular and
nerve protectant wrap (U.S. Patent No’s; 6,206,931 [134], 6,241,981 [135]), respectively. The
AxoGuard™ nerve connector is available in a range of inner diameters from 1.5 to 7 mm at a
standard length of 10 mm; while the AxoGuard^^ nerve protector is available in a range of inner
diameters from 2 to 10 mm with varying lengths between 2 to 4 cm. Smith et al. [128]conducted
the first preliminary study on a porcine SIS NGC to evaluate the integrity of sciatic nerve repair
over a period of 90days, in which distally directed growth of the proximal nerve was
demonstrated, via histology. Previously, Hadlock et al. [127]studied the introduction of a high
numbers of Schwann cells in monolayers via a novel rolled graft architecture consisting of rat
SIS harvested from adult Fisher rats, with a view to promoting robust nerve regeneration and
compared the results against acellular grafts and autografts. In this study, Schwann cells were
plated onto the pinned out SIS strips (7 mm x 8 cm) and allowed to reach confluence.
Subsequently, the material was rolled into a laminar structure for implantation across a 7 mm gap
in the rat sciatic nerve (n = 12). Control animals received SIS conduits without Schwann cells (n
= 11) or autograft repair (n = 12). After 10.5 weeks implantation, functional regeneration through
the Schwann cell-laden grafts was found to exceed that through the cell-free grafts and
approached results comparable to autografts. It was also demonstrated, however, that rat SIS is
not firm enough to prevent lamellae from collapsing onto one another, thereby prohibiting
further axonal regeneration. Porcine SIS is thicker and has greater mechanical strength than rat
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SIS and as a result may be deemed a more suitable scaffold material in peripheral nerve tissue
engineering applications. To date, there is limited peer reviewed data available for either device
in respect of clinical efficacy.
Key advantages:
• Appears to survive in a xenogenic host without obvious adverse immunologic consequences.
• Offers good biomechanical support.
• The microenvironment formed with this material appears to positively impact tissue
remodeling; (accelerating cell proliferation and differentiation.
• Inducing a body response to resist infection; and (iv) is harvested easily [132, 136].
Key limitations:
• The immune response, however, has been found to vary depending on the species from
which collagen has been isolated, processing techniques and the site of implantation.
• The high cost of pure collagen, variable physico-chemical and degradation properties and
the risk of infectious diseases transmission due to the allogenic or xenogenic origin of the
material [137] are limitations of note.
• A lack of available pre-clinical and clinical (controlled, randomized and/or retrospective)
data exists in the literature for this device for surgeons to suitably assess the efficacy of the
material.
1.2.4.5 Resorbable Devices (Synthetic Origin)
1.2.4.5.1

Polyglycolic Acid (Neurotube®)

Polyglycolide (PGA) is a rigid thermoplastic, highly crystalline polymer (45 - 55% crystallinity
[71, 138]) which exhibits a high tensile modulus with very low solubility in organic solvents
[139]. The glass transition for the polymer ranges from 35-40°C with a melting point in excess of
200°C [71, 138]. PGA has excellent mechanical properties for the indication due to its high
crystallinity and has a Young's Modulus of up to 12.5GPa [140]. PGA is a bulk degrading
polymer which degrades by the non-specific scission of the ester backbone. PGA begins to lose
its strength in 1 to 2 months when hydrolyzed and loses its total mass within 6 to 12 months
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[139]. Its hydrolytic degradation is initially independent of cells and released enzymes; yielding
glycolate, pyruvate, and, finally H2O + CO2 as the end product [141]. Due to a transient pH
decline during hydrolysis, the acid cannot be neutralized by the cellular microenvironment and
may result in tissue necrosis which limits the amount of PGA implant [141]. The use of PGA in
biomedical applications is limited by: (i) its high rate of degradation, (ii) acidic degradation
products and (iii) low solubility. (U. S. Patent No. 5,147,399 and Dellon et al. [142] describe (in
detail) a PGA-based bioabsorbable crimped tube device (Neurotube®) for the repair of
peripheral nerve discontinuities. The device may be fabricated to from a knitted or woven tubular
device, which is set (dry heat) to improve the tubes in vivo strength; followed by crimping of its
exterior to have a corrugated exterior surface. Neurotube® (Synovis Micro Companies Alliance,
Birmingham, AL) is the first synthetic highly porous bioresorbable NGC to receive 510k
approval by the FDA (K983007, Table 2.1) in 1999. Characteristics of this tube include
(Wolford et al. [143], (i) porosity, which provides an oxygen-rich environment for the
regenerating nerve; (ii) flexibility, to accommodate movement of joints and associated tendon
gliding; (iii) corrugation, to resist the occlusive force of surrounding soft tissue; and (iv)
bioabsorbability, eliminating the need for removal at a subsequent operation. The corrugated
Neurotube® device has an internal diameter of 2.3mm and a length of 4cm and is indicated for
the repair of peripheral nerve discontinuities not exceeding 3cm. In addition, the Neurotube®
device is available with alternative internal diameters of 4 and 8mm at a length of 2cm.
Neurotube® is considered the preferred synthetic NGC amongst surgeons [116], for indications
including the repair of peripheral and cranial nerve defects due to its advantages in length, price
and wide availability of clinical data. There are precise indications for which it can be used, such
as; digital and palmar nerve lesions with gap size less than 3 cm [144]. The results of the preclinical cases published using Neurotube® are summarized in Table 1.5. An animal study [145]
comparing three commercially available, synthetic, bioabsorbable nerve conduits (NeuraGen®,
Neurotube® and Neurolac®) against the currently accepted ‘gold standard’ autograft procedure
however, has shown the Neurotube® to exhibit the poorest results for functional motor recovery
in the rat model; with a recovery rate of 15% for compound muscle action potentials (CMAPs)
and 29% for muscle force. Moreover, Neurolac® and NeuraGen® remained structurally stable
after twelve weeks, while the Neurotube® had completely collapsed. Initial animal studies by
Rosen et al. [146] carried out on a thin walled PGA tube for repair of a transected rat peroneal
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nerve, demonstrated minimal host response after 10 weeks. Later studies by the same group
observed fragmentation 1 month post implantation, with no remaining material detected after 6
to 8 months. In contrast, an experimental trial in 16 Maccacynomolgus monkeys (see Table 1.5)
demonstrated an equivalent motor function for the traditional nerve graft versus the Neurotube®
[147]. Most recently, Waitayawinyu et al. [119] compared PGA tubes and type I collagen nerve
tubes with the gold standard of autogenous nerve grafting. Bridging a 10 mm segment of 45 rat
sciatic nerves, axonal sprouting was significantly less organized and less dense with the PGA
conduits when compared to nerve reconstruction with the type I collagen conduits and nerve
grafts (see Table 1.5).
The results of the clinical cases published since Neurotube® received FDA approval are
summarized in Table 1.6. In brief, the first clinical study for Neurotube® was reported by
Mackinnon and Dellon [148] on a series of 15 patients; in which they used PGA NGCs to repair
digital nerve defects up to 3 cm. In that study, excellent results were reported for 5 patients
(33%), good results for 8 patients (53%), and poor results for 2 \patients (14%). Later, Crawley
and Dellon [149] reported an isolated case in which a 2mm diameter PGA bioabsorbable NGC
was used. In this case study, a 51-year-old woman developed immediate and persistent numbness
of the right lower lip and chin with no associated dysesthesia after extraction of a right
mandibular molar tooth. Surgical repair of the right inferior alveolar nerve (IAN) was undertaken
16 months following the original extraction. The NGC was filled with autologous serum to
prevent blood clot formation and after surgery; the patient suffered no further facial pain. More
significantly, progressive improvement in sensation of the lower lip and chin was noted 6 months
post-surgery. At 12 months post-surgery, pressure and vibratory perception were similar to those
of the contralateral lip and chin area.
Weber et al [118] reported results for the first large multicenter clinical trial for Neurotube®
which generated very encouraging results. This prospective randomized trial used Neurotube® to
reconstruct sensory nerve defects in 136 nerve repairs in the hand, was divided between two
groups. Group 1 comprised patients receiving repairs with either end-to-end anastomosis (for
gaps less than 8 mm) or nerve graft repairs (for gaps exceeding 8 mm) Group 2 comprised
patients treated with Neurotube®. Sensory nerve defects were selected over motor nerve defects,
since these were the most commonly affected nerves within the 98 human subjects under
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assessment. The observations after 1 year showed superior sensory results were obtained in the
Neurotube® groups with excellent and good outcomes in 44% and 30% of the repairs
respectively; compared with 43% of both excellent and good outcomes after standard repairs. A
subgroup analysis was subsequently performed for nerve gap lengths ^mm, 5 to 7mm, and 8 to
30mm. Sub-group analysis demonstrated excellent results for gaps less than or equal to 4mm for
moving two-point discrimination (m2PD) in 91% of Neurotube® repairs compared with 49% for
standard repairs (P = 0.02). It has been well documented that motor neurons appear to prefer
regeneration across a motor nerve instead of a sensory nerve susbstratum and that the use of
motor nerve architectural units as opposed to sensory nerve architectural units results in an
improved rate of recovery [150-152]. In summary, there were no statistical differences between
the groups overall. However, 2-point discrimination (2PD) was better in the PGA NGC group
(6.8 ± 3.8 mm) than in the direct anastomosis or nerve graft group (12.9 ± 2.4 mm). The PGA
NGC provided a scaffold providing superior results and eliminated donor-site morbidity. Such
efficacy has been substantiated by Casanas et al. [153] reporting clinical data in a prospective
study of 17 patients with chronic lesion defects of the digital nerves of the hand exceeding 2 cm
and in a retrospective human study carried out by Kim et al. [154]. Additional research carried
out by Battiston et al. [155] on digital nerve injuries with gaps of various lengths (1.5, 2, 2.5, 3, 4
cm) using the Neurotube® (n=19 implants) to repair the nerve gaps showed ‘very good’ results
for 76.5% of cases ‘good’ results in 17.7% and 5.8% with poor results. The Neurotube® group
was compared statistically against a muscle-vein combined nerve conduit; no significant
difference (P>0.05) was detected between either group for any of the evaluation tests studied.
Further clinical reports have investigated the Neurotube® conduit for motor reconstruction and
specifically their efficacy in the reconstruction of the spinal accessory nerve due to cautery injury
[156]; the reconstruction of several facial nerves injuries [157] and median nerves in the forearm
[158]. Dellon et al. [159] later reported on the successful nerve regeneration of a right avulsed
thumb with a microvascular hallux transfer using a 2.3 mm internal diameter Neurotube® NGC
to bridge a 2.5 cm nerve gap defect between the radial sensory and peroneal nerve. Most recently,
Rosson [160] has published a retrospective chart review of six patients having received
bioabsorbable Neurotube® NGCs across short gap motor nerve injuries over a 7 year period.
The outcome demonstrated favorable results with all patients having some return of motor and
sensory function.
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Table 1.5: Experimental data on the PGA based FDA approved peripheral nerve regeneration device Neurotube®.
1st
Author
Waita
yawiny
2007

Animal
Nerve Location
Gap size

[119]

Methods
Controls
Group

Dellon
1998
[147]

Model

Results

Rats(25 Sprague Dawley)
Sciatic left nerves
10mm
Isometric muscle contraction, axonal
counting, wet muscle weight, and
histology
15 autografts

Statistically significant differences in
the isometric muscle contraction force.
axonal counts, and wet muscle
NeuraGen® and nerve graft compared
to Neurotube®, developed
autonomy (P < .01).

15 NeuraGen, 15 Neurotube

Follow up

15 wks

Animal
Nerve Location
Gap size
Methods
Controls
Group

Electromyographic evidence of
16 monkeys
intrinsic
Ulnar proximal to elbow
muscle recovery in five of the six
30mm
monkeys.
Morphometric analysis and electrophysiology
No difference in electron microscopy
sural graft
or electrophysiology between groups.
24 ulnar 8 graft, 16 Neurotube

Follow up

12 mths

The superior results achieved with this nerve graft conduit are related to the elimination of the
problems associated with a harvested nerve graft, host-donor differences in diameter,
mismatches in number and pattern of fascicles and cross-sectional shape and area, and morbidity
of the donor area. However, PGA conduit grafting results will still be affected by such factors as
time since injury, type and extent of injury, vascularity, graft size match, length of nerve graft
required (results are good for defects <30 mm), quality of repair, tension on the repaired nerve,
preparation of the host nerve, age of patient, and other health factors.
Table 1.6: Clinical data on the use of the Neurotube® devices in clinical trials.
1st
Author

Model

Results

Rosson

Study Design

Retrospective chat review

2009

Numbers

6 pairs

All patients had some return of motor

[160]

Patient Age

Ranges 9-61, Mean 47

function rated as M3* or greater by

Nerves Location

Median and ulnar

physical exam

Gap Size

Ranges 15-40 mm. Mean 28mm

Methods

Clinical motor strength and electro
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100% return to useful motor function.
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-diagnostic testing
Follow up

Range:4-66; Mean 39

Donoghoe

Study Design

Retrospective human

Each patient recovered two-point

2007

Numbers

2 patients; 4 repairs

discrimination with good localization in the

[158]

Patient Age

43 and 61 thumb,

index, and middle finger by 2 years after

Nerves Location

Median

the nerve reconstruction.

Gap Size

30mm

Almost 4 years post surgery, one had

Methods

s2pD and m2pD

recovered 2PD to ~4mm in the thumb and

Follow up

Retrospective human

S2PD of the hallux was 4 mm at 14.7g/mm

Numbers

1 patient; 2 repairs

The cutaneous pressure threshold for 1-

Patient Age
Nerves Location

42

point static touch was 0.7 g/mm.

Gap Size
Methods

25mm
s2pD and m2pD

Follow up

30 mths

Study Design

Retrospective human
13 patients, received muscle vein
-combined NGCs. 17 patients
(19 repairs) (PGA)

Dellon

Study Design

2006
[159]

Battiston

middle finger and 8mm in the index finger
Both patients recovered abductor pollicis
brevis function.

Digital

77% showed VG results (S3+ or S4)*
18% showed G* results (S2+ or S3) * in the
PGA group

2005

Numbers

[155]

Patient Age
Nerves Location

Range: 15-67; mean 40

76.9% showed VG* results, while only

Digital

Gap Size

Range: 10-40mm; mean 20mm
s2pD and m2pD MRC, QuickDASH

23.1% showed G results in the muscle-veincombined group
There was no difference between the two
groups in terms of functional recovery

Methods
Follow up

2nd Surgery

Range:6-74 mths, mean 30mths
The muscle-vein-combined group
where treated for a period of 1 to
16mths

Navissan

Study Design

Retrospective human

1 VG,

2005

Numbers

7 repairs

4G,

[157]

Patient Age

Mean 26

2P

Nerves Location

Facial

Gap Size
Methods
Follow up

10-30mm
exam muscular contraction of
individual muscles
Range:7-12

Study Design

Retrospective human

Ducic

PGA reconstructed nerve reached M5* and
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2005

Numbers

2 repairs, 1 autograft, 1 PGA

trapezius function by 3 months, while the

[156]

Patient Age

patient with the autograft reached M4*

Nerves Location

Cranial

Gap Size

<20mm

had persistent numbness of the ear lobe.

Methods
Follow up

-

Laraos

Study Design

Prospective human

2003

Numbers

24 pateints, 28 repairs

[161]

Patient Age

Palmar digital
s2pD and m2pD MRC, Quick-DASH

Nerves Location
Gap Size

function by 6 months after reconstruction.

93% G

Methods
Follow up

-

Kim

Study Design

Retrospective human

Pain resolved.

2001

Numbers

1 repair

At 8 months. Measurements for moving

[154]

Patient Age

11

two-point discrimination were 3.8 mm and

Nerves Location

Medial Plantar

2.6 g/mrrr^ for the right and 3.8 rnm and

Gap Size

5.0 g/mm^ for the left hallux

Methods

20mm
s2pD and sensation

Follow up

Range 1-10 mths

Weber

Study Design

2000

Numbers

RCMT
98 patients, 136 repairs (46 PGA,
56 controls

There were no statistical differences
Between the 2 groups (control and NGC)
overall.

[118]

Patient Age

Range: 17-6775; mean 35

Excellent results obtained in 91% in the

Nerves Location

Gap Size

Digital
7.0 (A gap of 5 mm was left inten
-tionnally, even in defects of 0 to
4mm); control 4.3mm

PGA group (3.7mm m2PD), whereas in the
end-to-end group, only 49% achieved
excellent results (6.1mm m2PD), with P
levels of 0.02 and 0.03, respectively.

Methods

s2pD and m2pD

The PGA NGC provided superior results

Follow up

Mean 9.4 mths, control 8.1 mths

and eliminated donor-site morbidity over

-

the standard end-to-end repair group
Casanas

Study Design

Prospective human study

All modalities

2000

Numbers

17 patients

Test demonstrated successful recovery

[153]

Patient Age

11

Nerves Location

Digital

Gap Size

20-35mm
s2pD and m2pD tactile perception
evaluation of sweating and nerve
conduction

Methods
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Follow up

Range 1-10 mths

Crawley

Study Design

Retrospective human

No recurrence of pain. At 24mths follow up.

1992

Numbers

1 repairs

pain relief remained excellent, and

Patient Age
Nerves Location

51
Right inferior alveolar

similar to the thresholds for these

Gap Size

25mm

perceptions on the contralateral lip.

Methods
Follow up

Tactile perception and pain relief
24 mths

Study Design

Series

Excellent functional sensation (moving two-

[149]

Mackinnon

perception of pressure and vibration was

Numbers

15 patients, 1 repairs

point discrimination less than or equal to 3

1990

Patient Age

30.5 (SD7.6)

mm and/or static two-point discrimination

[148]

Nerves Location

Digital

less than or equal to 6 mm) was present in

Gap Size
Methods

5-30mm, meanlVmm
s2pD and m2pD Digital nerve
block

Follow up

11-32 mths, mean 22.4 mths

33 percent and good functional sensation
(moving two-point discrimination of 4 to 7
mm and/or static two-point discrimination
of 7 to 15 mm) in 53 percent of the digital
nerve reconstructions
One patient with poor sensory recovery and
one with no recovery were judged as
functional failures (14 percent). Absence of
pain at the site of reconstruction was judged
by the patient to be excellent in 40 percent,
good in 33 percent, and poor in 27 percent.

- RCMT: Randomized controlled multi-centre trial
* Where results (outcomes) for sensory recovery are also grouped as: excel lent/very good (VG:
S3+ and S4), good (G: S2+ and S3), and poor (P: SO, SI, S1+, and S2). SO to S4 represents the
classification of sensory recovery as follows [155]:
50

No recovery of sensibility in the autonomous zone of the nerve

51

Recovery of deep cutaneous pain sensibility within the autonomous zone of the nerve

S1+

Recovery of superficial pain sensibility

52

Recovery of superficial pain and some touch sensibility

S2+

As in S2, but with over response

53

Recovery of pain and touch sensibility with disappearance of over response

S3+

As in S3, but the localization of the stimulus is good and there is imperfect recovery of
two-point discrimination

54

Complete recovery

53
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MO to M4 represents the classification of motor recovery as follows [155]:
MO

No contraction

M1

Return to perceptible contraction in the proximal muscles

M2

Return to perceptible contraction in both proximal and distal muscles

M3

Return of function in both proximal and distal muscles to such a degree that all important
muscles are sufficiently powerful to act against gravity

M4

All muscles act against strong resistance and some independent movements are possible

M5

Full recovery in all muscles

Key Advantages:
• Neurotube® has excellent degradability, good initial mechanical properties and is associated
with high levels of cell viability.
• In randomized clinical trials, the device has been reported to have comparable efficacy to
the gold standard in defects up to 20mm. In fact, based on this data (and current literature).
Neurotube® has the most clinical data available to surgeons for review of its safety and
efficacy compared to all the FDA approved devices. Moreover, pre-clinical data exists for
this device showing efficacy in gap defects up to 30mm.
Key limitations:
• The high rate of degradation and contiguous reduction in short term mechanical properties,
acidic degradation products and low solubility remain key limitation.
1.2.4.5.2

Poly D,L Lactide-co-e-Carprolactone (Neurolac®)

Poly D,L Lactide-co-£-Carprolactone (PCL) in the form of a hydrophobic semi-crystalline
polyester (crystallinity decreases with increasing molecular weight [137, 162, 163] has also
received approval as a resorbable device for peripheral nerve repair. PCL has gained
considerable interest in the research field due to its ease of fabrication and low processing costs;
polymerized via the ring opening polymerization (ROP) of the relatively cheap monomeric unit
8-caprolactone (CL). Its high processibility is attributed to the fact that PCL is highly soluble in a
wide range of organic solvents [71] and moreover, its crystalline nature enables easy formability
54

Chapter 1. Literature Review

at relatively low temperature [153]. Due to its semi-crystalline nature, its melting temperature is
between 59-65 °C, with a glass transition temperature at -60°C [71, 139, 162]. PCL has a
relatively low tensile strength of ~23MPa coupled with an extremely high elongation at breakage
(>700%). Degradation of PCL occurs in the form of hydrolysis due to the presence of
hydrolytically labile aliphatic ester linkages and may also occur actively (enzymatically) with a
slow rate of degradation between 2 to 3 years [116, 137]. Copolymerization with poly(D,Llactide)
modifies crystallinity pliability and melting point in order to accelerate the rate of degradation
[71]. Its degradation products consist of succinct acid, butyric acid, valeric acid and caproic acid,
which are non-toxic and do not cause an inflammatory response [164]. These degradation
products are less acidic than PLA and may cause less damage to the surrounding tissue
environment [70, 165]. PCL degradation via hydrolysis may lead to crack formation and result in
a loss of tensile strength [166]. In brief, the rate of PCL degradation may be adjusted by
modulating the ratio of its monomers (that is, lactide vs. e-caprolactone), water uptake, pH,
temperature and the chemical morphology of the copolymer (amorphous vs. crystalline / glass
transition temperature) [28]. Neurolac® represents the only transparent class II NGC which is
FDA approved (K032115/K050573, Table 1.1) and is based on the poly(65/35(85/15 L/D)
lactide-6'-caprolactone) polyester (Polyganics Inc., Netherlands). FDA approval was originally
obtained in October 2003 for Neurolac® dimensions of 1.5 to 3 mm inner diameter and two
years later in May 2005 for larger inner diameters of 4 to 10 mm. All Neurolac® NGCs are
available in a standard length of 3 cm.
The results of pre-clinical cases published using Neurolac® are summarized in Table 1.7. The
first studies were performed on the original poly(50/50(85/15 L/D) lactide-e-caprolactone)
composition by Den Dunnen [167-169] and Meek [170-175] across 10 to 15 mm nerve gap
defects of adult male lewis and black hooded rats. Den Dunnen [168] investigated the internal
diameter of the NGC compared with the NGCs wall thickness and correlated this to the
degradation and swelling characteristics of the 50:50 lactide: e-caprolactone copolymer NGC in
vivo. They subsequently proposed the use of thin walled NGCs but noted their susceptibility to
collapse easily. Consequently, further studies were carried out on poly(65/35(85/15 L/D) lactidee-caprolactone) NGC compositions with a higher lactide content to address the issues concerning
swelling. The same investigators have extensively published on the safety and efficacy of
Neurolac® in a wide array of animal studies, as outlined in Table 1.7. Varejao et al. [176]
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reported cases of automutilation in the rats implanted with Neurolac®; whereby the sciatic
functional index (SFI) was not possible to calculate. They did conclude, however, that the toes
out angle (TOA) measurements were not significantly influenced. The same investigators also
studied the effect of implanting Neurolac® filled with fresh skeletal muscle and reported no
significant statistical differences after a 24 week follow up period to demonstrate good nerve
fiber regeneration in all groups studied (refer to Table 1.7). Jansen et al. [177] were the first
investigators to report incomplete absorption of Neurolac® after 16 months of implantation with
small fragments eliciting a minor secondary foreign body reaction. Recently, Meek et al. [116,
178] have also discussed preliminary observations of small fragmentation of Neurolac® on the
edge of the epineurium (regenerated nerve post implantation) at 2 years. A year later. Meek et al.
[179] published results demonstrating nerve regeneration having occurred through the
Neurolac® NGCs with no biomaterial observed macroscopically after 2 years of implantation.
Although, biomaterial fragments in company of multi-nucleated giant cells and macrophages
were found along the regenerated nerve tissue. Collagen 111 and IV were both found around the
epineurium and perineurium in the regenerated nerve, the organization of these layers resembled
that of the contra-lateral non-operated nerve. Although sufficient nerve regeneration was
obtained after long-term implantation in the rat sciatic nerve, biomaterial fragments and foreign
body reactions against these fragments, even after 2 years of implantation, could still be found. It
is unknown whether the remaining biomaterial fragments and foreign body reactions may cause
granulomas or other complications after longer implantation periods.
Most recently. Meek and den Dunnen [180] evaluated the short term {in vivo) effects of
Neurolac® across a 10 mm nerve gap defect for evaluation after 12 weeks implantation in 10
male Black Hooded rats (see Table 1.7). After 5 wks, no improvement of nerve regeneration was
evident and the NGC walls were so swollen that lumen blockage and crack formation was
evident. At 8 wks, some myelinated nerve fibers appeared distal to the NGC due to lumen
blockage. After 12 wks, only some myelinated nerve fibers were evident, as at this time period.
Neuroamas had occurred proximal to the NGC with further evidence of fragmentation. In the
same year. Meek et al. [180] published results on 4 Neurolac® NGCs implanted into adult male
wistar rats across a 15 mm nerve gap defect; whose results indicated that the sciatic nerve
function was not measurable due to automutilation and flexion contractures, while the gait stance
duration showed no improvement with time coupled with the presence of a disturbed walking
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pattern. Moreover, a severe foreign body reaction was evident with severe swelling (complete
lumen blockage) the guide walls due to degradation of the polymer/water uptake and early
fragmentation preventing nerve regeneration from occurring. Early collapse of the tube severely
hampered nerve regeneration leading to neuroma formation and few myelinated nerve fibers
bridging the gap defect.
Neurolac® conduits have also been compared with PLGA (Lactide to Glycolide ratio: 90/10)
NGCs in vivo for healing (motor and sensory) efficacy against end-to-end nerve suture and
autograft [165]. In spite of a significant difference between the amount of biodegradation
between the two NGCs (with larger biodegradation of PLGA after a 20 week period),
morphological and histomorphometrical analyses indicated that axonal regeneration successfully
occurred in both; with no significant difference in the total number of regenerated fibers. These
findings suggest that the varied rate of biodegradation did not seem to influence the rate of nerve
regeneration. Whilst some clinical reports have been negative (Meek et al. [181]; Neurolac®
NGCs have been the basis of a randomized clinical trial (30 patients with up to 20 mm long
lesions of hand nerves were repaired [178]. Patients were randomized for treatment either with
autologous nerve grafts or with Neurolac®. Whilst more complications were reported for the
Neurolac® group; none were directly device related. During a period of 1 year, patients were
monitored every 3 months with regard to touch and pressure sensitivity. It was noted that
recovery of sensibility between groups was comparable, indicating that the synthetic material
could be an alternative biomaterial for peripheral nerve regeneration.
Table 1.7: Experimental data on the PGA based FDA approved peripheral nerve regeneration device Neurolac®.

1st
Author( Years)
Model

Results

Meek

Animal

Rats Male Black Hooded n=10

After 5 wks, no improvement of

2009

Nerve Location

Sciatic left nerves

nerve regeneration was evident or

Gap size
Methods

10mm
Functional analysis. Light
Microscopical

new axon and myelin degradation.
The NGC walls were so swollen that
blockage and crackes occurred.

Controls

N/A

At 8 wks, some myelinated nerve

Group

8 Neurolac

fibers were evident distal to NGC due

Follow up

3,5,8, and 12 wks

to blockage.

[180]

After 12 wks, only some myelinated
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nerve fibers were evident.Neuromas
had occurred proximal to
NGC with fragmentation
Meek
2009
[179]

Meek
2003
[182]

Animal

Rats(Male Wister n=4)

One rat died after 20 mths and was

Nerve Location
Gap size
Methods
Controls
Group

Sciatic left nerves
15mm

excluded from the study.
After 2 years, nerve regeneration was

Microscopy
Non-operated nerve
4 Neurolac

Follow up

2 years

evident in all rats.
Biomaterial fragments with
maximum diameter of 15pm.
Functional analysis was not possible
due to sever automutilation.

Animal
Nerve Location

Rats(Male Wister n=27)
Sciatic left nerves
15mm

In Neurolac®: 20 out of the 51 rats
exhibited automutilation of the

Group

Morphometrical video, nerve
conduction velocity, electromyography
(EMG)
and electrostimulation
(sensory nerve)
6 Non-operation nerves
51 neurolac

exhibited operated hind paw.
for which the SFl could not be
calculated SFI values did not differ
between both groups.
No difference in gait-stance for the
control group, while the gait-stance
duration of the repaired leg was of
shorter duration than the non-

Follow up

2,4,7,15,21, and 36 wks

Operated leg. EMGs during

Gap size

Methods
Controls

walking remained highly abnormal
Den
Dunnen
2001
[169]

Animal
Nerve Location
Gap size
Methods
Controls

Rats(Male Wister n=66)
Sciatic left nerves
2-12mm
Macroscopic evaluation and
electrostimulation
5, 10 mm gaps, Non-operated
12, 2mmgap with P(DLLA-e-CL)
20, 12mmgap with autograft

12mm gap bridged with P(DLLA-eCL) NGCs filled with MDMT
showed the best results in the electrostimulation tests and signs of severe
automutilation were not observed.
2 out of 5 rats showed improvements
to the sensory nerve function

Group

12,12mmgap with P(DLLA-e-CL)+
MDMT filling

Follow up

3,5,7,8,and 12 wks

Animal
Nerve Location

Rats(Male Wister n=12)

EMG patterns of the control side

2001

Sciatic left nerves

were normal, while EMG patterns on

[175]

Gap size

15mm, 12mm
EMGS of the gastrocnemius(GC)
and tibilais anterior(TA)

The operated side were irregular in
ail animals.
The quality of gait, however, was
better in the NGC group.

Group

6 Non-operation nerves
15 P(DLLA-e-CL)+ MDMT filling.
15 autografts

Follow up

3.5, and 5 mths

Meek

Methods
Controls
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Meek

Animal

Rats(Male Wister n=12)

First regenerating nerve fibers

2001

Nerve Location

Sciatic left nerves

evident at 3 wks

Gap size

15mm,

Methods

TEM (myelinated and nonmyelinated
nerve fibers and morphometric analysis

Controls

12 Non-operation nerves

Group

12 P(DLLA-e-CL)+ MDMT filling

Follow up

3,5,8,andl2 wks

Meek

Animal

RatsMale Black Hooded n=20

At 15 wks, 70% of the sciatic

1999

Nerve Location

Sciatic left nerves

function and 90% of the sensory

[172]

Gap size

10mm
Walking track analysis and electro
stimulation to evaluate motor and
sensory nerve recovery
20 Non-operation nerves

nerve function had been recovered.
After 15 wks, no improvement in the
SFI occurred, while the sensory nerve
function appeared to return to normal.

[174]

Methods
Controls
Group
Follow up

20 P(DLLA-e-CL)+ MDMT filling

RatsMale Black Hooded n=30

The NGC group recorded good

1999

Animal
Nerve Location

Sciatic left nerves

quality walking tracks, with the first

[173]

Gap size

10, 15mm
Walking track analysis (measurement
of SFI) and electrostimulation

signs of recovery at 3 wks; while the
Autograft group had dragging of the
operated foot was evident at 10 wks.

Group

6 Non-operation nerves
12 P(DLLA-e-CL)+ MDMT filling, 18
autografts

The autograft group showed no
significant recovery to 7 wks post
surgery. The NGC group showed

Follow up

12,3,4,5,7,8,10, 12, and 15 wks

sensory nerve recovery at 3 wks.
observed in the NGC group, except
for 2 cases of superficial wounds at 5
wks, while rats in the autograft group
showed the first signs of
automutilation at 2 wks.

RatsMale Black Hooded n=24

Varied dimensions of NGCs in the

Dunnen

Animal
Nerve Location

1998

Gap size

Meek

Methods
Controls

Den

[168]

3,5,8,15,21,26,34,43,and 52 wks

Sciatic nerves

NGC group affected the nerve

Methods

7, 10mm
Morphometri cal analysis and
histological evaluation

Function.
Too small an internal diameter led to
the problems at surgery telescoping

Controls

15 autografts

the nerve ends into the NGC.

Group

15 P(DLLA-e-CL)

Follow up

2-12 wks

Too thick a wall increased the
likelihood for swelling so that the
NGC became occluded.
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Regeneration across a 10 mm nerve
gap inside the NGC was faster in
comparison to the autograft.
Meek

Animal

Rats (Male Black Hooded n=20)

First signs of functional nerve

1997

Nerve Location

Sciatic left nerve

recovery observed at 5 wks. Despite

[171]

Gap size
Methods

10mm
Walking track analysis and
electrostimulation

the thin walled NGCs, functional
collapse of all nerve recovery
remained good after 26 wks for rats.

Controls

20 Non-operated nerves

Percentage of rats with hind paw

Group

20 P(DLLA-e-CL) NGCs

Follow up

3,5,8,15,21, and 26 wks

mutilation (moderate and severe)
increased with time. No neuroma
formation in collapsed NGCs.

Meek

Animal

Rats (Male Black Hooded n=30)

Incorporating the MDMT increased

1996

Nerve Location

Sciatic left nerve

the speed of recovery across a longer

[170]

Gap size

10,15mm
Walking track analysis and electrostimulation to evaluate motor and
sensory nerve recovery

nerve gap.
The first signs of motor nerve
recovery were observed at 5 wks in
the hollow NGC group, while the

Non-operated nerves
P(DLLA-£-CL) NGCs
P(DLLA-e-CL) tubes with MDMT

first signs of motor nerve recovery
were observed at 3wks in the NGC
group filled with MDMT. After 12
wks the SFI had wks in reached 60%
recovery.

Methods
Controls
Group
Follow up
Den Dunnen

Animal

Rats (Male Black Hooded n=20)

At 3 wks, both myelinated and non-

1996

Nerve Location

Sciatic left nerve

myelinated nerve fibers were

[170]

Gap size

observed in the distal nerve stump.

Methods

10mm
Light microscopy and transmission
electron microscopy (analysis of
myelinated and non-myelinated
regenerated nerve fibers: mean number
and diameter) and walking track
analysis

Controls

20 Non-operated nerves

Group

20 P(DLLA-8-CL) NGCs

Follow up

3,4,5,6,8,and 10 wks

60

At 10 wks, the proximal and distal
nerve stumps appeared to be equal
but were different to the control side
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Table 1.8: Clinical data on the use of the Neurolac® devices in clinical trials

1st Author
Model

Results
Both groups comparable considering
the demographics.
More complications in the NGC group
but none directly device related

Bertleff

Study Design

2005

Numbers

RCMT 5 hospitals(Aug 2002 - Mar
2003)
30 patiets, 34 repairs, (21
NGCs, 13 end-to-end suture

[181]

Patient Age

Range: 18-75, Mean: 43

Recovery of sensibility in the NGC

Nerves Location

Digital

group as least as good as in the control

Gap Size

^ - ^0 mm

group.

Methods

s2pD and m2pD

Nerve gaps of 2cm can be treated with

Follow up

3,6,9, and 12 mths

the NGC.

Key advantage:
• Neurolac® is, at present, the only FDA approved transparent NGC, a feature which may aid
the clinician during surgical placement (insertion) across the nerve gap defect.
• In randomized clinical trials the device has been reported to have comparable efficacy to the
gold standard in defects up to 20mm. In addition, Neurolac® has been subjected to
numerous pre-clinical studies by Meek and den Dunnen in gap defect up to 15mm. To this
end, Neurolac® has the most available sets of pre-clinical data in the literature when
compared to all the FDA approved devices.
Key limitation:
• Its high rigidity is limiting and it can only be utilized post immersion into a saline solution.
• Meek et al. [116] also noted frequent breakage of the needle once applied to suture the
device in place as a result of the NGCs rigidity. As such, additional complications result in
the use of a larger needle for suture application with more damage and foreign body
reactions more likely.
• The inflexibility of Neurolac® may also lead to the nerve stumps being tom out of the
NGCs lumen during the regeneration period as a result of inflexibility over the joints during
immobilization. Severe foreign body reactions, severe swelling (complete lumen blockage),
fragmentation (incomplete degradation) and early collapse of Neurolac® leading to neuroma
formation and few myelinated nerve fibers bridging the gap defect are considered to be the
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main limiting factors in selecting the Neurolac® device for correcting nerve gap defects
[176, 179, 180].

1.2.5 Conclusions
Since 1995, 11 devices (NGCs and nerve protectant wraps) based on natural and synthetic
materials have been approved by the FDA for the repair of peripheral nerve injuries. Whilst
autograft remains the gold standard, a large amount of published prospective and retrospective
clinical studies have been performed with NeuraGen® (collagen type 1 NGC) and have
demonstrated its comparable efficacy to autograft in discontinuities up to 20mm. In comparison
of natural and synthesis material for PNR, synthesis material is preferred since all the natural
material has immune response. In respect, of synthetic materials, and based on the weight of
published clinical evidence (including prospective, series, retrospective and RMCTs),
Neurotube® (PGA NGC) has the most comprehensive history when compared with other
synthetic devices. It should be noted that significant advantages may be derived from other
synthetic devices; however limited prospective randomized clinical data is published in the
literature to substantiate claims of superior safety and efficacy. It is noted that PLGA has offered
a tailored degradation rate while compare with PGA. Thus, it would be more suitable material
for a new NGC to repair peripheral nerve defects.
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1.3

Bioactive Glass

1.3.1 Glass Formation
A glass is defined as “an amorphous solid completely lacking in long range, periodic atomic
structure, and exhibiting a region of glass transformation behaviour”[183]. To date, every glass
found exhibits time dependent glass transformation behavior. It is normally discussed on the
basis of enthalpy^ versus temperature diagrams such as Fig 1.20 [183].

Figure 1.20: Effect of temperature on the enthalpy of a glass forming melt [183].

As indicated in Fig 1.20, it is necessary to envision a small volume of a liquid at a temperature
well above the melting temperature of the substance, if the liquid can be cooled below the
melting temperature of the crystal without crystallization, a supercooled liquid is obtained. The
structure of the liquid continues to rearrange as the temperature decrease; as the liquid cools
further, the viscosity increases, this increased viscosity becomes so great that the atoms can no
longer completely rearrange to the equilibrium liquid structure during this time. The temperature
region lying between the limits where the enthalpy is that of the equilibrium liquid and that of
the solid, is known as the glass transformation region [183]. The term glass transformation
^ Enthalpy (AH) is a function that describes energy changes at constant pressure. It includes the internal energy and
the environmental energy (displace space) and establishing its volume and pressure.
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temperature (Tg) is vaguely defined as the onset of glass transformation region for the
convenience of experimental methods. However, Tg indicates an approximate temperature where
the supercooled liquid converts to a solid on cooling.

1.3.2 Structural Theories of Glass
An understanding of the structure (and interpretation of structure) of bioactive silicate glasses is
requisite to the control of the bioactivity and properties of such material. The structural nature of
glasses may be based on considerations such as co-ordination number, bond type, bond strength
and field strength. However, the random network model of Zachariasen coupled with network
connectivity theory provides an excellent framework upon which one may understand and
control glass structure.
L3.2.1 Structural Theories of Glass Formation
Zachariasen [184] summarized, based on observations made from silicate glass systems, certain
conditions for oxide glass formation in a random network (as illustrated in Figure 1.21), in
particular;
1) each oxygen atom is linked to no more than two cations
2) the oxygen co-ordination number of the network cation must be small
3) oxygen polyhedral share only corners not edges or faces
4) At least 3 comers of each oxygen polyhedron must be shared in order to form a 3dimentional network.
The summary above has been modified for complex glasses, to state that;
5) The material must contain a high percentage of network cations which are surrounded by
oxygen tetrahedra or triangles.
6) The tetrahedra share only comers with each other.
7) Some oxygen are linked only to two network cations and do not form further bonds with
each other.
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A number of other theories of glass formation are based on the nature of the bonds in the
material. Smekal [185] proposed that glasses are only formed from melts which contain bonds
which are intermediate in character between purely covalent and purely ionic bonds. Stanworth
[186] attempted to quantify the mixed bond concept by using partial ionic character model of
Pauling. He classified the oxides into three groups on the basis of the electronegativity of the
cation. Cations which form bonds with oxygen with a fractional ionic character near 50% should
act as network formers, (e.g. Si02) which produce good glasses. Cations have slightly lower
electronegativity and form more ionic bonds with oxygen. They cannot form glass themselves,
but partly replace the network former, known as intermediates. Cations have very low
electronegativity and form highly ionic bonds with oxygen. They cannot form glass, but they
could modify the network structure and are termed modifiers. Rawson [187] has suggested the
high melting temperature means that considerable energy is available for bonding disruption.
Therefore, a material with a large single bond strength and low melting temperature will be a
better glass network former than one with similar single bond strength and high melting
temperature. Dietzel proposed the strength of a cation-oxygen bond as a parameter to classify
oxides and determine their effect on the behaviour of glass [188]. He defined the cation field
intensity ‘a’ as a charge to distance squared ratio,
rc

and

ro

z/(rc +rof,

are the cation and oxygen radii respectively

where z is the valence of the cation,

(a^ Vc +ro).

[188]. Field strength can be

considered indicative of the magnitude of the electrostatic attractive force between the cation and
oxygen. Using such classification, cations with high field strength (>1.3) such as silicon and
phosphorus tend to play the role of network formers. Those with much lower field strengths
(<0.4), such as sodium and strontium, encompass the network modifier group and those ranging
between 0.4-1.3, such as zinc, appear to play the role of network intermediates [189, 190].
1.3.2.2 Glass Network Connectivity
Network connectivity theory describes the nature of a glass structure on the basis of the ratio of
of bridging (an oxygen bonded to two Si), and non-bridging bonds (an oxygen bonded to one Si)
(equation 1.3) [184]. The network connectivity number of a glass can be calculated using molar
composition by equation 3.1 [191].
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NC

=

No . BOs - No . NBOs
Total No . Bridging
species

Equation 1.3

Where:
BO=Bridging Oxygens
NBO=Non-Bridging Oxygens
Many modem spectroscopic methods can be used to verify the NC; the advent of magic angle
spinning nuclear magnetic resonance (MAS-NMR), which has virtually removed the element of
speculation from models for the coordination states of Si'^^, Al^^, etc.

Figure 1.21: 2-D Illustration of the structure of soda-lime-silicate glass; a 4‘*' oxygen would be located above each
silicon in the 3-D structure [190].

1.3.3 Kinetic Theories of Glass Formation
Kinetic theories of glass formation address how rapidly a material has to be cooled to form a
glass, avoiding detectable crystallization. The term crystallization refers to a combination of two
processes: nucleation and crystal growth. A nucleus, which is a precursor to a crystal, is required
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SO that a crystal will subsequently grow to a detectable size [192]. If no nuclei are present,
crystal growth cannot occur and the material will form a glass.
1.3.3.1 Nucleation
Nucleation is the process by which constituent particles order spontaneously into tiny units or
embryos by virtue of thermal fluctuations [193]. There are two barriers to the formation of nuclei
- thermodynamic and kinetic. The thermodynamic barrier involves the free energy change in the
system associated with nucleus formation; the kinetic barrier is associated with moving or
rearranging the material to create or grow a nucleus [194]. The overall nucleation rate (I) can be
derived as the following equation:
I = Aexp[-(W*+AGD)/kT]

Equation 1.4

Where:
A, is the approximated constant for the exponential
W*, is the actual work required to form nucleus
AG, Kinetic free volume energy
k, is the Boltzmann constant
T, is the absolute temperature (K) [190]
The actual work required to form nuclei are the decreases in volume free energy due to the
crystalline arrangement and increase in the surface energy due to the formation of the different
structures interface. Thus the net change in energy (W) for a sphere of radius r is given by the
following equation:
W= (4/3) 7ir3AGv + 47cr^Y

Equation 1.5

Where:
AGv, is the change in volume free energy per unit volume
(4/3)7tr^, corresponds to the volume of a sphere [190, 194].
Y, is the surface energy (y) increases per unit area
47cr^, corresponds to the surface area of a sphere [194].
Nucleation is dependent on the balance between surface and volume energies and the net change
in energy. Since AGv is negative for temperatures below the melting point (Tm), and the nuclei
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are very small, the surface energy dominates on small r value, thus the net energy change
increase with increase of radius r, in addition the nucleus will be unstable. Stable nuclei can be
formed when r is great enough for the volume energy term greater than the surface energy term
in Equation 1.5. Derivation of w with respect to radius ‘r’ from Equation 1.5 will get a critical
size, r*, known as a critical radius thus forming critical size nuclei, r* is:
r-*= _

2y/AG,

Equation 1.6

If r* is substituted into Equation 1.5, and use free energy change per mole (AG) instead of the
free energy change per unit volume V^ACv in the system, W* can be defined:
W*= l6ir)'VmV3AG^

Equation 1.7

A graphical representation of the energy state for the nucleation is given in Fig 1.22. The initial
formation of nuclei increase the AG, until the critical radius r*, then nuclei grow and lower AG. It
is understood that as the temperature begins to decrease from the melting temperature (Tm), the
relative temperature differences are very small, since AG is proportional to the temperature
difference, then AG very small. However, as the temperature lowers, AG increases, thus
decreasing the critical radius. Eventually, the r* becomes very small, and nuclei will begin to
form in detectable quantities.
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Figure 1.22: (a), The net energy with respect to the critical radius 1195] (b), representation of the energy changes
needed in a system in order for nucleation [196]
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The kinetic barrier for nucleation, AGd, is related to how fast the material moves to the surface
of a growing nucleus and is expressed as a diffusion coefficient:
D = (kTr/h)exp(-AGD/kT)

Equation 1.8

Where:
X,

is the atomic jump distance,

h, is Planck’s constant,
k, is the Boltzmann constant.
The diffusion coefficient is related to the viscosity of the melt (q) by the following relation:
D = kT/3/iTi

Equation 1.9

Using the relations given by Equations 1.8 and 1.9, and the following expression can be obtained:
exp (-AGiykT)= h/STiX^q

Equation 1.10

Substituting Equation 1.10 into the Equation 1.4, the nucleation rate (1) can be determined by
following equation:
= (Ah/37i;i^Ti) exp (-W*/kT)

Equation 1.11

This expression indicates that increasing the viscosity (q) will decrease the nucleation rate.
However the viscosity is highly dependent on the temperature, thus the kinetic barrier to the
nucleation will increase rapidly with decreasing temperature.

1.3.2.2 Crystal Growth
Crystal growth is the second condition for crystallization. It includes a kinetic barrier due to
diffusion and a crystallization energy driving force (AG) due to the free energy of a particle in
the melt side being slightly higher compared to the free energy of the growing crystal [193]. Fig
1.23 illustrates the energy changes in the system for crystal growth.
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Figure 1.23: Representation of the energy changes needed in a system in order for crystal growth [196],

The rate of crystal growth (U) can be given by the following:
U = a<,v exp(-AE/kT)[ 1 -exp(AG/kT)]

Equation 1.12

Where:
ao, is the interatomic separation distance
V,

is the vibrational frequency.

Using the same theory as nucleation rate, and substituting Equation 1.10 with Equation 1.12, the
diffusion energy can be obtained as following:
U = (kT/3WTl)[l-exp(AG/kT)]

Equation 1.13

Once again if the viscosity is low, the growth rate (U) will be high. As the temperature decreases
the viscosity is increased, and thus decreases the growth rate, the diagram for growth rate (U)
verses temperature is similar to the nucleation rate (I) verses temperature, which exhibits a
maximum and finally decreases to zero.
The crystallization of a melt is driven by nucleation and crystal growth and the two phenomena
occur simultaneously during cooling of a melt. The temperature dependence of both can be
shown schematically as demonstrated in Figure 1.24. The metastable zone is used to describe
where the nuclei exist in the melts. Once the temperature passes below the lower level of
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metastable zone, the thermodynamic barrier will decrease with decreasing temperature. The
overlap between nucleation and growth rate mean the melts cooled faster than the nucleation and
crystallisation rates, thus the crystallization cannot be formed with the supercooling time, it is
glass forming tendency [183].

f
<7

Figure 1.24 : The rate of nucleation and crystal growth verses of temperature [196],

1.3.4 Bioactive Glass
Hench and his colleagues discovered that bone can bond chemically with certain glass
compositions. Those glasses are known as bioactive glass. A bioactive material being one '‘that

elicits a specific biological response at the interface of the material which results in the
formation of a bond between the tissues and the material’ [197]. Bioactive glasses have
numerous applications in the repair and reconstruction of damaged hard tissue. The nature of
such materials is heavily influenced by the structure and composition of the glass consequently,
an understanding of how the various elements of a glass affect its structure and properties is
necessary.

1.3.4.1 Composition of Bioactive Glass
The most studied bioactive glass is Bioglass® 45S5, which contains 45% Si02, 24.5% Na20,
24.5% CaO and 6% P2O5 percentage weight. This bioactive glass was generated from the ternary

71

Chapter 1. Literature Review

Si02-Na20-Ca0 diagram shown in Fig 1.25. The diagram shows the bioactive bonding of
compositions. In region A the bioactive glasses are able to bond to bone; in the middle of this
region i.e. the region S indicated with the green line the glasses are able to bond to soft tissue; in
region B glasses can be implanted but cause fibrous encapsulation. In region C glasses are
resorbable within 10 to 30 days in the tissue, and in region D the compositions have not been
implanted.

SiO^

B

A=B on e B on ding
B=Non-bonding (reactivity too low)
C=Non-bonding (reactivity too high)
D=Non-bonding (non glass forming)
S=Soft tissu bonding
E=Bioglass® composition

Glass Ceramics (variable P2O5)

CaO
Figure 1.25: Compositional diagram for bone-bonding. Note regions A, B, C, D. Region S is a region of Class A
bioactivity where bioactive glass bonds to both bone and soft tissues and are gene activating [198]

The structure of vitreous silica is described by Zachariasen (Section 1.3.1). Each oxygen atom is
shared between silicon atoms, which occupy the centers of the linked tetrahedral; disorder of the
network may be obtained by variability in the Si-O-Si angle connecting adjacent tetrahedra.
Glass containing less than 10% alkali are considerably more difficult to melt due to its high
viscosity, and sodium more than 33% extending to metastable immiscibity limit (Fig 1.23) [183].
The addition of alkali will occasionally break the network of Si-0 via the formation of non72
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bridging oxygen, and the non-bridging oxygen is associated with nearby alkali ions and
maintains a local charge neutrality. The concentration of non-bridging oxygen is proportional to
the concentration of alkali oxide in the glass. The consequence of the addition of network
modifiers is a decrease in network connectivity, reduction in the melting temperature, viscosity
and glass transition temperature concurrent with an increase in the thermal expansion coefficient
[190, 199]. In addition, the glass becomes more reactive and degradable - a key feature in the
functionality of bioactive glasses.
Calcium is an effective network modifier and it has been shown that an equimolar concentration
of CaO replacing that of Na20 does not change the concentration of the non-bridging oxygen
within the glass structure. The consequence of this replacement however, may be a slight
increase in viscosity and the strength of the network. The addition of calcium oxide in the alkalisilica glass would significantly increase the viscosity of the glass. The early studies assumed that
P2O5

was required for a glass to be bioactive; however, it is now known that phosphate-free

glasses could bond to bone as well.

Figure 1.26: Schematic of a 2D structure for soda-lime -silicate glass [183].

The network connectivity of a glass can be used to predict various physical properties of the
glass, including its solubility and, hence, its bioactivity. By altering the bioactive glass
composition, the rate of resorption can be controlled [200]. Glass solubility increases as network
connectivity is reduced. Specific substitutions are known to have a more significance on a
structural level a highly disrupted glass network with a network connectivity value of 2.00 [201].
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The glass transition temperature and the peak crystallization temperature decrease linearly with
increasing sodium oxide content. The glass density also increases with the increase in sodium
oxide content due to the oxygen packing atom Na20 provided.
1.3.4.2 Bioactive Glass Surface Reaction
Upon the implantation of bioactive glass, a series of reactions take place on the surface of glass
facilitating its bonding to tissue. These reactions can be summarized in three processes: leaching,
dissolution and precipitation. Leaching is the process of cation releasing alkali elements from the
bioactive glass due to the active Na^, and exchange with

or H30^ ions of alkali elements. This

ion exchange process leads to an increase in interfacial pH. The rapid exchange of Na^ process
can be represented using a chemical reaction equation:
Si-O-Na^ +

+ OH' -> Si-OH" + Na^ (solution) + OH'

Equation 1.14

Network dissolution occurs concurrently by the breaking of Si-O-Si bonds via resulting in the
release of various cations from the glass and the formation of a silica gel layer at the surface of
glass particle. Since, the ion exchange is diffusion controlled; it is found that the depth of the
hydrogen penetration into glasses increases with square root of time of the exposure hydrogen,
thus the concentration of Na^ is also released with respect to the square root time.

The

dissolution of silica acid can be represented uses a chemical reaction equation:
2(Si-0-Si) + 2(OH) -> Si-OH + OH-Si

Equation 1.15

The first two processes reduce the intensity of the Si-O-Na and Si-O-Ca vibrational modes (as
observed using spectroscopy) and are replaced with Si-OH bonds. Alkali content is depleted to a
depth >0.5 fim within a few minutes [202]. As the reactions continue, the Si-OH single, NBO
modes are largely replaced by a new mode assigned to the Si-O-Si bond vibration between two
adjacent Si04 tetrahedra, corresponding to the silica-gel layer. Precipitation occurs via the
migration of Ca

and PO4 ' groups to the surface through the Si02-rich layer forming a CaO-

P205-rich film on top of the Si02-rich layer. Subsequently, an amorphous Ca0-P205 film
crystallizes by incorporation of OH-, or CO3 ' anions from solution to form a hydroxycarbonate
apatite (HCA) structure. The only common characteristic of the implant bioactive materials is
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the formation of HCA, which could bond with tissue, and the rate of tissue bonding is considered
to depend on the rate of HCA formation.
Hench [203] and colleagues summarizes a number of effects of glass composition and solution
composition on the kinetics of such reaction processes. The presence of Ca and P in a simulated
body fluid (SBF) accelerates the Si-rich layer formation and the formation of amorphous CaP
layer. In addition, the HCA crystallization rate increases as the content of Ca and P in the
solution composition increased. Such data has allowed the development of degradable
biomaterials, which intimately interact with host tissue. A prime example of such interaction is
the use of a bioactive glass as a bone graft.
1.3.4.3 Bioactive Glass Bonding to Bone
The in vivo bone regeneration study revealed that the bioactivity of the glass samples was
composition dependent. The bioactivity of Bioglass® (Class A Fig 1.25) leads to both
osteoconduction and osteostimulation^ as a consequence of rapid reactions on the bioactive glass
surface. The surface reactions involve dissolution of critical concentrations of soluble Si and Ca
ions that give rise to both intracellular and extracellular responses at the interface of the glass
with its physiological environment.
There is a sequence of 11 reaction stages that occur at the surface of a Bioglass® while it is
bonding to bone. Figure 1.27 indicates in log time the first five stages of surface reactions occur
very rapidly, as discussed in Section 1.3.4.2. The consequence of the surface reaction is a high
surface area-hydrated silica and polycrystalline hydroxyl carbonate apatite (HCA) bilayer on the
glass surface enhancing the adsorption and desorption of growth factors. From stage 6 onwards
cells interactions predominate, consequently, progenitor cells of the osteoblast lineage rapidly
attach to the HCA surface (Stage 7). At stage 8, the stem cells attached and begin proliferation.
At Stage 9, differentiation of the cells occurs on the surface of Bioglass®. At stage 10, the
progenitor cells colonize the surface of Bioglass® (within 24-48 h) and begin the production of
various growth factors that stimulate cell division, mitosis, and the production of extracellular
matrix proteins. At stage 11, mature osteocytes encased in a collagen-HCA matrix, are the final
product by 6- 12 days in vitro and in vivo.
’. The rapid regeneration of bone is due to a combination of processes called osteostimulation and osteoconduction.
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Figure 1.27: Sequence of interfacial reactions involved in forming a bond between bone and a bioactive glass [198].

1.3.4.4 Bioactive Glass as potential material for PNR
Composite materials combining bioactive glasses (BG) and polymers have been explored [204208]. PLGA does not possess sufficient mechanical strength and stability to support tissue
growth. However, adding BG to a PLGA base in the form of a BG/PLGA composite material
enhances mechanical and biological properties without compromising degradability [209, 210].
BG/polyhydroxybutyrate (PHB) composites [211], also demonstrate in vitro biocompatibility
for use in augmentation of peripheral nervous tissue Furthermore, the in vitro degradation rate of
this composite is decreased, thus allowing for improved stability of mechanical properties over
time [208, 212]. Such composites are found to exhibit a strong interaction with soft tissue [213,
214]. The literature also describes improved cell adhesion and proliferation (in vitro) for BG
doped polymers [209, 214], with in vivo results showing increased vascularisation versus control
materials. In summation, initial studies which have examined composites incorporating BG into
a biodegradable polymer at varying degrees exhibit [215]: (i) improved biocompatibility (ii)
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improved degradability, and (iii) improved mechanical properties. However, the bioactive
glasses under consideration have been limited to phosphate-based materials relating to the
original bioglass composition [213, 216]. An emerging philosophy in tissue engineering is to
develop materials that establish key interactions with cells in ways that unlock the body’s
inherent ability to self-repair. In this respect the investigation of new compositions of glasses
may enhance current state of the art approaches and build knowledge in the area of compositionstructure-property relationships where BG composites are leveraged for soft tissue repair. Thus,
the investigation of new bioactive glass compositions designed to mediate specific host
responses in specific applications is valuable, and may provide for improved outcomes in respect
of peripheral nerve regeneration.
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1.4

Therapeutic Ions

An attractive feature of glass-based biomaterials is the ability to incorporate constituent elements
into a glass melt, which can subsequently be released in vivo to provide for clinically beneficial
effects. In the case of conventional bioactive glasses phosphate and calcium provide for
enhanced bone bonding, whereas in dentistry, fluoride is frequently added to provide for
anticariostatic effects. However the list of potential therapeutic agents is extensive, and
additionally incorporates such elements as Strontium and yttrium. The following section will
focus on the key elements under consideration in this thesis.

1.4,1 The Physiological Role of Calcium
Calcium ranks fifth in the elementary composition of the human body just after oxygen, carbon,
hydrogen, and nitrogen, and it makes up 1.9% of the body by weight [217]. Ninety nine percent
of the body’s calcium is located in the skeleton. The remaining 1% is equally distributed between
the teeth and soft tissues, with only 0.1% in the extracellular fluid (ECF). The ECF contains (4550%), active form, ionized calcium at about 1.20 mmol/1 (48ppm) maintained by the parathyroid
- vitamin D system as well as complexed calcium at about 0.4 mmol/1 (16ppm) [218]. In plasma,
there is additional protein-bound calcium in the form of calcium phosphate, bicarbonate and
citrate with calcium concentration of 0.8mmol/l (32ppm) [218]. In the cellular compartments the
total calcium concentration is comparable with that in the ECF, but the free calcium
concentration is lower by several orders of magnitude [219]. The role of calcium in biological
systems is very important, it is a fundamental element for skeletal mineralization, blood
coagulation, neuromuscular conduction, maintenance of normal tone and excitability of skeletal
and cardiac muscle, stimulus secretion of exocrine glands and preservation of cell membrane
integrity and permeability, particularly in terms of sodium and potassium exchange.
Calcium has numerous functions e.g. the presence of ions in a complex intracellular messenger
system is well known (Fig 1.28). Calcium mediates a wide range of biological processes, such as.
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Figure 1.28: Condensed overview of the interaction of Ca^^ with intracellular proteins [220]

muscle contraction, secretion, glycolysis *and gluconeogenesis^, ion transport, cell division and
growth. The release of calcium from the sarcoplasmatic reticulum of the muscle cells stimulates
and triggers the muscle [220]. Also, the present of calcium actives numerous secretion processes,
such as, insulin release from the |3 cells of the pancreas [217]. Calcium also acts as a blood
coagulation factor, participation in the blood coagulation system and the stabilisation of cell
membranes {via formation of a complex compound with phospholipids and/or phospholipids)

Before glucose can be converted into ATP, it has been broken down into two pyruvate molecules (the ionized form
of pyruvic acid). This process is known as glycolysis.
^ The process to generate glucose from non-carbohydrate carbon substrates, such as, lactate, glycerol
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[218]. Furthermore, calcium is an enzymatic co-factor; it regulates some key enzymes in
cooperation with the specific polypeptide calmodulin. With respect to the skeleton formation,
calcium favours osteoblast proliferation, differentiation and extracellular matrix (ECM)
mineralization [221]. At the cellular level, Ca plays a binding role in the complex
polysaccharides and proteins forming the cell wall and cytoskeletal functions in the outer cell
membrane [221 ]
The fluxes of Ca^^ ions and their regulation in higher organisms, as well as in microorganisms,
depends on several transport proteins in addition to vesicular and gated processes. An important
class of transport proteins is the Ca^^ ATPases, which are particularly abundant in muscle cells.
The major pathways for Ca^^ transport across cellular membranes involve three membrane
systems: the plasma membrane, the inner mitochondrial membrane, and the membrane of the
endoplasmic reticulum (ER) (or, in striated muscle cells, a specialized form of ER called the
sarcoplasmic reticulum (SR) [220].
Two of the membrane bound transport systems are Ca ATPases, the schematic mechanism of
Ca^^ transport is presented in Fig 1.29.The two stages of the transport protein are summed to be
"24El and E2. Staring from (a)-bonding of Ca and ATP, (b)-rapid phosphorylation of Asp-351 of
protein El and release of adenosine diphosphate (ADP), (c)-transformation from an energy-rich,
high Ca^^, affinity conformation (Ei) to a low energy, low affinity conformation (E2), (d)hydrolysis of the phosphorylated protein and release of the phosphate into the lumen; (e) return
to the original state. [218].
2Ca^"

ATP(lnM)

ADP(50^M)
ADPP

ATP
E , (Ca^ ‘

E.

E,'(Ca2-),
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Figure 1.29: Schematic reaction cycle of the Ca^^ ATPase of sarcoplasmic reticulum (SR) [220].
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1.4.2 Voltage-gated Calcium Channels and Na7Ca^^ Exchanger
In addition to the transport pathways already discussed, some cells seem to have Ca^^ channels in
the plasma membrane that can be opened by the action of an agonist on a receptor or that are
gated in response to changes in membrane potential [222]. Voltage-gated calcium channels
(Vgcc) are multisubunit, macromolecular machines that control calcium entry into cells in
response to membrane potential changes. Vgcc play a unique role in the interplay between
electrical and chemical signaling in biological systems. Vgcc possess self-regulatory
mechanisms which permit them to change their behaviour in response to activity, including
voltage-dependent

inactivation,

calcium-dependent

inactivation

and

calcium-dependent

facilitation. Vgcc respond to membrane depolarization by opening calcium-selective pores [223].
Calcium ion entry causes further membrane potential changes and, because calcium ions act as
chemical messengers, may also ignite intracellular signaling cascades. As one of the principal
sources of calcium in excitable cells, Vgcc are under intense pressure to control calcium influx
and to detect and respond to changes in intracellular calcium concentrations [223]. Many
different biological processes in eukaryotic cells are regulated by intracellular Ca^^ concentration
levels.
The NaVCa^^ exchanger of membrane transporters is widely distributed in cells and tissues.
Multiple Ca^"^ regulated processes within these cells are not all indiscriminately activated
simultaneously. The amount of Ca

sequestered in the stores, and thus potentially available for

release during cell activation, is largely dependent on [Ca^^]i*^(rest) An additional critical feature
of Ca

metabolism is its slow diffusion in the cytosol [224]. It is possible to generate local

increases in [Ca ]>, and local responses, without having to raise [Ca ].throughout the cell [225].
This is energetically important because only limited energy expenditure is then required to
remove this “local” Ca^^ from the cytosol. The NaVCa^^ exchanger, which operates in parallel
with the Ca^^ selective channels and the ATP-driven Ca^^ pump [226]. The NaVCa^^ exchanger
can move Ca either into or out of cells, depending on the net electrochemical driving force on
the exchanger. Interestingly, this driving force, and thus the net Ca^^movement mediated by the
exchanger, may change direction during a cell’s activity cycle, when the membrane potential (Fm)
varies and/or when the cytosolic Na^concentration ([Na^].) or [Ca^^]. is altered. Take neurons for
i, intercellular
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example, direct regulation of the NaV Ca^^ exchanger by nontransported ions can be expected to
alter the kinetics of exchange by either increasing or decreasing both Ca^^ influx and efflux. In
contrast, modulation of the Na^ pump can be expected to promote either Ca^^ influx or efflux, by
altering the electrochemical driving force on the exchanger [227]. Thus one can envision the
need for upregulation of the exchanger in neurons following a burst of activity, when simply
increasing the JmaxOf the exchanger will help to extrude Ca faster. Conversely, when increased
cellular responsiveness is required, increasing plasma endogenous ouabain-like compound
(EOLC) levels may reduce, and thus increase the amount of “signal Ca^^” stored in the SR/ER
[226].
Exchanger expression levels in neurons are very high, especially in regions where calcium
channels are found at high density at synapses and at growth cones [228], and inhibition of these
channels interferes with neurotransmitter release. Ca^^ entry via the exchanger contributes
significantly to the triggering of transmitter release, even in depolarized neurons. Thus the
primary role of the exchanger in the neurons is in Ca extrusion following activity; the important
constituent of the exchanger is to helps regulate resting [Ca ]. (in quiescent cells) and extrusion
store content (since the ER stores are a source of Ca^ for modulation of transmitter release;
[229]). Moreover, especially after repetitive firing, when [Na^]iand [Ca^^].may both be elevated,
the subsequent release of transmitter may be altered depending on how fast the various Ca^^
buffering by cytosolic proteins, extrusion via the exchanger and PMC A pump, and sequestration
in the ER can restore the normal resting [Ca^^]. and Ca^^ balance [230]. Many observations
indicate that release is modulated by the Na^gradient [229].

1.4.3 Calcium Signalling in Neurons
Calcium ions serve as second messenger signals that directly or indirectly regulated actions in all
neuronal functions [231]. The phenomena of rapidly (milliseconds) trigger transmitter release at
presynaptic terminals to essential changes in gene expression required a second massager action
of Ca^^ within neuron [231]. These functions are achieved through spatial localization of calcium
signals. Local calcium signaling is especially prominent at presynaptic active zones and
postsynaptic densities, structures that are distinguished by highly organized macromolecular
arrays that yield precise spatial arrangements of calcium signaling protein [232]. Understanding
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of local Ca

signaling begin with a consideration of the spatial gradients associated with the

movement of Ca^^ within neuronal cytoplasm. This movement arises from the passive entry of
Ca^^ through permeable membrane channels and the subsequent diffusion of Ca^^ forms away
from these sources and into the cytoplasm. Such diffusion is limited by homeostatic mechanisms,
such as, cytoplasmic buffers_membinding pumps and carriers, which affect the time course and
magnitude of the Ca^^ signal. Diffusing Ca^^ ions encounter Ca^^ binding effect or proteins,
which we will call Ca^^ sensors, and the binding of Ca^^ to these sensors ultimately is
responsible for the activation of physiological processes [233]. These different geometric
relationships have great impact upon the magnitude and time course of the Ca^^ signals that are
present at a Ca^^sensor. While the mathematics of Ca^^diffusion can be complex [234], the basic
rule is that the distance between Ca

sources and Ca sensors is all important: the speed and

■yi

magnitude of a Ca signal is inversely related to this distance.
A

Nanodomain

D

Dendritic segments

10 (xm

10 nm

Radial gradients
B

Microdomain

200 nm

C

Dendritic spine

0.5 M-in
Figure 1.30: Multiple spatial dimensions of neuronal Ca^^ signalling (Colour scheme: light green-plasma membrane;
dark green-synaptic vesicles; blue-ca signals; red-Ca channels) [235]
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As illustrated in Figure 1.30 (A), Nanodomain*’ arise from Ca^^ diffusing from a single open
Ca^^ channel and triggers the fusion of a synaptic vesicle, (B) Microdomains*^ arise from spatial
overlap of Ca^"^ contributed by the multiple channel of Ca^^ (C) Dendritic spines can
compartmentalize Ca^^ from the rest of the dendrite, (D) Ca^^ signal can be restricted to
segments of a dendrite, (E) Cell-wide radial gradients of Ca

arise from long-distance diffusion

2+

of Ca

In practice, the calcium signaling and control of dendritic development have been extensively
study based on experiment using calcium channel blockers, calcium ionophores, and
depolarizing agents such as elevated potassium. Schubert et al. [236] first implicated calcium in
the regulation of neurite outgrowth, and Elinas [235] to suggest that intracellular calcium plays a
major role in regulation of growth con motility and neurite outgrowth. Calcium signaling in
growth cone migration has investigated by Bolsover [237],

the results found was calcium

signals is calmodulin dependent protein kinase II (CaMKII). Repulsive cues generate spatially
and temporally more diffuse calcium increases that can be more readily detected using
fluorescent indicators. Furthermore, experiment carried out by Yangji Wu found CaMKII
overexpression stabilized dendritic structure in more mature neurons, whereas CaMKII
inhibition increased their dendritic growth [238]. direct evidence for nanoscale coupling of Ca^^
influx and downstream signaling mechanisms was shown in auditory hair cells [239]. Other
studies also demonstrates that calcium transients in growth cones in vivo are a major determinant
of axonal extension rates and provide for growth cone guidance [240-242]. Mattson and Kater
[243], and Millisi [244] data have shown that the dose-dependency of the effects of Ca2+
channel blockers on outgrowth revealed that specific, low concentrations of Ca^"^ channel
blockers (e.g., 10' M La ) caused, simultaneously a reduction of growth cone filopodia and an
acceleration of elongation; when there are optimum levels of Ca

influx that promote normal

neurite elongation and growth cone movements; these 2 components of outgrowth appear to have
differential sensitivities to Ca .

The relationship exists between intracellular calcium and

growth cone behavior was controversial even in. For instance, addition of inorganic calcium
* * The unitary
signal is a nanodomain caused by the influx of Ca^^ though a single Ca^^ channel. Indeed, the
Ca^^ sensor must be located no more than 50 nm from the Ca^^ channel.
The microdomain require Ca^^ sensor that is placed within a fraction of micrometer of the Ca^^ channel cluster to
allow detection of the imaging of Ca^^ signals.
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channel blockers to the growth medium as reported to inhibit neuiThis inhibition could be
reversed by moderate increases in extracellular calcium levels. Thjggestion that outgrowth
requires an optimal level of extracellular calcium for individual neuiof a neuronal population,
which have been studied by [245]. However, within the relatively d population of neuronal
types comprising the buccal ganglion of Helisoma, second messenj within different neurons
can act and interact in different ways to regulate outgrowth, ich makes the optimal
concentration of calcium is difficult to achieve.

1.4.4 The Physiological Role of Zinc
Zinc is the second most prevalent trace element in the body. The totady zinc content has been
estimated to be 30 mmol (2g) [246]. Skeletal muscle accounts for roximately 60 % of the
total body content and 30% in bone mass with a zinc concentratioi 1.5-3 mmol/g (100-200
mg/g)

[247]. Zinc plays critical roles in protein structure, enatic activity, and gene

regulation [248, 249]. Zinc is an essential component of over 300 ernes [250], where it can
interact with electronegative sulfur, nitrogen, and oxygen moietin multiple coordination
geometries serving catalytic and structural roles in maintaining ac peptide conformations
[249, 251]. Consequently, Zn impacts on a variety of cell processe^luding DNA synthesis,
cell proliferation and cell differentiation, influencing normal growirain development, bone
formation and wound healing [247]. In addition. Zinc is most known ts ability to stabilise the
molecular structure of cellular components and membranes and teins involved in gene
regulation in domains called zinc fingers, zinc clusters, and zinvists [252]. Since Zinc
involved in so much important role, the deficiency of zinc mest in multi-system of
dysfunction, such as growth failure, skin bone maturation, skin lesionc. [253]
Zinc also plays a central role in the immune system, affecting furn affecting both innate
immunity*^ and specific immunity*'^ [254]. One of the main compo; of the innate immune
system are natural killer (NK) cells, which is acting against tumours cells infected by viruses.
13

The innate immunity as the first line of defense represents a natural protection ag infections.

Specific immunity is also known as adaptive immunity or acquired immunity acti passive, normally comes
into play when innate or non-specific immunity can't handle the problem. This formnmunity is a more recent
evolutionary development than innate and is distinguished by its specificity for an iing organism and for its
ability to remember (anamnesis) an encounter so that the second time the same orga or invader is encountered a
more rapid and intense response can occur.
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(NK)cell activity, and phagocytosis of macrophages and neutrophire impaired by decreased
zinc levels [254, 255]. It was shown that zinc is involved in the de'pment of T lymphocytes
(T cells) in the specific immune system, thus influence humoraimune response and its
deficiency effect is associated with thymic atrophy [256]. Zinc aregulates the function of
mature T cells in the periphery and cytokine release by periphenlood mononuclear cells
(PBMC) [255]. Literature reveals that zinc deficiency leads the reduction of T-cell
proliferation decreases after mitogen stimulation [256].

Howevthe optimal therapeutic

dosage that is required. Since over dosage of zinc could cause nega side effects on immune
functions. Zn has been shown to play a role in the physiological suppion of apoptosis through
a direct effect on apoptotic regulators including the caspase family ozymes [257]. Therefore,
zinc plasma levels should not exceed 30 mmol of zinc/L (1.95ppm58]. On the other hand,
pathogens for proliferation decrease plasma zinc levels during an s phase in infection is a
defense mechanism of the human organism [255].

1.4.5 The Role of Zinc in Nerve System
Besides the structure and function of proteins. Zinc is also critical modulation of neuronal
activity with content of ~150 pM [246]. Zinc-dependent enzymes iproteins are involved in
brain growth and function [259]. Zinc is present in pre-synaptic ner\‘rminals by the neuronal
specific zinc transporter 3 (ZnT3)'^. Zinc released from pre-synapti«urons has few effect on
post-synaptic. Zinc is a potent inhibitor of NMDA receptors'^ [260]. c can potentiate glycine
receptors at submicromolar concentrations and inhibit them at sullimolar concentrations
[261]. In addition zinc can modulate ionotropic pathways; synaptic ; has also been reported
regulate metabotropic activity [262]. However, since the exact amide and time course of
synaptic Zinc remain unclear, the functional importance of vesicizinc is yet to be fully
established. The consequence of decreasing zinc availability in neurc that the modulating of
neuronal proliferation and the triggering of neuronal apoptosis [263].

^ The interrelationship between zinc and metallothionein (MT) is also regulated by.pecific proteins named zinc
transporters
NMDA receptor is a glutamate receptor, is the predominant molecular device for rolling synaptic plasticity
and memory function.
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Despite relatively high zinc content in the brain, the extracellular zinc concentration is normally
below 500 nM and the intracellular “free” zinc is less than 1 nM. [253]. Recent evidence
suggests that Metallothionein (MT) play a major role in regulating intracellular zinc homeostasis
by binding, releasing, and distributing zinc. Since the release of zinc by MT contributing to raise
the intracellular free zinc concentration plays a crucial role in modulating the production of proinflammatory cytokines and in the activation of immune cell [264]. In this context, the two
transporters families (ZnT and Zip) appear to have opposing roles in Zn^^ homeostasis. The ZnT
family decrease the cytoplasmic zinc concentrations by secretion, sequestration, or efflux, where
the Zip family increase the cytoplasmic zinc influx, or release of stored zinc [265]. This suggests
that zinc plays an important role in coordinating the expression of proteins involved in
intracellular zinc homeostasis. Recent studies also suggest that zinc entry through Ca^^ channels
contributes to the accumulation of the metal following ischemia [264]. Zn^^ is also known to
enhance wound healing.

It is thought to promote tissue repair and regeneration through its

involvement in re-epithelialisation and the synthesis of granulation and scar tissue [266].
Beside the well known effect on neuron, experiments have also assessed the zinc affect of zinc
on Schwann Cell (SC), and myelination in PNS was carried outs by Garbay et al. [267]. In detail,
Garbay have compared gene expression of normal mouse sciatic nerves to that of the trembler
mouse, whose SC were blocked in a pre-myelinating phenotype using delta-like protein (dlk),
resulted in dlk expression was down-regulated when myelin protein expression was up-regulated,
and no expression was observed in the developing brain. These results suggest that dlk
expression is required for Schwann cell acquisition of the myelinating phenotype. Further
investigation was done for Zinc finger protein of 55kDa and 29kDa instead of dlk, and similar
results was found. The results revealed the myelin molecules, which except for proteins
expressed at the very early stages of PNS development, and29 kDa protein (an anti-zinc finger)
is more expressed in the Trembler than in normal nerves [268]. Mechanisms of PNS development
by these proteins are not well characterized, but are believed to be mediated by Zinc finger protein or
its symporters, this sheds a new light on the mutant pathology, and may help elucidate and
enhance important steps in PNS myelination and PNR.
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1.4.6 Zinc Ion from Biomaterials
The biological response to artificial materials depends on many parameters such as chemical
composition, topography, porosity and grain size. In the context of tissue engineering application,
the potential biological role of Zn incorporation in biomaterials is focused on the Zn^"^ release
kinetic of the material and the specific effect of the released Zn^^ dissolution products on human
cell behaviour.
With respect to the surface reaction, it is important to control Zn

releasing rate in order to

prevent adverse reactions and to optimize the glass composition to reduce glass degradation
without affecting HA deposition [269]. The atomistic models obtained by Aina et aL, [270]
show that Zn is tightly trapped into the silicate network; in fact it copolymerizes with the Si
tetrahedra, causing an overall complexation of the network with respect to the Zn and Na ratio in
the bioglass [269]. Since, the electrostatic attraction exercised by the excess of negative charge
on the (Zn04)^"tetrahedral restrains further the Nations mobility. Therefore, the high percentage
of Zinc present in the bioglass (e.g., 20%) would decrease the solubility of the material, and alter
the surface chemical-physical characteristics, hence reducing the cell ability to adhere to the
surface [271]. Zn is also known to affect the mechanical properties of certain biomaterials.
Ramaswamy et al, incorporated Zn into a Ca-Si system (Hardystonite Ca2ZnSi207), leading to
increased bending strength and fracture toughness [272].

It is also known that zinc is a

constituent of the denture adhesive as a cross-linking agent to promote adhesion [273].
Zinc is known to play an important role in bone formation [271] and to have anti-inflammatory
effects

[274],

and

increases

ATPase

activity,

regulates

transcription

of osteoblastic

differentiation genes, e.g. collagen I, ALP, osteopontin and osteocalcin [271]. Zinc released from
bioglass has been shown to enhance acellular formation of calcium phosphate layer on the BG
surface after soaking BG substrates in biological fluids (Dulbecco’s Modified Eagle’s Medium,
DMEM), this is due to the surface area of the material is changed by Zinc [151]. Zn^"^ with
organoapatite (ZnOA) subsequently coating it on the surface of titanium mesh substrates have
been investigated to lead to the earlier onset of biomineralization and increased ALP activity in
pre-osteoblastic cells in vitro [275]. The incorporation of Zn

in biomaterials has also exhibited

anti-inflammatory effects. HA particles are known to induce inflammation and zinc-substituted
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HA has displayed anti-inflammatory effects on human polymorphonuclear cells (PMNs) [276]
and monocytes [277]. It has been evidenced that Zinc supplementation significantly decreased
the number of eosinophils and other inflammatory cells in the BAL fluid of OVA-treated mice
[274]. Although, Zinc is proven have an anti-inflammatory effect of the Zn-doped glasses
compared to the undoped control glasses [278, 279], the mechanism involved are not clear. On
the other hand, the high concentrations of Zn (up to 16 ppm) released into the cell medium being
toxic for cells. Zn concentrations in the range of 28 ppm can cause damage in human osteoblasts
via oxidative stress [280].
A primary advantage of the use of bioglass materials to fullfil clinical requirments is their ability
to trigger specific host responses by virtue of their degradation and contiguous release of
therapeutic dissolution by-products [281]. Consequently, the investigation of tailored bioactive
glass compositions designed to release specific degradation (Ca and Zn) products to mediate
specific host responses in nerve regeneration is a valuable approach to the clinical challenge of
peripheral nerve repair, and may yield significant improvements in NGC device design.

1.4.7 Bioglass Contents Therapeutic Ions
Consequently, the glass system which contains Zn^^ and Ca^^ may be of interest. This multicomponent system comprises ions that are known to have therapeutic effects on peripheral nerve
regeneration; as such the release of degradation products from such glasses in vivo may facilitate
a beneficial host response not seen in conventional BG composites for this indication [183, 282,
283]. Specifically, achieving optimal level of intracellular calcium within a NGC may promote
normal neurite elongation and growth cone motility [233, 237, 240-243, 284, 285]. Experiments
conducted to alter the intracellular calcium level by addition and reduction of the calcium
ionphone A23187of cultured chick dorsal root ganglia [286] demonstrated that calcium can act
as a regulator of actin filaments in living cell. Further investigations pertaining to the influence
of calcium on the growth cone behaviour in xenopus embryos have been carried out by Gamez
and Spitzer and demonstrated the importance of Ca^^ on growth cone guidance [240]. The
literature demonstrates that calcium transients in growth cones in vivo are a major determinant of
axonal extension rates and provide for growth cone guidance [240-242]. Thus, release of Ca^^ at
level s appropriate to mediate such responses may be beneficial with respect to design and
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performance of a NGC. Synergistically, the Zn

2^"

•

ion also has specific applicability to peripheral

nerve regeneration. There is a growing awareness that zinc plays a role as a signaling substance
through the body [248], in particular zinc ions are liberated to the synaptic space during normal
neuronal activity. The physiological significance of zinc as a modulator of neuronal excitability
in toad olfactory epithelia has been evaluated by Felip et a/.[287]. Felip found that at low
concentrations (0.065 to 3.27ppm) Zn^^ impacts on the opening kinetics of sodium channels (the
channel is voltage gated: it opens in response to a small depolarisation of the cell [14]) without
altering the closing kinetics and induced a concentration dependant increase in the neuronal
firing rate. In contrast, at higher concentrations of Zn^^ (6.5 to 32.7ppm), inhibited sodium and
delayed rectifier-type potassium currents and decrease the firing rates were observed [287]. Zn^^
may also act to inhibit bacterial growth and may facilitate multiple therapeutic effects, such as: (i)
neural growth [288],(ii) inhibited bacterial growth at the surgical site [289], and (iii) improve
wound healing [290]. Therefore its inclusion in the BG component of a NGC composite may be
beneficial.
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1.5

Rational of the Research Program

The regeneration of peripheral nerve fibers between the proximal and distal ends of a
peripheral nerve discontinuity remains a critical challenge in the field of neurosurgery [291].
After an extensive review on the current state of the art in peripheral nerve repair (Section 2),
the criteria for producing optimum NGCs is proposed, as being based upon its level of (i)
biocompatibility, (ii) biodegradability, (iii) semi-permeability, and (iv) have a supportive
structure

with

sufficient

mechanical

properties.

Composite

materials,

comprising

bioresorbable polymer matrices impregnated with bioactive glass fillers, have attracted
attention in soft tissue engineering; such composites offer exceptional potential for tailored
physical, biological and mechanical properties [292-295]. A primary advantage of the use of
bioglass materials in such composites is their ability to trigger specific host responses by
virtue of their degradation and contiguous release of therapeutic dissolution by-products
[281]. Consequently, the investigation of tailored bioactive glass compositions designed to
release specific degradation products to mediate specific host responses in nerve regeneration
is a valuable approach to the clinical challenge of peripheral nerve repair, and may yield
significant improvements in NGC device design [296-298]. The Silicate-Sodium-CalciumZinc-Cerium (CNG) glass system has been considered for this application; where such
glasses comprise 50% mol. fraction Si02 to achieve a

structure for bonding with soft

tissue with additions of NaO to facilitate dissolution [297]. CaO and ZnO are included in
such compositions on the basis that integrating Ca

into the local environment of a

regenerating nerve regulates turning (guidance) and extension of the growth cone [299, 300];
while the inclusion of zinc (Zn ) in such biomaterials has been shown to increase
antibacterial efficacy [301-304] and it is also an essential component for effective immune
system and wound healing mechanisms [304]. In respect of cerium (Ce'^^) it has been shown
that this oxide is capable of protecting nerve cells from oxidative stress [305] and as such
may have neuroprotective capabilities.
This objective of this project was to perform a preliminary evaluation of the compositionstructure-property relationships for a unique composite nerve grafts based on a degradable
PLGA/ Pluronic FI 27-glass composite material for repairing defects in the peripheral
nervous system. Such composites will be synthesized using a bioglass specifically designed
to release therapeutic ions to help regenerate a peripheral nerve. In order to achieve this
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objective a rational and systematic approach was adopted. The research has been carried out
as follows:

1.5.1 Synthesis and Characterisation of Glass Compositions
Three glass compositions were designed, synthesised with incremental additions of Na for Zn
such that the impact of substitutions may be controlled to tailor ion release from the glasses.
To evaluate the composition-structure relationships of these materials the glass structure and
resultant properties for glass particles >45 pm were evaluated. Each glass was characterised
using XRD (X-ray diffraction), Differential thermal analysis (DTA), and ^^Si MAS-NMR
(Magic Angle Spinning - Nuclear Magnetic Resonance Spectroscopy). In addition,
experimental data was cross referenced with theoretical stmcture as derived from the
Network Connectivity (NC).

1.5.2 Quantification of Therapeutic Ion Release
The specific surface area of each glass was determined using BET; the research project
quantified the Ca^^ and Zn^^ release from three glasses (CNG1-CNG3), using AAS (Atomic
Absorption Spectroscopy) and Inductively Coupled Plasma Mass Spectrometry (ICP-MS).
Therapeutic ion release profiles were recorded as a function of incubation periods over 1, 3, 7,
and 30 days under normal and extreme physiological conditions to evaluate the relationship
between degradation properties and the glass structure, therefore found the optimum ion
release profiles in order to function effectively as peripheral nerve grafts.

1.5.3 Evaluation of Cytocompatibility
In order to examine the biocompatibility of the glass component, each glass compositions
was examined using cell culture testing, as per ISO 10993-5. Extracts of each glass were
^

'y

produced by exposing Im glass powder to a fixed volume of sterile tissue culture water.
Extracts were prepared based on 1, 3, 7 and 30 day exposures.

Cell viability following

exposure to each extract was examined using L929 mouse fibroblast cells and the MTT assay
technique.
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1.5.4 Synthesis, and Investigate of the PLGA/F127 Conduits
The impact of the poloxamer FI27 was evaluated by synthesizing glass free NGCs
comprising 1% additions of FI27 (range 0-5%) into a 20wt% PLGA base via precipitating
methods. The Young’s modulus of the five conduits was evaluated as a function of
incubation time (1, 3, 7, 14, and 28 days) and compositions. The effect of FI27 to the
mechanical property of the conduits was examined.

1.5.5 Design and Synthesis of the PLGA/Fl27-glass Conduits (CNGCs)
Based on the cytocompatibility work for the CNG glasses, the best performed glass have
been chosen for the following experiments. Sixteen CNGCs comprising PLGA (5, 12.5, 20
wt. %), the polaxomer: Pluronic FI27 (0, 2.5, 5 wt. %) and CNG glass (0, 20, 40 wt. %) was
design via Design Experts Software in order to evaluate the interaction effect of each element.

1.5.6 Evaluation of Mechanical Properties and Cytocompatibility of
CNGCs
Ba.sed on the Design Expert results and the formation of the Sixteen CNGCs, six CNGC
compositions were carried on for the following experiments. The Wet-State mechanical
properties of the six CNGCs were explored as function of incubation time (1, 3, 7, and 28
days)., and compared to a state-of-the-art control (Neurolac®). Furthermore an analysis of the
cytocompatibility of experimental compositions with compared with the commercial product
Neurolac over incubation periods of 1, 3, 7, and 28 days.

1.5.7 Quantification of Ion Release from CNGCs
Based on the performance of the original sixteen CNGCs, Six CNGC (grouped by 20wt%
and 40wt% glass groups) were selected for additional analysis comprising ion release from
each CNGC composition over incubation periods of 1, 3, 7, and 28 days. The Si'^^, Na^, Ca^^’
and Zn

release of glass from six CNGCs was measured using Inductively Coupled Plasma

Mass Spectrometry (ICP-MS).

93

Chapter 2. Materials and Methods

Chapter 2; Materials and Methods

2.1 Glass Design, Synthesis and Characterizations
2.1.1 Glass Design and Synthesis
The Silicate-Phosphorus-Calcium-Zinc-Cerium glass system were designed with increased of
phosphorus corresponding to decreased Calcium percentage (Table 2.1) or with increased of
phosphorus corresponding to decreased Cerium percentage (Table 2,1). However, those new
glass compositions have formed stone like crystal not glass. Thus those glass compositions have
been disproved for use in tissue regeneration, since amorphous glass structure is to bond to tissue
as discussed in Section 1.3.
Table 2.1: Composition of the bioglass (mol. fraction).

Glass ID

Si02

P2O5

CaO

ZnO

Ce02

CNGl

0.4

0.14

0.2

0.13

0.13

CNG2

0.4

0.19

0.15

0.13

0.13

CNG3

0.4

0.24

0.1

0.13

0,13

CNG4

0.4

0.14

0.13

0.13

0.2

CNG5

0.4

0.19

0.13

0.13

0.15

CNG6

0.4

0.24

0.13

0.13

0.1

CNG7

0.4

0.15

0.15

0.15

0.15

The Silicate-Sodium-Calcium-Zinc-Cerium (CNG) glass system were designed with increased
of Sodium corresponding to decreased Cerium percentage as illustrated in Section 1.5. The
highest Cerium content glass composition is content 13% of Cerium, since the more cerium
would produce more forms on the top of the container during glass heating process. Therefore,
three glass compositions (Table 2.2) were designed and synthesised.
Glasses were prepared by weighing out the appropriate amounts of analytical grade silicon
dioxide, calcium carbonate, zinc oxide, sodium carbonate and cerium oxide (Sigma Aldrich,
Wicklow, Ireland) into a plastic container. Each formulation was thoroughly mixed by shaking
in the closed container for 30 minutes. Compositions were then fired (1520°C, 1 hour) in
platinum crucibles (Johnson Matthey, Ireland) and the glass melts shock quenched into water
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(Figure 2.1). The resulting frit was dried (120°C, 1 day) ground using a Gyro-mill and tungsten
carbide grinding dish (Glen Creston Ltd, UK) and then sieved to achieve a glass powder with a
particle size in less than 45iLim for all subsequent analysis.
Table 2.2: Composition of the bioglass (mol. fraction).

Glass ID

Si02

Na20

CaO

ZnO

Ce02

CNGl

0.5

0.04

0.2

0.13

0.03

CNG2

0.5

0.09

0.2

0.13

0.08

CNG3

0.5

0.14

0.2

0.13

0.03

(a).

(b).

Figure 2.1: (a), Glass composition were placed in the furnace (b), Shock quenching of glass melts into water

2.1.2 Glass Characterisation
2.1.2.1 Differential Thermal Analysis (DTA)
DTA is a thermo-analytical technology for determination of melting point of a crystal, glass
transformation point, and crystallisation temperature of glasses by detecting the release or
absorption of heat, which is associated with chemical and physical changes in materials as they
are heated or cooled. The concept of DTA is quite simple, a differential thermocouple, which
consists of two identical thermocouples connected in the opposing polarities is place in a fiimace
in a position which allowed the bead of one thermocouple to be inserted into the interface of the
reference material, while the bead of another thermocouple is inserted into the sample. When
the sample material and the reference material are undergo identical thermal cycles; more or less
heat will need to flow to it than the reference to maintain both at the same temperature. Whether
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less or more heat must flow to the sample depends on whether the process is exothermic or
endothermic. Any temperature difference between sample and reference is recorded, and this
differential temperature is then plotted against time, or against temperature (DTA curve to
provide data on the transformations that have occurred, such as glass transitions, crystallization,
melting. The area under a DTA peak is the enthalpy change and is not affected by the heat
capacity of the sample. Therefore, a DTA curve can be used only as a finger print for
identification purposes.

heating
coi I

Figure 2.2: Schematic illustrate a DTA Apparatus [306]

The onset of the glass transition temperature (Tg) were determined using a combined thermal
analyser-thermal gravimetric analyser (DTA-TGA) (Stanton Redcroft STA1640, Rheometric
Scientific, Epsom, UK). Between 60 and 70 mg of each glass (<45pm) was heated in a platinum
crucible, A heating rate of 10°C min'' (up to 950°C)was used in an air atmosphere with alumina
as a reference in a matched platinum crucible. Sample measurements were performed every six
seconds. The Tg onset was determined graphically based on the onset point of the glass transition
endotherm. The tolerance of the DTA used in this work is 2%. [307].
2.1.2.2 X-Ray Diffraction (XRD)
X - Ray Diffraction (XRD) is a rapid analytical technology by which X-rays of a known wavelength
are passed through a powder sample to fully investigate its crystal structure and provide information
on unit cell dimensions. X-ray diffraction is based on constructive interference of monochromatic
X-rays and a crystalline sample. These X-rays are generated by a cathode ray tube, filtered to
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produce monochromatic radiation, collimated to concentrate, and directed toward the sample.
The interaction of the incident rays with the sample produces constructive interference and a
diffracted ray (Figure 2.3) Diffraction occurs only when Bragg’s Law is satisfied condition for
constructive interference (X-rays 1 & 2) from planes with spacing d.

X- 3.0

^

6-

-

Atomic planes
Figure 2.3: Bragg’s law and incident light diffraction [308]

Bragg’s Law:
nX,=2d sin 0

Equation 2.1

Where:
n is integral

X is the wavelength of the x-rays (X-=3A, in Figure 2.3)
d is the distance between different plane of atoms in the crystal lattice(d=3A, in Figure 2.3)
0 is the angle of diffraction (0=30”, in Figure 2.3)
The Bragg’s Law relates the wavelength of electromagnetic radiation to the diffraction angle and
the lattice spacing in a crystalline sample. These diffracted X-rays are then detected, processed
and counted. In detail, by scanning the sample through a range of 20 angles, the sample and
detector are rotated, the intensity of the reflected X-rays is recorded. When the geometry of the
incident X-rays impinging the sample satisfies the Bragg Equation, constructive interference
occurs and a peak in intensity occurs. A detector records and processes this X-ray signal and
converts the signal to a count rate which is then output to a computer monitor.
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X-ray diffraction (XRD) analysis was performed using a Philips Xpert MPD Pro 3040/60 X-ray
Diffraction (XRD) Unit (Philips, Netherlands) (Fig 2.4). Zero background nickel coated sample
holders were used for analysis of the <45pm glass particles with Cu ka radiation (at 40kV and 35
mA). Diffractograms were collected in the range 1O°<20<7O°, at a scan step size 0.00334° and a
step time of 59.69 seconds. Any crystalline phases present were identified using JCPDS (Joint
Committee for Powder Diffraction Studies) standard diffraction patterns using Xpert Highscore
plus software (Panalytical, US) [307].

Figure 2,4: The Philip Xpert XRD Unit and placed test sample

2.1.2.3 Specific Surface Area Determination
Brunnauer Emett Teller (B.E.T.) technique is using the absorption theory to determine the
specific surface area of a material. This standard method for measurement of specific surface
area is based on the physical adsorption of nitrogen (or helium) on the solid surface using the
B.E.T. method. The BET theory can predict multilayer adsorption, by calculating the rate of
adsorption and evaporation of gas molecules on an already adsorbed layer; therefore, it is
convenient for adsorption to mesoporous materials. As the pressure is increased during the B.E.T.
process, adsorption of a vapour (nitrogen) onto a solid surface occurs until the surface becomes
progressively coated with the adsorbate (the saturation pressure is achieved). The determination
of the surface area using BET theory requires the application of the B.E.T. Equation 2.2

V

1-P/Po

Where:
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V is the volume of gas adsorbed at pressure P
P is the gas pressure
PO is the saturation pressure of the gas
Vm is the volume of monolayer capacity
C is the related exponentially to the enthalpy of adsorption in the first adsorbed layer
A plot of 1/[V* (Po/P-1)] versus P/Po, will yield a straight line in the range 0.05< P/Po <0.35
Figure 2.3 with slope A Equation 2.3 and intercept, I Equation 2.4.
The slope A of the B.E.T. Linear plot:
A=

c-i

Equation 2.3

V™*c

7 he intercept of the B.E.T. Linear plot:
Equation 2.4
Solving Equations (2.3) and Equation (2.4) gives the monolayer absorbed gas quantity Vm and
constant C in term of A and 1,
The monolayer absorbed gas quantity:
Equation 2.5
The B.E.T. constant C:
C = 1+I

Equation 2.6

The total surface area (St) and specific surface area (S), of a solid material can be expressed as
the product of the number of molecules of adsorbate in a monolayer; the specific surface area
was calculated as per unit weight of the powder (m /g).
_ VmNs

•bet,total —
Sbet —

^total

Where:
N is Avogadro’s number
S is adsorption cross section of the adsorbing species
V is molar volume of adsorbate gas
A is mass of adsorbent (g)
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Figure.2.5: A plot of 1/[V* (Po/P-1)] versus P/Po for BET Techniques [309]

N2 adsorption/desorption was determined by Brunauer-Emmett-Teller (BET) measurements
using an ASAP-2010 surface area analyzer (Micrometries Instrument Corporation, Norcross,
USA) to determine the specific surface area (SSA) and porosimetry of the prepared glass
powders. Glass samples (~0.15g ± 0.05g) were placed under a nitrogen atmosphere at 77.35 K
with an equilibration interval of 10s.

2.1.2.4 Network Connectivity
The network connectivity (NC) of the glasses was calculated with Equation 2.9 [183] using the
molar compositions of the glass (see Table 2.2)

NC =

No.BOs-No.NBOs
Total No.Bridging Species

Where:
NC= Network Connectivity
BO = Bridging Oxygens
NBO = Non-Bridging Oxygens

100

Equation 2.9

Chapter 2: Materials and Methods

2.1.2.5 Magic Angle Spinning - Nuclear Magnetic Resonance (MAS-NMR) Spectroscopy
NMR spectroscopy is one of the principal techniques used to obtain physical, chemical,
electronic and structural information about molecules due to either the chemical shift. The
principle of NMR phenomenon is based on the fact that nuclei of atoms have intrinsic magnetic
moment and angular momentum that can be utilized to yield chemical information. Quantum
mechanically subatomic particles (protons, neutrons and electrons) have spin. In some atoms (i.e.
'^O,

the number of neutrons and the number of protons are both even, those spins are

paired and cancel each other out so that the nucleus of the atom has no overall spin. However, in
many atoms (i.e. H, C,

P,

Si,

F etc) the number of neutrons plus the number of protons is

odd, then the nucleus has a half-integer spin (i.e. 1/2, 3/2, 5/2), and the nucleus does possess an
overall spin. If the number of neutrons and the number of protons are both odd (i.e.’^^N), then the
nucleus has an integer spin (i.e. 1, 2, 3). These over spin quantum number refer as I. In quantum
mechanical terms, the nuclear magnetic moment of a nucleus will align with an externally
applied magnetic field of strength Bo in only 21+1 ways, either with or against the applied field
Bq. For a single nucleus with 1=1/2 and positive y, only one transition is possible between the
two energy levels. I’he nucleus has two possible spin states: the magnetic moment aligned
parallel with the applied field (spin m=+l/2) the notation is given as a, or the higher energy anti
parallel orientation (spin m=-l/2) is referred to as p rotation. The rotational axis of the spinning
nucleus cannot be orientated exactly parallel (or anti-parallel) with the direction of the applied
field Bo (defined in our coordinate system as about the z axis) but must process motion similar to
a gyroscope (in other ward, the number of atoms will be approximately the same in those two
states) about this field at an angle, with an angular velocity given by the expression;
(0o=y* Bo

Equation 2.10

Where:
coo is the precession rate which is also called the Larmor frequency
r is the magnetogyric ratio
Magnetogyric ratio (y) relates the magnetic moment p and the spin number I for a specific
nucleus:
y = 27ip/hl
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Each nucleus has a characteristic value of y, which is defined as a constant of proportionality
between the nuclear angular momentum and magnetic moment. Magnetogyric ratio (y) for

Si is

-5.319.
If an electrical current is applied to generate a magnetic field externally, electrons around nuclei
in a molecule generate their own magnetic field (internally), the lines of force (magnetic moment)
generated by this magnetic field will run in the opposite direction as the lines of force generated
by the external magnetic field Bo. This will reduce the net magnetic moment affecting the proton.
If the external magnetic field be greater or higher in order to overcome this opposition then an
NMR signal may be generated. This electronic magnetic field effect will cause protons with
different chemical environments to yield resonance frequencies perturbed from the frequency
defined by the applied external field Bq. In order to standardize the NMR scale it is necessary so
set a 0 reference point to which all protons can then be compared. The standard reference that
could be tetramethylsilane (TMS) or 2,2, dimethyl - 2 siIapentane-5-sulfonate sodium salt (DSS).
Those compounds have multiple CHs methyl groups single bonded to a silicon atom. All of the
protons on the methyl groups are in the same electronic environment. Therefore only one NMR
signal will be generated. Furthermore, the electronegativity of the carbon atoms is actually
higher than the silicon atom to which they are bonded. This result in the sigma electrons being
shifted toward the carbon atoms in the methyl groups and consequently, the protons will be
heavily shielded causing the one signal to be generated at a very high magnetic field strength
setting. It is that signal that all other NMR signals of a sample are referenced to. This association
with the reference signal is called the chemical shift. This shift is measured in parts per million
(ppm).
To investigated a solids (powder, crystal, polymers) chemical structure with a broaden peak the
Magic-Angle Spinning (MAS) technique is required. The concept of MAS is to reduce the peak
broadening by average the interaction time through dipole-dipole interaction (dipole coupling,
which is direct interaction between two magnetic dipoles). The condition for dipole coupling is
dipolar=0, therefore.
3*cos^0-l=O
Where: 9 is the rotating angle
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Thus, cos^0= 1/3

Equation 2.13

0 = cos-l(l//'3)
0 = 54.74° (Magic Angle)
Spinning the sample at the magic angle, averages anisotropic (chemical-shielding, dipolar, or
quadrupolar) interactions and leads with increasing MAS rates, to high-resolution spectra.
"^Si MAS-NMR was used to analyze the different glass samples at 7.05T using a Bruker AV300
NMR spectrometer (Bruker BioSpin, Germany) equipped with a BLMAS probe (4mm 0) and
wide bore superconducting magnet operating at a resonating frequency of 59.6MHz. Powdered
samples were packed into a 4mm zirconia rotor and spun at the magic angle (54.74°) to remove
anisotropy effects. The ^^Si MAS-NMR spectra of the glasses were recorded at a spinning
frequency of 5 kHz using a high power pulse (PI) acquisition of 1.5|is for silicon, where a total
number of signals of 20,000 pulses were accumulated. The

Si MAS-NMR samples were spun

with a recycle/delay time set to ~2 s. ^^Si NMR chemical shifts are reported in ppm and recorded
at an ambient probe temperature with ^^Si referenced externally relative to 2,2, dimethyl - 2
silapentane-5-sulfonate sodium salt (DSS). For solid state NMR, shifts recorded using MAS are
independent of the isotropic bulk magnetic susceptibility of the sample, and therefore external
referencing should be quite accurate. ^^Si NMR chemical shifts are reported in ppm, with PDMS
(polydimethyl silane) as the external reference (-34 ppm vs. TMS 0 ppm). All NMR spectra
were recorded in a room for exclusive use of NMR, where the room temperature was kept at
300°K by means of an air-conditioner [307].
2.1.2.6 Particle Size Analysis
Particle size analysis was performed in this research, via a single lens laser diffraction system,
using a small helium neon laser of the order of 2 mW power to measure the size of particles. It
operates on the principle of laser scattering using Mie theory and Fraunhofer analysis [310]. The
light from the low power Helium-Neon laser is used to form a collimated and monochromatic
beam of light (typically, 18 mm in diameter). This beam of light is known as the analyser beam
and any particles present within it, seatter this laser light. The particles are introduced to the
analyser beam by the sample presentation modules or by direct spraying through the
measurement area [311] Laser scattering consists of a two-stage process aimed at measuring the
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low angle scattering characteristic of the sample particles. The measurement is in two stages
since the sample measurement also contains light picked up from other sources (such as, daylight
and flare off optical surfaces). Separate measurement of these non-sample scattering sources
make it is possible to subtract out this contribution from the sample measurement [311]. Fig 2.6
illustrates the Fourier Optics optical configuration employed by the Malvern Mastersizer. The
scattered light data is then transferred to the software running on the PC. The knowledge gained
from the scattering theory and particle properties was used to transform the scattered light data to
a distribution of particle size information.

Figure 2.6: Optical Set-Up; Particles are in parallel beam before and within working distance where 1 is the
Detector, 2 is the Fourier Lens, 3 is the Particle ensemble, 4 is the working distance and 5 is the focal distance [311].

The determination of mean particle size and particle size distributions was carried out using a
Malvern Mastersizer Type S Laser Diffractometer. The dynamic range of the Malvern
Mastersizer S was at 0.05 to 3500 microns. One g of sodium hexametaphosphate was mixed
intensively via a magnetic stirrer in 1000ml of deionised water to act as a dispersant. Glass
powder (0.5 g) of sample was dispersed in 30ml of the above prepared dispersant in an 80 100ml heavy-duty beaker. The wet method for powder sample preparation was used according to
ISO 14887 [312].
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Sample Presentation Unit

Figure 2.7: External view of the Malvern Mastersizer particle size analyser and sample preparation unit

1.1.2.7 Scanning Electron Microscope (SEM)
Surface morphology of each glass tubes were observed by an environmental scanning electron
microscope (ESEM: Hitachi S-3700N Ultra Large Variable Pressure) operated at an accelerating
voltage of 5 kV in back scattered electron mode with Energy Dispersive Spectrometer (EDS:
Oxford Instruments) capability. Sample powder was carefully stacked onto each SEM sample.
Secondary and backscattered electrons were used to generate 3D-like high resolution images.
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2.2 Quantification of Therapeutic Ion Release from Glass
2.2.1 Evaluation of Degradation Products
In order to simulate normal and extreme pH environments, TRIS-HCL buffer and Citric acid
buffer solutions were prepared to have a pH of 7.4 ± 0.1 and pH 3.0 ± 0.2 respectively at a
temperature of 37°C ± PC, according to ISO 10993-14 [313]. An equivalent specific surface
area of Im ^ of each glass powder was immersed in lOmls of each solution (n=3) in
polypropylene tubes maintained at 37°C in a shaking waterbath (Stuart Sb40, Reagecon,
Shannon, Ireland), agitated at 2 Hz (longitudinal movement) (Fig 2.8). Specimens were stored
for 1, 3, 7, and 30days. After each time period, specimens were removed and filtered through
Grade 5 Whatman filter paper and filtrates stored under standard laboratory conditions before
ionic content analysis.

Figure 2.8: The incubated Inf Glass Powder in 10ml TRIS-HCL buffer and Citric acid buffer solutions for 1, 3, 7,
and 30 days incubation periods

2.2.2 Quantification of Therapeutic Ion Release
Atomic spectroscopy is the sub-division of spectroscopy to determinate the elemental
composition of an analyte by investigates its line spectra or mass spectrum that are observed
upon interaction of electromagnetic radiation with free atoms. Atomic spectroscopy can be
divided by atomization source or by the type of spectroscopy used. With respect to the
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atomization source, as free atoms can absorb as well as emit electromagnetic radiation of the
same energy (wavelength), atom.ic spectra can be observed as absorption spectra, emission
spectra and fluorescence spectra, a combination of the former two. In the latter ease, the main
division is between optical and mass spectrometry.
The optical spectra are closely related to the structure and the properties of atoms, from which
they are absorbed or emitted, they are specific for the atom under consideration and can be used
for its detection (Fig 2.9). After detection of the wavelength, the data will convert to the property
of atom by Beer Lambert’s Law.

ATOMIC EMISSION

ATOMIC ABSORPTION

.....................

Lamp

Rame

,*’*'••••4

Monochromalor

1

Datadof

Monochromator

Detector

(a)
Figure 2.9: The principle of (a) Absorption Spectroscopy and (b) Emission Spectroscopy [314]

Fig 2.9, (a) A cathode lamp is provide for a stable light source to emit the sharp characteristic
spectrum of the element to be determined. A different cathode lamp is needed for each element,
although there are some lamps that can be used to determine three or four different elements if
the cathode contains all of them. The flame is required for the nebulisation of sample solution
into a fine aerosol solution, and dissociation of the analyte elements into free gaseous ground
state form (both absorption and emission). As the sample passes through the flame, the beam of
light passes through it into the monochromator. The monochromator is aimed to isolate the
specific spectrum line emitted by the light source through spectral dispersion, and detected
sequentially by the detector. The determination of the position of the wavelength makes possible
a qualitative analysis of a sample. A quantitative determination can be carried out by correlating
the intensity of the lines with the concentration or mass of the element via Beer Lambert’s law.
The Beer Lambert’s Law states that the absorbance A is proportional to the thickness (path

107

Chapter 2: Materials and Methods

length) / of the absorbing layer and the concentration c of the absorbing species. The molar
absorbance coefficient e is specific for the absorbing species and, under stable external
conditions, a concentration-independent constant that can be used to characterise the absorbing
species. The absorbance yf is illustrated in Equation (2.14):
^ =

^og'j =

£ * C* I

Equation 2.14

Where:
‘lo’ is the incident radiation intensity
T is the transmitted radiation intensity
‘E’ is the Molar absorbance coefficient
c ’ is the concentration of absorbing species
Y ’ is the thickness of the absorbing layer
Thus, if the thickness of the absorbing layer and the Molar absorbance coefficient are known and
the absorbance is measured, the concentration of the substance can be deduced.
In contrast, the density of lines in the spectrum emitted by the Inductive Couple Plasma (ICP) is
much higher than the spectral interferences due to direct line overlap. ICP-MS do not observe
radiation that is emitted or absorbed by atoms, but measure the impact of ions on a detector,
depending on their mass. The ions generated in the argon ICP plasma are extracted into high
vacuum, focused in an electrical ion lens system and separated according to their mass-to-charge
ratio (Figure D-6). Ions of the selected mass-to-charge ratio are then directed to a detector that
determines the number of ions per mass. This makes quantification of elements possible
including isotope determination. Advantages of ICP-MS in comparison with AAS are the fast
sequential multi-element determination and the excellent sensitivity.
The Zn^^ concentration of each filtrate was analysed using flame Atomic Absorption
Spectroscopy (Varian AA240FS Fast Sequential AAS) using a Zn hollow cathode lamp at a
wave length of 213.9nm. The Ca^"^ concentration of each filtrate was determined using
Inductively Coupled Plasma - Mass Spectrometer (Varian 820 ICP-MS). Analysis of each each
extract was performed in triplicate (n=3 (extracts per condition), 3 analyses performed on each
extract) [315].
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2.2.3 Analysis of Ion Release Profiles
2.2.3.1 Exponential Function in Graph Pad
2.2.3.1.1

One Phase Association

The function describes the pseudo-first order association kinetics of the interaction between a
ligand and its receptor, or a substrate and an enzyme. During each time interval a certain fraction
of the unoccupied receptors become occupied. But as time advances, fewer receptors are
unoccupied so fewer ligand bind and the curve levels off. The function of one phase association
is described in Equation (2.15) and Fig 2.8.
Y=Y0 + (Plateau-YO)*(l-exp(-K*x))

Equation 2.15

Span

Figure 2.10: Graph illustration of one phase association

2.2.3.1.2

One Phase Decay

An exponential decay equation models many chemical and biological processes. It is used
whenever the rate at which something happens is proportional to the amount which is left. The
function of one phase association is described in Equation (2.16) and Fig 2.9.
Y=(Y0 - Plateau)*exp(-K*X) + Plateau
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Span

Time
Figure 2.11: Graph illustration of one phase decay

Where:
YO is the Y value when X (time) is zero. It is expressed in the same units as Y,

Plateau is the Y value at infinite times, expressed in the same units as Y.
K is the rate constant, expressed in reciprocal of the X axis time units. If X is in minutes, then K
is expressed in inverse minutes.

Tau is the time constant, expressed in the same units as the X axis. It is computed as the
reciprocal of K.

Half-time is in the time units of the X axis. It is computed as In(2)/K.
Span is the difference between YO and Plateau, expressed in the same units as your Y values.
2.2.3.2 Exponential Function for Ion Release Profiles
Diffusion of ion which is a primary component of a glass, in theory, the diffusion coefficient is
proportional to the time square [183]. Thus, the Zn^^ and Ca^^ ion release profiles were fitted in a
nonlinear fashion to obtain the analytical function in order to examine degradation. Based on the
literature, the first part of the ion release profile was fitted with the function y=a*x^ [316], whilst
the second part of the ion release profile was fitted with a association exponential function
y'~yo"i"ymax (l-exp-‘^’‘)[3l7].
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2.3

In vitro Evaluation Using Cell Culture Techniques

2.3.1 Cell Culture
Determination of biocompatibility and cytotoxicity has become the central requirement for the
medical application of materials and devices. The concept of material biocompatibility was
defined as “The ability of a material to perform with an appropriate host response in a specific
application” [318]. Such a definition allows biocompatibility to be perceived as not only the
absence of a toxic effect, but also the presence of a positive influence in terms of biofunctionality.
In relation to bioactive glasses in a nerve graft capacity, their ability to attract and regulate
osteogenic cells is paramount. The objective of in vitro biocompatibility tests is to simulate
biological reactions to materials when they are placed on or into tissues of the body. The
spectrum of changes elicited ranges from cell death to alterations of cell adhesion, proliferation
and biosynthetic activity. Such test systems may involve the direct contact of cells with the
biomaterials or the use of soluble extracts of the latter [319, 320]. The extract assay procedure
involves using an appropriate liquid in which the material has been stored for various time
periods and has the added benefit of aiding in the identification of toxic leachates and allows for
the prediction of the temporal effect on a materials in vivo behaviour.
Cells used for these in vitro assays are usually derived from established cell lines. Cell lines
maintain their genetic and morphological characteristics throughout a long life span. Primary
cells are seldom used, as they cannot be maintained indefinitely in cell culture as after a few
passages cells can lose their proliferative capacity which can subsequently influence the
experimental outcome [321]. Common cell lines used and those advocated by ISO standards
include fibroblast cells [319]. Fibroblast cells give rise to connective tissue, are among first cells
to populate a healing wound and are widely distributed throughout the human body including in
bone [322], making them particularly suitable for testing bone substitute materials. L929 mouse
fibroblast cells have been used most extensively for biomaterial evaluation. These cells have the
added advantage of being easy to maintain in cell culture and are known to produce results which
exhibit high correlation with specific animal assays. Determination of cell viability and
proliferation has become a key technology to assess the effect of test materials in a cell culture
system [321]. A quantitative measure of material cytotoxicity can be obtained using 3-(4,5111
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).

The mitochondrial enzyme,

succinate-dehydrogenase, within viable cells, is able to cleave MTT into a blue coloured product
(formazan), which can be spectrophotometrically measured and it is proposed that the amount of
formazan produced is proportional to the number of viable cells present [323].

2.3.2 Glass Extract Preparation
Each glass was sterilised using X irradiation (Isotron, Westport, Co. Mayo, Ireland) in
accordance with TSOI 1137: 2006; Sterilisation of healthcare products’ [324]. The minimum and
maximum doses recorded during sterilisation were 30.5 and 30.8 kGy, respectively. The specific
surface area of glass sample was determined as stated [325]. An equivalent surface area of I m^
of sterilised glass were immersed in 10 ml of sterile tissue culture water (Sigma-Aldrich, Ireland)
for 1, 3, 7 and 30 Days (n = 3) at 37°C in a dynamic Waterbath (Binder, Germany). After each
storage period, samples were filtered using a sterile 0.20 mm^ filter (Sarstedt, Ireland), and
filtrates were stored at 4°C for future in vitro evaluation.

2.3.3 Cell Culture of Mouse Fibroblast Cell Line L929
The established mouse fibroblast cell line L929 (European Collection of Cell Cultures (ECACC),
NCTC clone 929) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma
Aldrich, Wicklow, Ireland) supplemented with 10% foetal calf serum (ECS, Sigma Aldrich,
Wicklow, Ireland), 1% (2mM) L-glutamine (Sigma Aldrich, Wicklow, Ireland), and 1%
Tryptose Phosphate Broth TPB (Sigma Aldrich, Wicklow, Ireland). Cells were incubated in T75 flasks (Sarstedt, Ireland) at 37°C in a 5% CO2 incubator, cell culture media was changed
every 2-3 days. When the cells reached confluency (~70%), they were detached using 0.25%
trypsin EDTA Solution (Sigma Aldrich, Wicklow, Ireland), centrifuged and re-suspended in
fresh culture media with an appropriate cell concentration (0.1ml) of cells to new 75 ml flasks to
create a new single cell suspension until desired passage was reached.

2.3.4 MTT Assay
L929 cells that were grown to the desire passage (passage 7) were used for 3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. 1 ml of L929 cells were
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seeded at a density of 1 x lO'^/ml in 24 well plates (Sarstedt, Ireland). Culture media was used as
a negative control in row 1 and culture media plus cells used as a positive control in row 2. Plates
were then incubated for 24hrs in a cell culture incubator at 37°C (5 % C02, 37 °C, > 90 %
humidity) [53]. 24hrs later, 100 pi of sterile tissue culture water was added to negative and
positive control wells. 100 pi of experimental samples were added to appropriate wells for
testing. The plate was then incubated for another 24hrs in a cell culture incubator at 37°C (5 %
CO2, 37 °C, > 90 % humidity) [53] as per [54]. 24hrs later, 3ml PBS was added in each MTT
vial and an amount equal to 10% of culture medium (lOOpl) of MTT was added in the each well
of 24 plates. Plates were then returned to the incubator for 4hrs. 4hrs later, an amount of MTT
solubilisation solution equal to original culture medium volume (1ml) was added in each well of
the plates to dissolve the resulting formazan crystal. Each well was titrated using a pipette in
order to enhance dissolution of the crystals, 2 sample extracts (lOOpl) from each well were taken
and aliquot in 96 well plate. The spectrophotometric absorption was measured (TriStar LB 941,
Berthold Technologies, US) at a wavelength of 570nm and the background absorption of the 96
plates was recorded at a wavelength of 650nm [53], then subtracted from the 570nm
measurement to get the accurate spectrophotometric absorption of the testing samples [53]. Cell
viability was calculated by comparison with the positive control (100%) using the following
equation [54]:
Cell Viability= 100*OD570e/OD570c

Equation 2.17

Where:
ODsjoe

is the mean value of the measured optical density of the extracts of the experiment

sample
OD570C is the mean value of the measured optical density of the positive control [55]

2.3.5 Statistical Analysis
Each experiment was performed in triplicate and all data were expressed as means ±standard
deviation (SD). All measurements was analysed using GraphPad Prism 5.03 software (GraphPad
software Inc.) and analysis of the results was carried out using Paired Students’s t-test, with a
significance level of P<0.05.
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2.4

Modulus of PLGA/F127 Nerve Guidance Conduits

2.4.1 Synthesis of PLGA/ F127 Conduits
PLGA (lactic to glycolic acid mole ratio, 75:25; Mw, 113kDa; IV, 0.74 dL/g; Lot #: LP-443;
Lakeshore Biomaterials, Birmingham, AL, USA) was dissolved in tetraglycol (T3396: Sigma
Aldrich, Wicklow, Ireland) in an airtight container (lOOmL) at 60 °C (20% w/w) in a waterbath
overnight. Asymmetrically porous PLGA/F127 tubular scaffolds were prepared in the form of
nerve guidance conduits (NGCs) by a modified immersion precipitation method [326]. 1%
additions of Pluronic FI27 were (0 - 5% w/w, PLGA base: P2443: Sigma Aldrich, Wicklow,
Ireland) incorporated into prepared 20% (w/w) PLGA solutions at 60°C and allowed to dissolve.
Calcium alginate hydrogels (rod-shaped) were fabricated by the injection of 4% (w/w) sodium
alginate, NaC6H706, (medium viscosity: W201502: Sigma Aldrich, Wicklow, Ireland) into 2%
(w/w) calcium chloride, CaCL, solution (C4901: Sigma Aldrich, Wicklow, Ireland) using a
stainless steel 316 syringe needle, pipetting blunt 90° tip^"^ (Sigma Aldrich, Wicklow, Ireland) of
gauge size, 14. The prepared calcium alginate hydrogel rod (diameter, -1.5 mm) was immersed
into the PLGA/F127 mixture solution (lOmL) for a period of 3min at room temperature. The
PLGA/F127 solution was precipitated onto the surface of the calcium alginate hydrogel rod by
the diffusion of water molecules from the hydrogel rod into the PLGA/F127 solution (in
tetraglycol co-solvent). After washing the PLGA/F127 coated calcium alginate hydrogel rod with
water to remove any residual tetraglycol, the calcium alginate hydrogel was removed from the
PLGA/F127 thin walled tube to form the final PLGA/F127 NGC. NGCs were then submersed in
deionized water and 25% (w/v) glycerine for 24h [327]. All NGCs were suspended in separate
test tubes (laminar flow hood 48h) [328] and were cut into segments (dimensions: ID: 1.5mm
and Length: 30mm) using a surgical blade to avoid any compression of the thin walled
membrane. Specimens (PLGA: 20% (w/w); FI27: 0 - 5% (w/w)) were incubated in PBS under
dynamic conditions (agitated at 2Hz).

2.4.2 Mechanical Properties of PLGA/fl27 Conduits
Tensile testing was performed to investigate the effect of Pluronic FI27 additions on the
resulting mechanical strength of 20% (w/w). All specimen samples had the following dimensions:
14
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25mm (+/- 5mm) by 1.8 (+/- 0.2 mm) and exact measurements for each of the scaffolds were
found prior to testing using vernier callipers. Each specimen was carefully fixed in the grips
(2710-100 Series Screw Side-Action Grips) attached to an Instron Model 3345 Uni-axial tensile
machine. Specimens were pulled at a crosshead data were expressed as means ±standard
deviation (SD) for n = 3. Statistical analysis was performed with one-way analysis of variance
(ANOVA) followed by a Tukey’s post hoc test for comparisons between groups, with the level
of significance set at p < 0.05 (GraphPad Prism 5.0).
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2.5

Design of Experiment for Nerve Guidance Conduits

2.5.1 Optimisation (Box-Behnken) Design in Design Expert
Design Expert software was used to correlate between the process factors and the responses
using the Multiple Linear Regression (MLR) method for both the screening (fractional factorial)
experimental design and the optimisation (Box-Behnken) design. Box-Behnken design is a
response surface methodology design. It is used to further study the quadratic effect of factors
after identifying the significant factors using screening factorial experiments. With the response,
second order polynomials were fitted to the experimental data to obtain the regression
coefficients of individual linear, quadratic and interaction terms using the sequential F-test, lack
of fit test and other adequacy measures were performed to select the best fit. The term with the
highest partial probability value (P-value) was used to fit the second order polynomial Equation
(2.18) to the experimental data and find the significant model terms.

^X

^X

XX

j

Equation 2.18
Where:
Y is the response function of the experimental data
Ao is constant.
Ai, Aii and Ay are the coefficients of the linear, quadratic and interactive terms, respectively

Xi and Xj are coded independent variables
In order to visualize the relationship between the response and experimental levels of each factor
and to deduce the optimum conditions, the regression coefficients were then used to make
statistical calculation to generate 3-D surface plots and contour plots from the fitted polynomial
equation. P-values of less than 0.05 were considered to be statistically significant. The same
statistical software was used to generate the statistical and response surface plots as well as the
optimisation.
Desirability approach was also used in this research. It is solving such multiple response
optimisation problems using this technique involves using a technique for combining multiple
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responses into a dimensionless measure of performance called the overall desirability function.
The desirability approach involves transforming each estimated response, Yi (single response),
into a unit less utility bounded by 0 < di<l, where a higher di (desirability value) indicates that
response value Yi is more desirable, if di= 0 this means a completely undesired response.
The optimisation module in Design-Expert searches for a combination of factor levels that
simultaneously satisfy the requirement placed (optimisation criteria) on each of the responses
and process factors (multiple response optimisation). The numerical optimisation method
involves combining the goals into an overall desirability function and finds one point or more in
the factors domain that would maximize this objective function. For multi-response graphical
optimisation, the statistical software defines regions where requirements simultaneously meet the
proposed criteria. Superimposing or overlaying critical response contours allows for a visual
inspection for final selection of the best compromise in factors and responses.

2.5.2 Design of Experiment
A Box-Behnken design (BBD) with three independent variables (A: % PLGA (w/w); B: % FI27
(w/w); C: % glass (w/w)) at three levels was performed, according to Table 2.3, Thirteen CNGC
compositions (Table 2.3) were derived from this approach and synthesized for sixteen
experimental runs using Design-Expert 8.0,2 software (Stat-Ease).
Table 2.3: Independent variables and their levels used in the response surface design

Independent variable
NO.

Factor levels

Variable

0

1

12.5

20

% PLGA (w/w)

5

C

% Pluronic FI27 (w/w)

0

2.5

5

B

% Glass (w/w)

0

20

40

17

Chapter 2: Materials and Methods

I'he wt% of the FI 27 phase is relative to the PLGA content and not the overall composite. The
wt% of the glass phase is relative to the PLGA/ FI27 composite content. Second order
polynomials were fitted to the experimental data to obtain the regression coefficients of
individual linear, interaction and quadratic terms using; sequential F-test, lack of fit test in
addition to other adequacy measures performed to select the best fit as per the literature [329332]. In order to visualize and optimize the relationship between responses and each factor,
regression coefficients were used to generate 3-D surface plots and contour plots from the fitted
polynomial equations [333]. The desirability approach was adopted based on the literature [333]
and in terms of the desired responses. All data were expressed as mean ± standard deviation (SD).
Table 2.4: Box-Behnken design matrix of design variables, in coded {and real values), F127 (0 - 5% w/w, PLGA
base). Glass (0-40% w/w, PLGA/F127)

Sample

Std. no.

Factors
A/PLGA

B/F127

(% w/w)

(% w/w)

(% w/w)

C/Glass

CNGC-A

1

-1/5

-1/0

0/20

CNGC-B

2

+ 1/20

-1/0

0/20

CNGC-C

3

-1/5

+1/5

0/20

CNGC-D

4

+ 1/20

+ 1/5

0/20

CNGC-E

5

-1/5

0/2.5

-1/0

CNGC-F

6

+ 1/20

0/2.5

-1/0

CNGC-G

7

-1/5

0/2.5

+1/40

CNGC-H

8

+ 1/20

0/2.5

+1/40

CNGC-I

9

0/12.5

-1/0

-1/0

CNGC-J

1

0/12.5

+1/5

-1/0

CNGC-K

11

0/12.5

-1/0

+1/40

CNGC-L

12

0/12.5

+1/5

+1/40

CNGC-M

16

0/12.5

0/2.5

0/20
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2.6

Fabrication of Nerve Guidance Conduits

The porous NGCs from biodegradable synthetic polymers have been fabricated by many
methods, including immersion precipitation particulate leaching, extrusion, injection molding,
non-woven or woven mesh rolling, and centrifugal casting, inefficient nutrient permeation into
the NGCs caused by their hydrophobic character and residual organic solvents are still remains
limitation for nerve regeneration. To achieve controlled porous structure, in our study, we have
applied a modified immersion precipitation method modified based on OH and Lee’s work [326,
334]. The process is illustrated in Figure 2.12 and explained as following:
1.

PLGA was weighted in appropriate amount that is 5, 12.5, 20 wt% percentage to the
solvent Tetraglycol, and dissolved in tetraglycol at 60°C over night.

2.

Pluronic FI27 was weighted (0, 2.5, 5 wt %) and added in the PLGA solution.

3.

Appropriate amount of CNG glass (0, 20, 40 wt% to PLGA) was weighted and slowly
added in the PLGA/F127 solution in an ultrasonic water bath (approximately 30 mins is
required for dissolving).

4.

The calcium alginate hydrogel rod was fabricated by injecting 4 wt% of alginate into2 wt%
CaCb solution via a syringe with a needle gauge size of 14. The diameter obtained for the
prepared calcium alginate hydrogel rods can be controlled via the injection process: using
different needle gauge sizes in order to obtain the desired inner diameter of the resulting
NGC.

5.

The hydrogel rod was immersed for 3 mins to allow the precipitating of the PLGA/F 127glass mixture onto the hydrogel rod surface for a desired NGC thickness.

6.

The hydrogel rod with coating was taken out and submersed in deionised water and 25%
(w/v) glycerine for 24h in order to protect the tube walls during the post drying process.

7.

After 24 hrs, the hydrogel rod was slide out from the NGC produced

8.

Then the porous NGC was placed under laminated hood for 48 hrs to allow the water
evaporate from the tubes.

The CNGCs were cut into segments (Length: 30mm; inner diameter 1.5mm) using a surgical
blade to avoid any compression of the thin walled membrane and stored under moisture free
conditions in desiccators (at <10°C) for subsequent testing.
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Precipitated
PLGA/F127-Glass
Calcium Alginate
Hydrogel Rod
(substrate )

PLGA/F127-Glass
In Tetraglycol
(co-solvent)

PLGA/F127-Glass
in Tetraglycol
(Co-solvent)

PLGA/F127GlassNGC with
Hydrogel Rod

Drying under
Laminated Hood
for 48 hrs

vv
j

,0

25wt*/o Glycerine
in Water
(Immersing 24hrs)

Glass particles
(0, 20, 40 vvt%)

A
»|Sn*

•MM,

PLGA (5,
12.5, 20 wt%)

Tetraglycol
(Co-solvent)

PLGA in Tetraglycol
(Co-solvent)

• M

PLGAyF127in
Tetraglycol
(Co-solvent)

Ultrasonic
Water bath (30mins)

60“C Water bath

Figure 2.12: The Schematic diagram showing PLGA/F127-giass conduits (CNGC) fabrication
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2.7

Evaluation of Mechanical Properties and Cell Viability

2.7.1 Sample Preparation
Compositions containing 12.5wt% and 20wt% PLGA were prepared (see Table 2.5 for
compositions) as those based on 5wt% additions PLGA were of insufficient integrity for testing.
CNGC specimens (25mm (+/- 5mm) length x 1.8 (+/- 0.2mm) diameter were incubated in 10ml
of phosphate buffered saline (PBS, Sigma Aldrich, Ireland) at 37°C for 1, 3, 7, 28 days (n=3 for
each material) under dynamic condition (frequency=2Hz).
Table 2.5: Compositions of Composite Nerve Guidance Conduits (CNGC), F127 (0 - 5% w/w, PLGA base), Glass
(0-40?/ow/w, PLGA/F127)

Deucalex

PLGA (wt %)

Composites (CNGC)

Pluronic-F127

Bioactive Glass

(wt %)

(wt %)

CNGC-M

12.5 (0)

2.5 (0)

20 (+1)

CNGC-D

20 (+1)

5(+l)

20 (+1)

CNGC-B

20 (+1)

0(-l)

20 (+1)

CNGC-J

12.5 (0)

5(+l)

0(-l)

CNGC-I

12.5 (0)

0(-l)

0(-l)

CNGC-F

20 (+1)

2.5 (0)

0(-l)

2.7.2 Mechanical Properties
Tensile testing was performed to investigate the effect of Pluronic FI27 or glass particle
additions on the resulting mechanical strength of PLGA. All specimen samples had the following
dimensions: 25mm (+/- 5mm) by 1.8 (+/- 0.2 mm) (as per section 2.5) and exact measurements
for each of the scaffolds were found prior to testing using vernier callipers. Each specimen was
carefully fixed in the grips (2710-100 Series Screw Side-Action Grips) attached to an Instron
Model 3345 Uni-axial tensile machine. Specimens were pulled at a crosshead data were
expressed as means ±standard deviation (SD) for n = 3. Statistical analysis was performed with
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one-way analysis of variance (ANOVA) followed by a Tukey’s post hoc test for comparisons
between groups, with the level of significance set at p < 0.05 (GraphPad Prism 5.0).

Figure 2.13: Instron-3345 Tensile Machine and PLGA/F127 Scaffold Mechanical test

2.7.3 Biocompatibility Test
CNGCs (as shown in table 2.5) were fabricated according to methods illustrated in section 2. All
specimen samples had the following dimensions: 25mm (+/- 5mm) by 1.8 (+/- 0.2 mm) were
used to prepared extracts for indirect contact cell viability test. Specimen were immersed in
70v/v% ethanol solution for 30 mins for sterilization, and then wished with PBS. After that all
the specimens were incubated in 10mm cell culture water at 37°C for 1, 3, 7, 28 days (n=3 for
each material) under dynamic condition (frequency=2Hz). After each incubation periods,
samples were filtered using a sterile 0.20 mm^ filter (Sarstedt, Ireland), and filtrates were stored
at 4°C for future in vitro evaluation. The cell viability test was carried out for those extract as per
section 2.3.3 and section 2.3.4.
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2.8

Evaluation of the Ionic Profile of the Conduits

2.8.1 CNGC Fabrication and Extract Preparation
PLGA (LA:GA, 75:25), (Lakeshore Biomaterials, Birmingham, AL, USA) was dissolved
overnight in tetraglycol T3396, (Sigma Aldrich, Wicklow, Ireland) at 60°C at an appropriate
weight percentage (refer to Table 2.6 for ranges investigated). Six CNGC compositions (Table
2.6) were prepared, based on a modified immersion precipitation technique described previously
(Section 2.5). Following fabrication, the CNGCs were subsequently suspended in separate test
tubes in the laminar flow hood to dry (48 h) for evaporation of any residual solvent under
atmospheric pressure as per methodology outlined by Wen and Tresco [327]. The CNGCs were
cut into segments (30mm length x 1.5 mm inner diameter) using a surgical blade to avoid any
compression of the thin walled membrane.
Table 2.6: Compositions of Composite Nerve Guidance Conduits (values expressed as wt%), FI 27 (0 - 5% w/w,
PLGA base). Glass (0-40% w/w, PLGA/F127)

PLGA

Pluronic F127

Glass

CNGC-B

20

0

20

CNGC-M

12.5

2.5

20

CNGC-D

20

5

20

CNGC-K

12.5

0

40

CNGC-H

20

2.5

40

CNGC-L

12.5

5

40

NGC
Designation

The sample CNGCs were immersed in lOmL of tissue culture water (Sigma Aldrich, Ireland) for
1, 3, 7 and 28 day (n=3) time periods. Each specimen was stored in polypropylene tubes
maintained at 37°C in a shaking waterbath (Stuart Sb40, Reagecon, Shannon, Ireland), agitated
at 2 Hz (longitudinal movement) according to ISO 10993 part 14 [335]. After each storage period,
individual extracts for CNGC specimens were filtered using a sterile 0.2 Im filter (Sarstedt,
Ireland). Following that, 3ml of each filtrate was diluted to 30ml extract with tissue culture water
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and stored at 4°C for future in vitro evaluation. For enhanced clarity, the experimental CNGCs
may be considered as two groups; those comprising 20wt% glasses and those comprising 40wt%
glasses.

2.8.2 Ionic Content Analysis
The Si"^^, Na^, Ca^^, and Zn^^ ionic concentration of each CNGC extract was analysed using
inductively coupled plasma atomic emission spectroscopy (ICP-AES, Perkin Elmer Optima 3000,
MA, USA). The absorption wavelengths used for the determination of Si'^^, Na^,

and Zn^^

are reported in Table 2.6. Before each cycle of measurement, calibration curves were obtained by
preparing standard solutions containing Si"^^, Na^, Ca^^ and Zn^^ (JVA Analytical Ltd, Ireland) at
concentrations reported in Table 2.7. Standard sample concentrations were measured periodically
to ensure the accuracy of the calibration curve. Triplicates of each extract (from each incubated
CNGC) were measured for each element, with appropriate adjustments in outputs being
deployed to balance dilutions of original extracts.
Table 2.7: Emission lines used for the ICP measurements

Absorption
Element

Lower Limit

Upper Limit

Background
Correction

Wavelength

Si

288.158

288.073

288.256

±0.026

Na

330.237

330.136

330.348

±0.030

Ca

396.847

396.679

397.039

±0.072

Zn

334.501

334.400

334.614

±0.031

Ce

418.660

418.482

418.864

±0.076

124

Chapter 2: Materials and Methods

Table 2.8 : Standard concentrations used for the ICP measurements

Standard

Si'‘^(mg/L)

Na^(ing/L)

Ca^^ (mg/L)

1

2

1

0.5

1

2

4

2

1

2

3

6

3

2

3

4

19

4

3

4

5

15

5

4

5

(mg/L)

2.8.3 Statistical Analysis
Results are expressed as mean ± standard error of the mean of triplicate determinations. Analysis
of the results was carried out using the Student’s t-test, with a significance level of P<0.05. The
ion release levels of each element are divided into two groups’ relative-to their bioglass (20wt%
group (a) and 40wt % group (b)) content.
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3.1

Glass Characterisation

3.1.1 The Transition Temperature and Specific Surface Area
Tg and SSA results obtained for each glass are presented in Table 3.1 The mole fraction of Si02,
ZnO and CaO remains constant for all glass compositions, the only variant being the ratio of
Na20

to

Ce02.

The

Tg

of the

three

glasses

follows

the

diminishing

order

of

CNG1>CNG2>CNG3 within the range of 655°C (CNGl) to 568°C (CNG3).
Table 3.1: Tg, SSA and Na20; Ce02 ratio for each glass.

Class ID

Na20: Ce02 Ratio

Tg(°C)

Specific Surface Area(m^/g)

CNGl

0.308

655

8.3299

CNG2

1.125

601

10.7441

CNG3

4.667

586

16.0334

3.1.2 The XRD Patterns
The XRD patterns of the prepared glass compositions (CNGl to CNG3) are shown in Figure 3.1,
and confirm the amorphous nature of the glass powders.

Position of [20°]
Figure 3.1: XRD pattern for each glass composition (CNGl to CNG3).
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3.1.2 Particle Size Distribution (PSD)
The graphical representation of the particle size distributions attained for CNG glass particles
(CNGl - CNG3) analysed in this study is shown in Fig 3.2.
.olume

Particle Diameter 'pm,

(a).
VclMe(%)

Vokine(%)

(b).

(c).

Figure 3.2: The graphical representation of the particle size distributions of CNGl (a), CNG2 (b), and CNG3 (c).
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The mean particle diameters of the glasses (CNG1-CNG3) are 36.72}im, 33.42}xm, and 33.30pm,
respectively. This confirmed the particles of CNG glass are less than 45pm (as in section 2.1)
which is extremely fine particle size [89].

3.1.3 SEM image
The SEM image (Fig3.3) confirms the amorphous nature of the glass; it also indicates that the
glasses are significantly less than 45 pm.

Recently, some studies have demonstrated anti

microbial and anti-inflammatory properties on particulates of average particle size smaller than
100 mm [336, 337] that are potentially very promising for regenerative medicine; there has been
little research on the mechanisms of these antimicrobial and anti-inflammatory properties of
these small particle size glasses, and it is difficult to elucidate the reason for this.

CNGl

CNG2

CNG3

Figure 33: Comparable glass surface morphology of 3 CNG glasses

3.1.4 Network Connectivity and MAS-NMR Spectroscopy
Figure 3.2 illustrates the ^^Si MAS-NMR spectra collected from each glass with chemical shift
data collated in Table 3.3. The peak chemical shift for each glass was -84ppm, -82ppm, -80ppm
for CNGl, CNG2, and CNG3 respectively indicating a predominantly
The network connectivity of each glass was determined to be 2.
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Figure 3.4: ^^Si MAS-NMR spectra for glasses CNG1 - CNG3
Table 3.2: Network Connectivity (NC), Predominant Q" structures, ^‘’Si MAS-NMR peak positions and Na20: Ce02
ratios for each glass.

Glass

NC

Designation

Predominant

Si peak (ppm)

Na20: Ce02 Ratio

-84

0.308

Qn Structure

CNGl

2.0

CNG2

2.0

O'

-82

1.125

CNG3

2.0

o'

-80

4.667

^^Si MAS-NMR spectra for glasses CNGl to CNG3 (Figure 3.4) indicate chemical shifts
between -60 and -120 ppm; typical of Si in tetrahedral configuration [338-340]. The chemical
shift is dependent upon the ratio of BOs to NBOs present in the glass, where an increase in the
number of NBOs is found to result in peak maxima moving in a positive direction due to
increased shielding of the

Si nucleus. Alternatively, an increase in the number of BOs is

associated with a movement of the peak in a negative direction due to a decreased capacity of
shielding to the nucleus [339]. However, specific resonances within the range are subject to some
debate. Elgayar et al. [341, 342] and Oliveira et al. [343] associated resonances between -60ppm
and -83ppm with

structural unit, while, Matsuya et al. have identified peak maxima of -81.6
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to -104 ppm for commercial ionomer glasses to

to

structures, respectively [342].

Shrikhande et a/.[344], on the other hand report values of chemical shift corresponding to Q*,
and

structural configurations at about -78, -85, -95, -105, respectively, which is also in

good agreement with values reported by Fayon et al [345]. In addition, it must be noted that
Lockyer et ^r/.[346] have identified precedence for peak merging as a result of two resonances
corresponding to different Q structures overlapping and merging into one peak. The ^^Si MASNMR results (Table 3.3 and Figure 3.2) indicate that the glasses studied are structurally similar,
with the exception of the decreased peak width evident with CNG3. The decreased peak width
appears to be attributable to a tightening of the peak from a more negative position toward a
more positive position about the peak maxima. This feature is likely attributable to the
destruction of

species in the network as a result of an increasing Na20:Ce02. An additional

feature associated with the CNG3 spectra is the emergence of a double-shoulder at a chemical
shift between -60ppm and -20ppm, indicating the increased prevalence of qV

within CNG3 as

compared with the CNGl and CNG2. All spectra obtained exhibit large broad symmetrical peaks
with resonating peak maxima at a chemical shift ranging between -84 to -80 ppm: a chemical
shift which the authors have previously established as being associated with

units in similar

silicate glasses [347]. An increase in the Na20:Ce02 ratio from 0.308 to 4.667 causes an increase
in the chemical shift of the peak maxima in the glass network from -84 to -80 ppm indicating
increased disruption of the glass due this altered ratio. In summary, the peaks broaden towards a
more negative direction for lower Na20:Ce02 ratios.
In accordance to literature, its is accepted that the ^^Si peaks for each glass implicate the
presence of a wide array of Q" structures in the glass network, such that, it may be assumed,
based on the NC calculations and the chemical shift data that the

structure is pervasive to

glasses CNGl to CNG3. Furthermore the replacement of Na20 with Ce02 in the glass
formulation affects the resultant glass network: such that, a subsequent increase in the
Na20:Ce02 ratio may results in a tightening of the curve about a peak maxima which moves, in a
limited way, toward a more positive chemical shift. Similar findings may also be interpreted
when comparing the glass structure to the Tg values for the glasses. Finally, the data herein
indicates that the

ions are predominantly network- modifying and as such is in agreement

with work previously reported by the authors [339].
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3.2

2+>
Quantification of Degradation Products (Zn^^ and Ca'^^)

3.2.1 Zinc Ion Release Profiles
The

release profile of each glass composition incubated at pH 7.4 are shown in Figure 3.5.

CNG2 and CNG3 exhibited the highest levels of Zn^^ release after a 30 day period (35.21 ppm
and 38.71 ppm, respectively) in comparison to CNGl which released 21.21 ppm ofZn^^. After 30
days incubation CNG3 released nearly twice as much Zn

as CNGl.

■
A

CNG1
CNG2
CNG3

Figure 3.5: Zn^^ release profiles under normal physiological condition (pH7.4) at 1,3, 7, and 30 days.

The Zn^^ release profiles of each glass composition incubated at pH 3 are shown in Figure 3.6.
CNG2 displays the highest level of Zn^^ release after 30 days incubation reaching levels of up to
4904ppm in contrast to 4594ppm for CNG3 and 2552ppm for CNGl. The lowest level of Zn^^
release identified was observed for CNGl after 1 day (1423 ppm) about half of the Zn^^ release
observed for CNG3 (2994ppm) at the same time period.
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CNG1
CNG2
CNG3

Figure 3.6:

release profiles under extreme physiological condition (pH3) at 1,3, 7, and 30 days.

Tables 3.3 and 3.4 indicate best fit parameters for Zn^^ release as derived from the nonlinear two
phase analysis. At pH7.4, CNGl displayed the longest half life (3.799 Days), whilst the half life
for CNG2 and CNG3 was 2.026 and 1.446 days respectively. Table 3.4 indicates the best fit
parameters for Zn^^ release from the nonlinear two phase plot. At pH3 CNGl again displayed the
longest half life (3.171 Days), whilst the half life for CNG2 and CNG3 was 2.627 and 0.5152
days respectively. The shortest half life recorded was for CNG3 at pH3 with t'^^=0.5152 days and
the longest half life was CNGl under normal condition with t

=3.799 days. The value of ts,

found by separating the two phase function for the curve fit of the ion release concentration,
correlated the half life for three glasses under normal physiological condition; on the other hand,
CNG2 had the highest ts value of 4.297 days under extreme physiological condition, while
ts=2.86 days for CNGl, and CNG3 had the lowest of ts=1.425 days. The

obtained for CNG2

and CNG3 at pH7.4 was very high (R^>0.95) and R^ obtained for all three glasses under both
normal and extreme condition were between 0 and 1.
Table 33: The best fit parameters for Zn

release under normal physiological condition

Glass

t'^"^ (days)

tau (days)

ts (days)

ymax (ppm)

CNGl

3.799

5.48

3.102

21.78

0.8877

CNG2

2.026

2.923

2.4

39.21

0.9632

CNG3

1.446

2.086

2.05

35.45

0.9529
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Table 3.4: The best fit parameters for Zn

Glass

(days)

tau

(days)

release under extreme physiological condition

ts (days)

ymax (ppm)

CNGl

3.171

4.574

2.86

2534

0.9116

CNG2

2.627

4.232

4.297

4934

0.5064

CNG3

0.5152

0.7433

1.425

3415

0.396

3.2.2 Calcium Ion Release Profiles
The

release profiles of each glass composition incubated at pH 7.4 are shown in Figure 3.7.

CNG2 and CNG3 exhibited the highest levels of Ca^^ release after a 30 day period (78.24ppni
and 133.72ppm, respectively) in comparison to CNGl which released 47.42ppm of Ca^^. After a
30 day incubation periods CNG3 released over twice as much Ca^^ as CNGl.

CNG1
CNG2
CNG3

Figure 3.7:

release exponential profile under normal physiological condition (pH7) at 1,3, 7, and 30

The Ca^"^ release profiles of each glass composition incubated at pH 3 are shown in Figure 3.8.
CNG3 displays the highest Ca^^ release after 30 days incubation reaching levels of up to
3000ppm in contrast to 2422ppm for CNG2 and 875ppm for CNGl. The lowest level of Ca^^
release identified was observed for CNGl after 1 day (1539 ppm) with about one third of the
Ca^^ release observed for CNG3 (2726ppm) at the same time period.
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•

CNG1

■

CNG2

A

CNG3

Figure 3.8: Ca^^ release exponential profile under extreme physiological condition (pH3) at 1,3, 7, and 30 days

Tables 3.5 and 3,6 indicate the best fit parameters for Ca

release as derived from the nonlinear

two phase plot. The associated half life of each glass follows the order of CNG2>CNG1>CNG3
under normal physiological condition. Under extreme physiological condition, the half life of
CNGl and CNG2 follows the reverse order of that observed at normal physiological condition
(CNG1>CNG2). The dissolution associated with CNG3 does not fit the model outlined, thus did
not allow for evaluation of its half life. The shortest half life observed occurred for CNG2
incubated at pH3 where t''^^ =1.698 days. The longest half life observed occurred for CNGl
incubated at pH3 where t'^^=3.0895 days. The value of ts was obtained to separate the two
functions for the best fit; whereby the ts value was in the same order as the half life for three
glasses under extreme physiological condition. The

obtained for CNGl and CNG2 under

normal physiological condition were very high (R^>0.90) in comparison to the R^ value obtained
at extreme physiological condition (0.40<R^<0.66) (refer to Table 3,5 and 3.6).
Table 3.5: The best fit parameters for Ca^^ release under normal physiological condition

Glass

t’^^ (days)

tau (days)

ts (days)

ymax (ppm)

r"

CNGl

3.766

5.433

3.15

48.99

0.9702

CNG2

3.955

5.706

3.406

103.7

0.939

CNG3

2.077

2.997

2.418

133.8

0.8957
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Table 3.6: The best tit parameters for Ca^^ release under extreme physiological condition

Glass

t*'^ (days)

tau (days)

ts (days)

ymax (ppm)

CNGl

3.895

5.619

3.416

1444

0.6613

CNG2

1.698

2.45

2.811

2576

0.1586

CNG3

Intersect

NA

1.308

NA

NA

3.2.3 Analysis of Zinc and Calcium Ion Release Profiles
The study of glass dissolution has been challenging scientists for more than 40 years [317]; with
the heterogeneous and homogenous models preferred in the literature [317, 348]. In respect of
the heterogeneous model, two stages are recognized during the reaction between glass and an
aqueous solution [349]. During the first stage, extraction of alkali metals varies with the square
root of time, and for the second stage the extraction is logarithmic with time [317]. In order to
examine the dissolution of each glass, and examine the burst effect of ion release observed in the
results (Section 3.2.2), the ion release profiles were fitted, as per the literature, with an
exponential equation and a logarithm equation. The first part of the ion release profile was fitted
with the function y^a^t"^, (In section 3.2.2, the grey dash line indicated the exponential function);
the second part of the ion release profile was fitted with function y=yo+ymax (l-exp'''’^). (In
section 3.2.2, the coloured line indicated the logarithm function), tswas defined as the period of
time up to which the first stage of dissolution occurs. Therefore, for x< U, the curve fitting
function employed is required to be y=a*t’^ (the ion release concentration is related by the powerlaw to incubation time). When x= ts, the plot fits both curves. To enable the continuity of the ion
release profile, for x>ts, the curve fitting function is y=yo+ymax (1-exp''^’^), the ion release function
is the original concentration yo (that ion release at x= ts) plus the decay exponential relate to the
incubation time, ts was obtained for different glasses under both sets of conditions. Tlie smallest
value for ts recorded related to Ca^^ release (CNG3) exposed to the extreme physiological pH
and was observed to be 1.3078 days. The largest value of ts recorded related to Zn^^ release
(CNG2) exposed to extreme physiological pH and was observed to be 4.297. Two time points
were used to estimate the ion release y ppm at x=ts, with the results parameters being highly
dependent on the first set of data (1 day ion release), this means the observed results of
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may be higher than the original value, consequently t’^ and tau
indicators. The t

should be considered as

and tau were obtained for each CNG glass under different physiological

conditions form the Prism5 (GraphPad Software) in Table 3.3 -Table 3.6. As one would
anticipate the data indicates that glass dissolution proceeds at an accelerated pace under extreme
physiological conditions (pH=3) compared to normal physiological conditions. CNGl had the
longest half life followed by CNG2 then CNG3; a result explained by increased sodium in the
glass composition leading to increased dissolution [200]. Synergistically, the role of cerium in a
glass network as reported by Mansour et al. [350], observed that cerium could act as a network
former or a net work modifier, dependant on the concentration of cerium present [350, 351]. In
the current study, the cerium content was reduced from 0.13mol to 0.03mol for glasses CNGl to
CNG3, respectively. The lower concentration of cerium was found to limit the cerium,
environment in the form of Ce^^ (which acts as a glass network former). This observation may
indicate that competing process of glass stabilisation and disruption are occurring up to a critical
concentration of Na in the glass, hence the observed chemical shift response in Figure 3.4 and
Table 3.2.
1 he data observed, and subsequent functional analysis of the degradation profiles indicates that,
in general, upon exposure to normal physiological pH each glass undergoes heterogonous
dissolution (R^ values range 0.88-0.97 for heterogonous dissolution model). Interestingly, the
heterogonous model of dissolution breaks down when the glasses are exposed to the extreme
physiological pH (3); with the exception of CNGl (R^=.91 for heterogonous dissolution model),
all other glass show poor fitting to the heterogonous dissolution model proposed by the literature
(R' as low as 0.39). It is proposed that the poor fit

is a function of rapid dissolution and

subsequent release of Ca^\ Ce^^ and Zn^^ into the citric acid solution [200]. The ions released
decrease the overall chemical durability, with the cation exchange between the glass surface and
the aqueous environment (Ca^^, Na^ with H^/H30^), which results in a pH excursion from de
alkalization in the early periods of immersion - glass dissolution [352]. In addition, the H^ in the
acidic environment can promote the breaking of the Si-O-Si bonds and the chain structure of the
glass matrix may become destroyed, thus increasing the number of Si and may alter the
surrounding pH environment. The Ca^^ ions initially released by the glass may be exchanged
with H^ or H30^ in the solution and precipitate onto the entire surface of the sample to form a
hydrogel like layer on the glass surface and further impact the rate of ions released from the glass
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[353, 354J [355]. This gel layer formation is dependent on the glass composition; with different
compositions having the capacity to form various multi layered structures. Further dissolution is
found to result in the mass transport of alkali ions from the center of the particulate glass through
the hydrogel rich layer into the aqueous media, causing a reduction in the rate at which
dissolution of the particulate occurs. The Ca release for CNG3 (at pH 3.2) followed the order: 1
days > 7 days > 3 days which may be attributed to the Ca^^ originally acquired in the hydrogel
formation being faster than the process of Ca

transfer from the inner phase to the reactive

surface layer of glass over 3 days [352, 356]. As immersion time increases, the release of glass
constituents depends on the penetration of water molecules into the subsurface layer, thus the
alkali ions may be mobilized again with continued degradation of the glass [356]. This effect is
more pronounced for larger particle sizes [352, 357]. On the basis of these results, further in vitro
and in vivo investigations are required to assess various composition - particle sizes and their
corresponding ion release profiles (for all the alkali ions) to assess their optimum therapeutic
efficacy.
The Zn^*^ release concentrations for all three glasses varied from 5.97 to 38.91 ppm under normal
physiological conditions and from 1229 to 4904ppm under extreme physiological conditions (see
Figure 3.5and 3.6). Zn^^ levels previously reported to have clinically beneficial effects on nerve
growth were reported in the range of 0.065ppm to 3.27ppm in toad olfactory epithelia, with
higher levels appearing to inhibit neural firing rates [358]. Similarly, early research has also
demonstrated that Zn^^ may be required for neuroprotection following sub-lethal ischemia in
both in vivo and in vitro models [359]. More recently, it has been suggested that Zn^"^ may also
be valuable in specific therapies, such as uremic polyneuropathy, with the preferred
concentration of Zn^^ release in this regard between 12 - 16uM (0.784 - 1.046 ppm) and the
optimal Zn^"^ release for muscle cells about 40 - 50uM (2.615 - 3.27ppm) [360]. Moreover, Zn^^
has been suggested to act as a type of neurotransmitter. The concentration of Zn^^ released
during transmission is found to be approximately 300uM (19.614ppm) which is more than
sufficient to be neurotoxic in neuronal cell culture [361]. In addition, the antibacterial effects of
Zn^^ have been evaluated by broth dilution methods [362], in which bacterial growth was
inhibited in the most concentrated Zn^^ oxide (0.719ppm and 1.046 ppm) suspension under the
same conditions [363]. For these applications, the appropriate Zn^^ concentration was found to
range between 0.065ppm to 19.614ppm. These rapid therapeutic effects for zinc supplementation
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on neuronal cell may involve some aspects of peripheral nerve regeneration (PNR) function.
Moreover, there may be greater benefit of zinc supplementation for infections in implantation
sites specific to nerve (motor and sensory) recovery. Unfortunately, there is limited information
concerning the effects of Zn^^ release in clinical PNR. While the Zn^^ release from the glasses in
this study (CNG1-CNG3) were observed to cover a wide range ofZn^^ ion release under normal
physiological conditions, the highest Zn^"^ release value seen was approximately double that
reported as an appropriate range in literature. Adversely, Zn^^ release under extreme
physiological conditions exceeded the reported optimal ranges, which may produce undesirable
cytotoxic effects [364]. It is well published that the structural role of zinc in sodium zinc silicate
glasses is dependent on the initial concentration of the sodium present [365]. This phenomena is
based upon the assumption that the greater the sodium concentration present the more likely that
zinc will act as a network former [278]. This correlates well with the results obtained comparing
CNGl (0.04 sodium mole fraction) to CNG2 (0.09 sodium mole fraction), whereby the reduced
sodium content results in the zinc acting in the role of network modifier. This suggests that the
final Zn^^ release concentrations of the bioactive glasses produced herein, may be controlled via
alteration of the composition, thus facilitating the degradation rate and hence ion release
concentration of the proposed nerve guidance conduits to promote peripheral nerve regeneration
post trauma.
The Ca^^ release concentrations for all three glasses ranged from 19.16ppm up to 143.07ppm
under normal physiological conditions and from 857 up to 3130ppm under extreme physiological
condition (see Figure 3.7 and 3.8). A central role of Ca^^ is the regulation of the nerve growth
cone motility [233]. It has been reported that there are grades affecting Ca^^ ion concentration on
the growth cone behaviour, with maximal activity occurring at an optimal level within this
permissive range. This expanded model resembles other graded calcium-dependent processes;
whereby many of these processes also display a similar dependence on optimal calcium [366].
The intracellular Ca^^ levels may regulate outgrowth by affecting the stability of the peripheral
cytoskeleton, as investigated by Janet (about 0.008ppm) who claim the extension of growth
cones appear to be greatest at an optimal Ca

level [367]. The dorsal root ganglia (DRG) from

white chick embryos have been used to evaluate the optimal Ca
(2.5pM calcium

level for neuritis outgrowth,

ionophores A23187 (27.196ppm)) as used in culture medium to examine

optimal levels of Ca

[286]. In addition, the same group observed how the calcium ions
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influence the modification polymerization/ depolymerization and enzymatic degradation of many
different cytoskeletal components [286]. The role of Ca^^ in secretion has been studied by Care

et al [368]. and the concentration required to depolarize chromaffin cells was found to range
from 0.16*10’ up to 0.21*10’ ppm [369]. Hence, it can be perceived that any glasses releasing
Ca^^ levels within these ranges will have similar beneficial effects. The Ca^^ release from the
three glasses synthesised under normal physiological conditions therefore may be deemed to suit
the intended medical application (PNR). However, the Ca^^ release under extreme physiological
conditions is much higher than the optimal ranges reported in literature. This sufficient amount
of Ca^^ release provides suitable conditions for flirther development of the proposed PLGA/BG
composites which may be further investigated further for its therapeutic effect regarding the ions
released from the glass housed in its polymeric structure in final composite form. In effect, this
will not limit the function of the glasses designed herein, since the ion release concentration may
be tailored by the pore size and the Na: Ce ratio of the glass synthesised prior to fabrication of
the final composite material. In addition, the degradation of PLGA/BG composite is controlled
by the weight ratio of PLGA, the poloxF127 and BG, once the glass in combined with PLGA.
1'his suggests further investigation of the therapeutic ion delivery and biocompatibility is
necessary for the PLGA/F127 and glass composite material.
This initial study has shown that the structure of the glasses indicates a predominate Q
speciation which may be controlled by modification of composition with respect to controlling
the Na20:Ce02. The results indicate heterogeneous dissolution of the glasses upon exposure to
physiological pH whereby the ion release profiles recorded indicate that all three glasses have
potential to provide delivery of therapeutic Zn^^ ions. Ca^^ ion release also indicates potential
value in this application. Following this research, the in vitro biocompatibility of glass will be
investigation.
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3.3

Biocompatibility of Glass

3.3.1 The MTT Assay Results and Discussions
The MTT assay results displayed in Figure 3.9 were evaluated by percentage viability respective
to controls. The cell viability for CNGl in 7 day incubation is significantly higher in comparison
with the cell viability of 1 day and 3 day incubation periods. For the cell viability of CNG2, the
7 day samples have the highest call viability over all incubation periods, while there is a
significant difference between the cell viability of 1 day and 3 day incubation periods. The only
significant difference for the cell viability of CNG3 is between 1 day and 7 day incubation
periods. The cell viability of all three CNG glasses has reached their maximum levels after the 7
day incubation period. The reason for this was believed to be due to the Si"^^ release from the
CNG glasses, according to the author’s previous report [370] on the ion release of the same glass,
the ion release reached plateau level after 7 day incubation . Studies done by Frewin et al.,
[371] has shown that Si'*^ release levels from bioactive glass have a positive effect on PC 12 cells.
As is indicated in the graph, the cell viability of the three CNG glasses is in the order of CNGl
<CNG2 < CNG3. Relative to the cell viability results with the particle size of each glass, the
smaller particle size give the greater cell viability, possibly because the smaller particle size
gives a larger surface area, leads to higher Si"^^ release; therefore results in the better cell viability.
The other reason for the highest cell viability indicated by CNG3 could be the higher Na"^
content in the glass. Since the sodium is a glass network former, the greater the Na^
concentration present, the fast the silicon glasses will degrade [278]. The bioactive glass with
mol% of (0.5SiO2 -0.2CaO-0.13ZnO-XNa2O-(0.27-X) Ce02) where, (X= 0.04, 0.09, and 0.14)
were referred as glass CNGl, CNG2 and CNG3, respectively. MTT assay results indicate that
the glass compositions with x=0.14 have the highest cell viability, equivalent to (93-102%) in the
three glasses.
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CD 1 day

■I 7 day
CD 30 day

CNG1

CNG2
Class Type

CNG3

Figure 3.9; The cell viability of three CNG glass over 1, 3, 7, and 30 day incubation periods (*, p<0.05; **, p<0.005)

In conclusion, the CNG glasses can be tailored to provoke no significant cytotoxicity in terms of
cell viability. Specifically, as the higher Na^ (mol %) enhances the cell viability in the design
range. 14% of Na20 contents in the glass offers the smallest particle size and the best cell
viability versus the negative control (tissue culture water). This preliminary study demonstrates
suitable cell viabilities in vitro. Future investigations on this specific glass composition will now
be

incorporated

into a polymer-glass scaffold
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3.4

Mechanical Properties of PLGA/F127

The inclusion of FI 27 in the ranges 1-5% did impact on the E of the PLGA/F127 NGCs. Figure
3.10 shows the value of E for each composition at a defined period of incubation under
physiological conditions.
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Figure 3.10: Modulus values for each material composition grouped with respect to incubation period

The observed range of modulus across all material compositions and incubation periods was 7107MPa. At time zero no significant change in E is observed based on the inclusion of FI27.
After 1-day incubation the NGC comprising 0% has the highest mean value of E and is not
significantly altered with 1-2% additions of FI27. However, significant differences were
observed between the 0-3wt% group, the 3-4wt% group and the 4-5wt%. Specifically, FI27
inclusion on the order of 3 and 4% lead to a decrease in E after 1-day. Interestingly, the
significant difference recorded between the 4-5% group represents an increase in E. After 3 days
incubation, additions of 2, 4, and 5% FI27 all give rise to significantly reduced E when
compared with the 0% FI27 material. The 5% FI27 material displays a higher value of E than
the 0% FI27 material. The inclusion of FI27 caused no significant difference in E at 7 or 14
days, with the exception of increased E for the 2% FI27 when compared with the 0% FI27
material at 14 days only. After 21 days incubation the 0% FI27 material was significantly stififer
than those materials synthesized with 1, 2, 3, 4 % F127 but not different to that containing 5%
FI27. It is also noted that additions within the range 1-4% FI27 do not alter E after 21 days
incubation. In order to examine the time dependant changes for individual additions of FI 27, the
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E data for individual compositions is presented in Figure 3.11, with significant differences
between time-points noted in Table 3.7.

(a).

(b).

(c).

(d).

(e).

(0.

Figure 3.11: Modulus values for individual compositions grouped with respect to incubation period, (a), (b), (c), (d),
(e), and (f) represent conduits contain 0%F127, 1% F127, 2% FI27, 3% FI27, 4% FI27, and 5% FI27 respectively.
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Table 3.7: Significant differences observed between time points for each material composition
Time points

0% FI27

1%F127

2%F127

0-1 day

*

*

*

*

0-3 day

*

0-7 day
1-3 day

5% F127

*
*

1-14 day
3-7 day

*

*

3-14 day

*

*

3-21 day

*

*

7-14 day

*

7-21 day

*

*

*, is represent there is significant different where p<0.05.

There is no difference in the value of E for those materials synthesized with 3 and 4% FI27 as a
function of incubation time up to 21 days. For the 0% FI 27 material the modulus increases from
0-1 and 1-3 days (2 - 103MPa respectively), then decreases and plateaus at 56MPa between 7-21
days. Overall this trend of an early increase in modulus is present for all inclusions of FI27,
though the peak value of E appears to deviate between 3 and 7 days (depending on FI27
inclusion levels). The general trend is interesting, so too is the fact that it also occurs for 0%
FI 27 material, indicating that such behaviour of these NGCs may, in general, be independent of
FI 27 additions, acknowledging that the FI 27 additions may push the direction of the peak value
of E in a time dependant fashion. T he importance of E on neurite extension is of crucial
importance. With respect to PLGA/F127 NGCs such data is very limited in the literature,
consequently the impact of E when selecting optimum compositions of PLGA/F127 NGCs has
been overlooked. It has been shown that neurite extension increases with increasing elasticity.
Extending nuerites will exert tension on the PLGA/F127 substratum and sense the underlying
elasticity through cellular receptors (primarily integrins) which act as mechano-transducers. If a
material exhibits too high a modulus the tension produced by cells to allow extension along the
substratum may be too great and limit regeneration. As such examination of the time dependant
behaviour of E with respect to PLGA/F127 NGCs is requisite for further material development,
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especially in light of the fact that increased FI 27 content (up to 5%) enhances hydrophilcity of
the NGCs to allow for immediate water absorption [326].
The time dependant nature of Young’s modulus with respect to time and environment for
PLGA/F127 NGCs has been established in this letter. It has been shown that FI27 exerts
influence on the modulus of PLGA/F127 NGCs. Contrary to current philosophy (based on dry
state, un-incubated specimens of such devices) a 5% loading of FI27 in such NGCs will yield
appropriate mechanical properties for such devices whilst ensure rapid adsorption of local fluids
with concurrent permeation of nutrients at the implant site. Based on these results, and the cell
viability results of glass the three glasses will be incorporated into degradable polymeric
matrices for further in vitro and in vivo investigation on biocompatibility and mechanical
properties in order to assess the composition and corresponding behavior for an optimum
peripheral NGCs
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3.5

Design of Expert Results and Discussion

3.5.1 Analysis of Variance (ANOVA)
The lest for significance of the regression models, test for significance on each model
coefficients, and the lack of fit test were carried out. Backward regression methods were selected
to determine the significant model terms automatically. The reduced quadratic and linear models
present the ANOVA for each response and show the significant model terms. Abstracted
ANOVA results are provided in Table 3.8.
Table 3.8: Abstracted ANOVA table for the cell viability reduced quadratic polynomial models (3, 7 and 28 days)
and UTSo reduced linear model

Mean

Lack

F

Prob.>F

Adj-

cv

Adq-

R^

(%)

prec

SSniojjei

DF

Square

of fit

value

model

2076.27

3

1692.1

Not sig.

11.56

0.0028

0.813

0.742

11.64

11.06

5750.61

7

821.52

Not sig.

18.13

0.007

0.969

0.916

5.35

13.40

(28 days)

2744.21

6

457.37

Not sig.

7.93

0.0191

0.905

0.791

6.33

10.75

UTSo

3100.87

1

3100.87

_

8.35

0.0045

0.676

0.595

_

4.086

Response
Cell viability
(3 days)
Cell viability
(7 days)
Cell viability

The same tables show additional adequacy measures R^, adjusted

and the adequate precision.

All R^ and adjusted R^ adequacy measures are close to 1, while all values of adequate precision
for each response exceed the desired value of >4, which is also in reasonable agreement and
indicates significant relationships.
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3.5.2 Development of Mathematical Models
Table 3.8 and 3.9 illustrates the cell viability response based on the compositional variables (A,
B and C as outlined in section 2.5). In a limited number of cases, large deviations about the mean
are recorded, and acknowledged.
Table 3.9: Summary of the significant (positive and negative), main, interaction and quadratic effects associated
with compositional factors (order of significance for positive significant effects: highest to lowest and negative
significant effects: lowest to highest)

Ranking

Effect of increasing

of effect

factor on response

Responses
Ceil viability

Cell viability

Ceil viability

(%), 3 days

(%), 7% days

(%) 28 days

ETSfl

Positive
effect

1

T

A

A

2

T

AC“

AC“

C

A'
AB^

Negative
effect
AB"

1

I

2

i

BC“

3

i

B^

4

i

A^

5

i

AB"

C

The final mathematical models in terms of coded factors as determined by design-expert
software are shown below in Eqs.(3.1, 3.2, 3.3). Based on Eq. (3.1) the level of significance of
positive quadratic effects (based on compositional variables) follows the order (A^) > (B^). A
significant negative interaction was observed to be (AB). Eq. (3.2) demonstrates that the level of
significance for the positive main and interaction effects on cell viability after 7 days was (A) >
(AB) while the significance of the negative main, interaction and quadratic effects follows the
order (A^) > (AB) > (B^) > (C). With respect to Eq. (3.3) the significant positive main and
interaction effects on cell viability after 28 days are (A) > (AB) while the level of significance
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for the negative main, interaction and quadratic effects follows the order: (C) > (BC) > (B1>
(a2)>(AB).

% Cell Viability (3 days) = +85.06 - 32.06 AB + 27.20A^ + 17.99B^

Equation 3.1

% Cell Viability (7 days) = +119.58 + 58.70A - 30.93C - 11.86AB + 41.74AC - 30.79BC 21.49A^-25.50B^

Equation 3.2

% Cell Viability (28 days) = +122.25 + 36.79A - 11.96C - 15.99AB + 33.71 AC - 23.53A^ 15.36B^

Equation 3.3

3.5.3 Composition-property Relationships with Respect to Cytotoxicity
Figure 3.12 represents the perturbation plots, which illustrate (in a decoupled manner) the effect
of each compositional factor on cell viability.
Penurbation

Perturbation

Deviation from Reference Point(Coded Units)

Deviation from R^erence Point(Co(ied Units)

Perturbation

Deviation from Reference Point (Coded UInts)

Figure 3.12: Perturbation plots showing the effect of each factor on the cell viability at a 3 days, b 7 days and c 28
days from the centre point of the BBD space (0, 0, 0: 12.5, 2.5, 20 wt%)

3.5.3.1 Factor A (PLGA Content: Range 5-20wt%)
With respect to independently evaluating the impact of Factor A on cytocompatibitly, variable
responses were observed as a function of time. At 3 days (Figure 3.12 a), varying the content of
PLGA between 5-12.5wt% decreases mean cell viability from 113% to 85% as compared with
the control (tissue-culture water). Interestingly, an increase in PLGA content from 12.5-20wt%
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results in mean cell viabilities recovering to 113%, as compared with the control. At 7 days
(Figure 3.12 b), increasing the PLGA content of the CNGC approximates linear behaviour with
cell viability in the range 50% to 150%. By 28days (Figure 3.12 c). Factor A shows a linear
effect on cell viability between 5-12.5wt%, thereafter its impact is observed to approach a
quadratic relationship. The observed dependency of increased cytotoxicity with decreasing
PLGA content is likely attributable to reductions in pH associated with the faster degradation of
conduits comprising <12.5wt% PLGA [372]. Even though cytotoxicity is observed for certain
additions of PLGA, it must be noted that such observations are limited in terms of severity [373].
More significantly, the results point to optimum contents of PLGA additions in respect of the
overall composite; a feature further elucidated in section 3.5.4. PLGA is the only factor, in terms
of the proposed models, to have a positive main effect on cell viability (Table 3.5.4).
3.5.3.2 Factor B (FI27 Content: Range 0-5wt%)
With respect to Factor B, cell viability follows the same behaviour patterns as noted for Factor A
(Figure 3.12). Succinctly, a parabolic effect is noted at 3 days between a maximum of 103% cell
viability, to 85% cell viability, recovering to 103% cell viability for loadings of FI27 of 0, 2.5
and 5wt%. However, for 7 and 28-day cell viabilities, a reverse quadratic effect is observed
(Figure 3.12b and 3.12c). Whilst other studies have shown that low concentrations of FI27 may
alter transport of compounds across cell membranes (normally impermeable), in general FI27
has been shown to have good cytocompatibility similar to this ranges reported here [48, 374].
Nevertheless, whilst all cell viabilities recorded represent reasonable levels of cytocompatibility,
the reason for the reverse quadratic effect is difficult to explain based on the present data. Based
on the models developed and when examined as an isolated factor, FI27 does not significantly
affect cell viability.
3.5.3.2 Factor C (Glass Component: Range 0-40wt%)
For Factor C there is no impact on 3-day cell viability as a result of the glass content (Figure
3.12a). This observation is likely due to the fact that there is a limited surface area of glass
particles exposed to the incubation media up to this time point. However, the glass component
exerts a marked influence on cell viability at 7 and 28-days (Figure 3.12b and 3.12c). By 7 days,
0wt% glass provides for cell viabilities in excess of 150% as compared with the control (tissue
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culture water), which decreases in a linear fashion to c.100% cell viability with the addition of
40wt% of glass. Similar reductions are noted for the 28-day data. As incubation time increases,
and polymeric degradation ensues, increased glass particle exposure to the media (which
increases with glass content) occurs and results in the accumulation of metal ions in solution;
such accumulations being associated with increased cytotoxicity [280]. However, an interesting
point of note is that whilst cell viabilities decrease, the reduction is towards a viability of 100%
as compared with the control. Whilst cell viabilities in excess of 100% have been previously
reported for zinc-silicate glasses [375] the authors have pointed out that enhanced cell viability
(evident by induced cell proliferation) may not correspond with beneficial effects. Rather,
genotoxic effects can cause cell DNA damage resulting in malfunctions within the regulation of
the cell cycle and subsequent uncontrolled proliferation of mutated cells. As such, relevant
genotoxicity testing is warranted for these glasses and their composite derivatives. Based on the
models developed, and when examined as an isolated factor, the glass component exerts a
significant negative effect on cell viabilities at 7 and 28-days.

3.5.4 Examination of Significant Interactions between Compositional Factors
on Cell Viability
Figure 3.13, 3.14 and 3.15 represents eontour plots, which illustrate the significant interaction
between compositional factors on cell viability (highlighted in Table 3.9). The significant
interactions are; AB, AC and BD. With respect to the interaction AB (Figure 3.13), this
interaction has negative significance at each time point (Table 3.9). At 3 days (Figure 3.13 a,
3.13 b and 3.13 c) lowest cell viabilities (87%) are obtained for median concentration of PLGA
and FI27. Enhanced cell viabilities (up to 150%) appear to be dependent on increasing PLGA
and decreasing FI27, from c.l 1% and c.1% respectively.
However, counter-intuitively, increasing FI27 from c.1% and decreasing PLGA below 11% also
provides for increased cell viability (again up to 150%). Based on the data, the glass component
exerts no influence on this interaction with respect to cell viability at 3 days. However, by 7 and
28-days the glass exerts influence over the interaction AB (for reasons discussed in section
3.5.3.1 (A)), at 7 and 28-days, it is clear that increased cell viabilities can be controlled based on
composition. Specifically, 0wt% glass will allow for cell viabilities of c.l50%. However, the
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same ratio of A: B with 20wt% and 40wt% additions of glass reduces cell viability to c.125%
and c.100% respectively. Interestingly, the effect of increased glass content on cell viability may
by controlled (increased) by increasing the PLGA content from 14wt% to 20wt%, and decreasing
FI27 to <3wt% (Figure 3.13d-i).
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Figure 3.13: Contour plots showing the significant interaction effects of AB on the cell viability (a-c 3 days, d-f 7
days, g-i 28 days) for three loadings of glass (0, 20, and 40 wt%)

With respect to the interaction AC (Figure 3.14), which has a positive significant effect at 7 and
28days (Table 3.10), the following observations are noted; lowest recorded levels of cell viability
(<50%) are typically associated with reduced PLGA content (for all additions of FI27),
indicating that FI 27 exerts little influence on the AC interaction with respect to low levels of cell
viability.
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Figure 3.14: Contour plots showing the significant interaction effects of AC on the cell viability (a-c 7 days, d-f 28
days) for three loadings of FI27 (0, 2.5, and 5 wt%).
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Furthermore, as noted for the AB interaction, increased glass content and increased PLGA
content offer highest levels of cell viability (Figure 3.14 a-f). Again, the contour plots provide an
exacting mechanism for selecting preferred viability (between <50% up to in excess of 150%)
based on composition, (previously noted for the interaction AB). For example, based on the
interaction AB, increased cell viabilities at 7 and 28-days (>140%) may be obtained where the
following conditions are met:
i)

0 and 2.5wt% FI27 is used in the CNGC.

ii)

PLGA is kept in the range 17-20wt%.

iii)

Glass content is in excess of 25wt%.

For the interaction AC, it is noted that incorporation of 5wt% FI27 requires reduced levels of
PLGA at 7 days; for example PLGA in the range 7-19wt% and glass loading <3wt% confer
largest cell viabilities at this time point. The final significant interaction reported (Table 3.9) is
BC and demonstrates negative significance at 7 days (Table 3.9). More particularly, at low
concentrations of PLGA (5wt%), it is required that additions on the order of at least 2wt% FI 27
and 2.5wt% glass are required to obtain cell viabilities exceeding those of the control. It is also
evident that increased additions of factors B and C is permitted where the PLGA content is in the
range 12.5-20wt%. Enhanced evaluation of composition-property relationships with respect to
cell culture was possible at the main level for the CNGC. The main, combined and quadratic
effects of composition on the experimental CNGC have been established in this section, and will
allow for enhanced material design and development of these materials.
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Figure 3.15: Contour plots showing the significant interaction of BC on cell viability (7 days only) for three
loadings of PLGA (0, 12.5, and 20 wt%).

3.5.5 Composition-Property Relationships with Respect to UTSq
CNGC synthesized with 0 and 5wt% additions of PLGA were unsuitable for mechanical testing
due to lack of structural integrity (irrespective of glass content). However, for CNGC
synthesized based on 12.5 and 20wt% additions of PLGA (with a glass content <20wt% glass),
UTSo values in the range 2.6 -L4MPa were recorded (Table 3.10), with highest values being

observed for those with 20wt% additions of PLG A. As expected (Eq. 3.4), the glass composition
was the main factor, which allowed for a significant effect in achieving the UTSo within a
desirable range (Eq 3.4, developed for this response will be used in section 3.5.6 to optimize the
composite).
UTSo = +52.88 + 45.47C

Equation 3.4

It was noted that glass loadings over 20wt% compromised the processing of conduits;
specifically, high loadings of glass appeared to inhibit precipitation of composite (in solution
form) onto the alginate rods. It appeared that the FI27 also exerts control on the UTSo, which is
counter to recent literature [57]. Specifically, CNGC-B and CNGC-D differ only in FI27 content,
0 and 5wt% respectively (Table 3.10) yet observed UTSo of 38MPa and 77MPa was observed
respectively. The reason for this observation, which is counter to published literature is unclear at
present, however interaction effects between the glass and the FI27 may be the determining
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factor here. Further analysis, over extended periods of time with additional experimental runs
may clarify the root cause of this observation.
Table 3.10: Box-Behnken design matrix of design variables, in coded {and real values) and responses for cell
viability (3, 7 and 28 days) and initial ultimate tensile strength

Sample

Factors

Std. no.

Responses
Cell Viability

Initial UTs

A/PLGA

B/F127

C/Glass

3 day

7 day

28 day

(% w/w)

(% w/w)

(% w/w)

(%)

(%)

(%)

(MPa)

CNGC-A

1

-1/5

-1/0

0/20

-

-

-

-

CNGC-B

2

+ 1/20

-1/0

0/20

137

143

127

38

CNGC-C

3

-1/5

+ 1/5

0/20

-

-

-

-

CNGC-D

4

+ 1/20

+ 1/5

0/20

107

120

104

77

CNGC-E

5

-1/5

0/2.5

-1/0

104

112

108

-

CNGC-F

6

+ 1/20

0/2.5

-1/0

103

146

113

13

CNGC-G

7

-1/5

0/2.5

+ 1/40

-

-

-

-

CNGC-H

8

+ 1/20

0/2.5

+ 1/40

113

167

157

-

CNGC-I

9

0/12.5

-1/0

-1/0

97

94

118

1

CNGC-J

1

0/12.5

+ 1/5

-1/0

104

156

119

6

CNGC-K

11

0/12.5

-1/0

+ 1/40

91

94

94

-

CNGC-L

12

0/12.5

+ 1/5

+ 1/40

-

-

-

-

CNGC-M

16

0/12.5

0/2.5

0/20

85

119

127

-

3.5.6 Optimization Based on Cytotoxicity and UTSo
To ensure that CNGCs developed are of adequate mechanical strength and cytocompatibility, it
is recommended that the optimal compositions be used. The models established in this work
have been developed and checked for their adequacy [332]; consequently, optimization criteria
can be set to find the optimum compositions based on the composition-property responses
examined. Three optimization criteria (Table 3.11) were used.
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Table 3.11: Design optimization parameters

First criterion

Second criterion

Third criterion

Goal

Importance

Goal

Importance

Goal

Importance

PLGA%(w/w)

In range

-H-+

In range

+++

In range

-H-+

Pluronic

In range

H—1—h

In range

+++

In range

+++

In range

+++

In range

+++

In range

+++

Maximise

-H-+

Maximise

+++

Maximise

+++

Maximise

+++

Maximise

+++

Maximise

+4 +

Maximise

+++

Maximise

+++

Maximise

++-f

None

N/A

In range

4-++++

In range

+ 4-+-f-+

Factor

F127%(w/w)
Glass%(w/w)
response
Cell viability.
3 days (%)
Cell viability.
7 days (%)
Cell viability.
28 days (%)
Initial UTSo
(Mpa)

(5-30MPa)

(5-20MPa)

Weight is given for all the factors in the range 1,0. The goal of the first criteria is to identify the
optimal composite compositions to maximise the cell viability with no limitation set on either the
compositional factors or the mechanical strength. On the other hand, the second criterion is
investigated to identify the optimal composite compositions, with no limitation set on the
compositional factors, but would maximise the cell viability while achieving an UTSo in the
range: 5-30MPa: to provide CNGCs of optimal cell viability with greater tensile strength than the
Neurolac® device . In addition to this, for the third criterion, the goal was to identify the optimal
compositions with no limitation set on the compositional factors: to maximise the cell viability
while achieving an UTSo in the range: 5 - 20MPa: to provide CNGCs of optimal cell viability of
a comparable tensile strength to the Neurolac® device [376]. The top five optimal solutions that
fulfil these three sets of criteria are presented in Table 3.12
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Table 3.12: Optimal solution as obtained using Design-Expert (using the parameters in Table 3.11)

Solution
number

Cell

Cell

Cell

Initial

viability

viability

viability

UTSo

A

B

C

(%) 3 days

(%) 7 days

(%)28days

(Mpa)

Desirability

1

18.89

0.52

12.71

137.74

135.4

131.56

-

1.00

2

19.9

0.16

26.78

156.94

158.38

144.16

-

1.00

3

18.31

0.48

17.18

133.25

139.19

134.61

-

1.00

4

19.56

1.03

13.91

133.16

145.45

133.56

-

1.00

5

17.97

0.25

34.8

134.99

158.22

143.98

-

1.00

First criterion

Second criterion
1

18.34

0.62

9.83

130.45

132.24

130.06

29.77

1.00

2

18.49

0.7

9.5

130.11

133.53

130.02

29

1.00

3

18.27

0.6

9.92

130.19

131.9

130.08

29.95

1.00

4

19.08

0.95

9.74

130.32

138.51

130.18

29.56

1.00

5

18.86

0.84

9.53

130.71

136.24

130.05

29.08

1.00

Third criterion
1

18.63

0.77

5.54

130

130

127.01

20

1.00

2

19.02

0.94

5.54

130

133.15

126.6

20

1.00

3

19.1

0.98

5.54

130

133.75

126.47

20

1.00

4

19.45

1.13

5.54

128.6

130

127.32

20

1.00

5

19.45

1.13

5.54

130.11

136.1

125.7

20

1.00

From the optimal solutions outlined (Table 3.12) it is evident that for the three sets of criteria (as
per the top 5 ranked solutions for each criterion), the working ranges for both PLGA and FI27
compositions are similar. RSM graphical optimization (Figure 3.16) allows for visual selection
of the optimum compositions for each of the components in order to form an idealised CNGC of
tailored mechanical strength and biocompatibility.
The results for the graphical optimization are also displayed as overlay plots (for enhanced
detail), as shown in Figure 3.16, which satisfy the first solutions in both the first (Fig. 3.16 a) and
second criteria (Fig. 3.16 b).
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Figure 3.16: RSM plots (in 3D and 2D) show the desirable region for optimal compositions of PLGA, Pluronic
F127 and glass in the final CNGC based on the second and third criterion

In fact, to reach any of the three criteria, the PLGA and FI27 are required to range between
17.97 to 19.90wt% and 0.16 to 1.13wt%, respectively, while the working range for glass addition
varies between 5.54 to 34.80wt%. With respect to the glass content, the prediction of up to
34.80wt% is based on responses examined and does not recognise difficulties in synthesizing
CNGC with >20wt% glass. As such a glass loading of <20wt%, based on the results is preferred.
If the compositions of the three components in the CNGC are free to change in order to
maximise the cell viability (3 days ~ 138%; 7 days

135%; 28 days = 132%) without any

limitations on the mechanical strength, the PLGA composition needs to be between 17.97 to
19.90wt%, with a low level of FI27 composition between 0.16 to 1.13wt% and glass
composition ranging between 13.91 to 34.80wt%. On the other hand, if an UTSo of ~30MPa is
required using the same conditions as set for the first criteria, it is verified that, the PLGA
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composition has to range between 18.27 to 19.08wt% and the FI27 composition between 0.60 to
0.95wt%.
These types of plots may be used as a manufacturer’s reference guide to prepare the proposed
CNGCs in choosing the values of the compositions for the composite material comprising of
PLGA, FI27 and glass, which would achieve the appropriate levels of mechanical strength
tailored to suit the anatomical site at a maximum level of biocompatibility. The yellow/shaded
areas on the overlay plots are the regions that meet the proposed criteria. The mechanical
stability of the conduit is an additional requirement for the success of tissue regeneration. For the
case of the CNGCs developed in the present study, the conduit requires a high degree of porosity
to allow rapid tissue infiltration, while having enough composite matrix material to retain its
structural integrity for an appropriate duration to enable the degradation process match the rate of
peripheral nerve regeneration. The addition of rigid fillers to polymer matrices is common
practice in composite technology to improve the stiffness, mechanical strength and structural
integrity of components. Boccaccini et al. [213], applying a model developed based on an
equation by Ishai and Cohen [377], estimated that the addition of 1 wt% Bioglass® particles in
their composites lead to a 5% increase of elastic modulus of neat PLGA materials of equal
porosity. The approach in this study and the RSM outputs allow enhanced evaluation of
composition-property relationships with respect to such composites.

3.5.7 Limitations of the DOE Study
As a preliminary study, limitations exist which must be noted. Primarily, rather than evaluate
specific cell responses {e.g. biosynthetic activity) this study emphasized phase 1 cytotoxicity
evaluation using L929 mouse fibroblasts. Whilst, this is a robust and accepted model for
preliminary screening, additional experimentation using more representative cells {e.g. glial cells)
is now warranted. Secondly, and again in respect of the cell culture experimentation; whilst the
study did capture the influence of individual components (main effects) and the interaction of
components on cytocompatibility, the study did not capture the root-cause of enhanced cell
proliferation associated with some CNGC; a feature which may or may not be positive. As
pointed out in the discussion, full genotoxicity screening of the materials is warranted based on
these results.
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This Section has successfully synthesized a unique set of CNGC based on i) a unique, phosphate
free ion leachable glass comprising elements associated with enhanced peripheral nerve
regeneration and protection, alongside ii) a PLGA / FI27 polymeric matrix, synthesized as
tubular constructs. The main (individual), interaction and quadratic effects of composition of
experimental CNGC has been rigorously examined with respect to cytotoxicity and mechanical
properties using a design of experiments approach. The desirability / optimization methodology
employed was used as a basis to select preferred compositions (based on cytotoxicity and
mechanical properties). The preferred compositions are in the range 17.97wt%-19.90wt% PLGA,
0.16-1.13wt% FI27 and between 5.54 and <20wt%. The experimental material warrants further
examination as a CNGC.
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3.6

Evaluation of Mechanical Properties and Cell Viability

3.6.1 Ultimate Tensile Strength (UTS)
Figure 3.17 compares the UTS for each CNGC at each discrete incubation periods (1, 3, 7, and
28 days). The UTS for each CNGC composition after Iday incubation (Figure 3.17 a) is in the
range of l-4MPa. No significant difference in UTS was observed between CNGC-M, D, B, and
F. The observed UTS for CNGC-J and 1 was significantly less when compared with that of
CNG-M and B. CNG-I exhibited the lowest mean UTS at 1 MPa, significantly less than that of
CNG-F (3MPa). The UTS for each CNGC after the 3 days incubation (Figure 3.17 b) is in the
range 3-7MPa. CNGC-D exhibited the highest mean UTS at 7MPa. The following significant
differences are noted after 3days incubation; The UTS of CNGC-M was significantly higher than
the UTS of CNGC-B, J, and F. The UTS of CNGC-D was significantly higher than CNGC-B, J,
1, and F. The UTS of CNGC-I (4MPa) was significantly higher than the UTS of CNGC-B
(2MPa) and J (3MPa).
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Figure 3.17: Bar graph comparison of UTS for 6 CNGC conduits over incubation periods; (a) UTS after 1 day
incubation, (b) Ul’S after 3 day incubation, (c) UTS after 7 day incubation, and (d) UTS after 28 day incubation. {*
P<0.05, ** P<0.005, ***p<0.0005).

The UTS for each CNGC after 7 days incubation (Figure 3.17 c) is in the range 5-7MPa. No
significant difference was noted between the UTS of the strongest CNGCs (7Mpa): CNGC-M, D,
B, and F. The UTS of CNGC-I (5MPa) was significantly lower than CNGC-M (7MPa), and F
(7MPa). The UTS of CNGC-J (5MPa) was significantly lower than UTS of CNGC-B (7MPa).
The UTS for each CNGC after 28 days incubation (Figure 3.17 d) is in the range 3-6MPa. The
only significant different was between UTS of CNGC-M (6MPa) and CNGC-I (3MPa). Even
though the mean UTS of CNGC-D (2.9MPa) is smaller than 1 (3.3MPa), there was no significant
difference between the UTS of CNGC-M and D due to the larger Standard deviation (SD) error
bars in the UTS results of CNGC-D (2.9+0.73MPa) than the error in the UTS of CNGC-I (3.3+
0.21 MPa).
Figure 3.18 compares the UTS data for individual CNGCs as it varies with respect to incubation
period. Among the 6 CNGC conduits, M and F had the highest UTS results (about 7MPa) after 7
day incubation period.
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Figure 3.18: The Wet-State UTS of each CNGC conduits compared by the incubation periods of 1, 3, 7, 28 days. (*
P<0.05, ** P<0.005).

With the exception of CNGC-D, which showed peak UTS after 3 days incubation, each CNGC
exhibited peak UTS after 7 days incubation. It was found that UTS of CNGC-M remained stable
over all incubation periods; while the UTS of CNGC-D increased between 7 and 28day
incubation periods. The UTS of CNGC-1 and J significantly increased from Iday to 3day and
from 3days to 7days. The UTS of CNGC-B declined between 1 and 3 days. The UTS of CNGCF had increased significantly between 3 and 7day incubation periods, subsequently decreasing
between 7 day and 28 days.

3.6.2 Young’s Modulus
Figure 3.19 compares Young’s Modulus (E) for each CNGC at each discrete incubation period
(1, 3, 7, and 28 days). The value of E for each CNGC after Iday incubation (Figure 3.19 a) were
in the range 5MPa to 103MPa. The Young’s Modulus of CNGC-1 was significantly lower than
each CNGC with the exception of CNGC-J (17MPa). The Young’s Modulus of CNGC-B
(70MPa) was significantly higher than each CNGC with the exception of CNGC-D. The value of
E for each CNGC after 3days incubation (Figure 3.19 b) were in the range 9-180MPa. No
significant difference was observed between the Young’s Modulus of CNGC-D (114+12 Mpa)
and B (180 +58 Mpa). The Young’s Modulus of CNGC-D and B were significantly greater than
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those of the other CNGCs (M, J, I and F). Also of note is that the Young’s Modulus of CNGC-J
(9 +7.6 Mpa) and I (23 +12.2 Mpa) were significantly different after 3days incubation.
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Figure 3.19: Bar graph comparison of Young’s Modulus for 6 CNGC conduits over incubation periods; (a)
Young’s Modulus after 1 day incubation, (b) Young’s Modulus after 3 day incubation, (c) Young’s Modulus after 7
day incubation, and (d) Young’s Modulus after 28 day incubation. (* P<0.05, ** P<0.005, ***p<0.0005)

The value of E for each CNGC after 7days incubation (Figure 3.19 c) were observed to be in the
range 12-930MPa. I'he Young’s Modulus for CNGC-M (70MPa) was significantly greater than
that of CNGC-J, I, and F. In addition, the Young’s Modulus of CNGC-D (93MPa), was also
greater than that of CNGC-J, and I. CNGC-B also had a greater Young’s Modulus than CNGC-I.
No significant difference between the Young’s Modulus of CNGC-B (88 + 42MPa) and J (12 +
2MPa). However, large variability between the SD of CNGC-B and SD of CNGC- J is noted.
165

Chapter 3: Results and Discussions

The value of E for each CNGC after 28 days incubation (Figure 3.19 d) were observed to be in
the range 42-204MPa. It was observed that CNGC-I showed a significantly reduced modulus
(41.8 ±7.3 MPa) when compared with CNGC-B (203 ±58.2 MPa).
Figure 3.20 compares the E for each CNGC as it varies with respect to incubation period.
Increased modulus was observed for CNGCs with 20% bioglass (M, D, and B) as compared with
those containing 12.5% bioglass (J, I, and F).
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A
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▼

7 Day

♦

28 Day

6 CNCC Compositions
Figure 3.20: The Wet-State Young’s Modulus of each CNGC conduits compared by the incubation periods of 1, 3,
7, 28 days. (* P<0.05)

The only significant change in Young’s Modulus associated with incubation period was
observed for CNGC-B between 7 and 28days. Over all time periods, CNGC-1 had the lowest
Young’s Modulus of 5MPa (1 day). CNGC-B had the highest Young’s Modulus of 204MPa after
28days.
3.6.3 Cytotoxicity Results of CNGCs
Cytotoxicity results are presented in Figure 3.21 including a state-of-the-art commercial NGC
Neurolac.
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Figure 3.21: The Cell Viability of 6 CNGC conduits compared with Neurolac over 24 hours incubation. (* P<0.05,
** P<0.005, ***p<0.0005)

3.6.4 Analysis of the Mechanical Properties for CNGCs
The CNGCs examined in this research paper were previously identified as candidate
compositions for peripheral nerve regeneration based on a preliminary DOE analysis, which
evaluated (in a dry state) a Box-Behnken design matrix of 13 compositions; identification of
suitable candidates was based on mechanical strength (UTS), ease of processability, and
retention of structural stability [378].
The UTS of the CNGCs examined in this study fell within the range of l-7MPa, which contrasts
well with the limited literature available on the time dependant properties of PLGA/F127
polymer conduits for nerve regeneration. Oh et. al. [48] reported that 10wt% of PLGA
augmented with l-5wt% of FI27 the UTS was 0.05-0.08Kgf/mm^ (i.e. 0.5-0.8MPa). The
increased values of UTS associated with the experimental conduits presented in this work arise
due to the increased PLGA content of the CNGC (12.5-20 wt%) and glass loading. In particular,
CNGC-B, D, and M (20% glass) generally demonstrated higher mean UTS that glass free
conduits. The exception to this observation occurred for CNGC-B after 3days incubation where
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its strength was diminished with respect to CNGC-J and I; a result difficult to explain in light of
the body of evidence available. It is important to note that while the glass loadings in this study
were fixed, previous examinations of the composition-property relationships in these materials
(in their dry state) has quantified the impact of glass content (0-40%) on UTS using a surface
response methodology and is available elsewhere in the literature [379]. The data acquired
illustrates that under simulated physiological conditions, control of the UTS of the CNGCs can
be modulated in the range l-7MPa by modification of the concentrations of PLGA and glass
component as outlined. It is also clear that the CNGCs are extremely sensitive to the
physiological environment. Previous work by the authors has shown that post synthesis (fully
dried), and prior to exposure to aqueous media the CNGCs examined in this work exhibit values
of UTS ten times greater than those incubated under physiological conditions; observations
which are consistent with the literature. Wu et. al. [380], found that the mechanical properties of
biomedical polyesters only retain c.10% of their ‘dry-state’ properties after exposure to aqueous
media and whilst they are evaluated in a wet state.
Figure 3.19 illustrate the Young’s Modulus of all the CNGCs, as expected glass filled
composites demonstrate increased E as compared with unfilled materials [48]. The overall range
of E was between 5.5 and 203MPa. With respect to the data pertaining to Modulus, for glass
filled CNGC, it is observed that where significant difference arises (1 and 3days); such changes
are attributable to Pl.GA content (i.e. CNGC- B, CNGC -D, Vs CNGC-M). However this
compositional difference appears to no longer provide for significant changes in strength at 7 and
28days. With respect to the impact of FI 27 on the E of the CNGCs it is observed that in general
FI27 does not significantly impact on E for filled or for unfilled materials, with the exception of
data collected at 3days.
Critically, From a clinical standpoint and based on current synthetic devices which have
demonstrable safety and efficacy in the indication it is clear from the literature (based on
predicate device properties and ex vivo data (Table 3.13)) that the CNGCs examined in this work
offers appropriate strength over the time period examined.
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Table 3.13: Mechanical property of existing copolymer for NCG application and predicted compositions material
property of PLGA in vitro

Material
Poly(DLLA
-CL)

PLGA
(LA:GA,
80:20)

maximum
strength
(IV^aT

Young's
Modulus

Diameter
(mm)

Thickness
(mm)

Length
(mm)

Rate
(mm/Min)

7

2.36

0.33-0.4

30

10

100

3.4 (± 0.5)

13.0 (±
5.5)

[166]

14

2.36

0.33-0.4

30

10

100

2.6 (± 0.2)

9.9 (±
2.8)

[166]

28

2.36

0.33-0.4

30

10

100

2.2 (± 0.3)

3.0 (±
1.8)

[166]

1

80

0.5

5

[381]

1

80

0.5

3.6

[381]

1

80

0.5

3.4

[381]

1

80

0.5

4.5

[381]

1

80

0.5

3.5

[381]

1

80

0.5

3.8

13811

7
14
28

PLGA
(LA;GA,
70:30)

Load
Cell

Incubation
Time
(days)

7
14
28

10
(width)
10
(width)
10
(width)
10
(width)
10
(width)
10
(width)

Reference

3.6.5 Analysis of the Cell Viability for CNGCs
The cell viability of all the CNGCs was greater than 85% for each incubation period and
contrasts well with previous literature which reports viabilities of PLGA scaffolds in the range of
86-91% [382] over 1,3, 14 day periods (cultured with stem cell lines) and 83% - 101% for L929
mouse fibroblasts [383]. The cell viability of CNGC with 12.5 wt% PLGA and 20 wt% bioglass
had an inhibitory effect at the start of incubation (1 day and 3 day incubation). This was possibly
due to the acid degradation products of PLGA, which lead to the pH decrease in the test extract
[384], and then the acidic product was balanced by the alkali product of bioglass [325, 385],
thus the cell viability increased after 7 day incubation in the naturalized solution [386]. This
inhibitory phenomena had also occurred for the cell viability of CNGC-I (12.5% PLGA only),
since there was no alkali of bioglass to balance the acidic solution, the inhibitory remain after 7
days incubation, and the cell viability recovered after that. The similar tendency have been
observed by Wu [385], through proliferation of osteoblastic-like cell culture over 1, 3, and 7 day
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incubation period. In addition, the investigation carried out by Helen [387J on the response of
osteoblasts-like cell on polymer-bioactive glass composites over 1, 5, 7, 14 day have indicated
the increase of ALP activity after 7 days for polymer/bioglass composites (10% bioglass), and
PLGA had increase ALP activity in 14 days incubation. The cell viability of CNGC-J (12.5%
PLGA, 5 wt% FI27) was above 100% over all incubation periods, and there was no significant
difference between each time periods. The addition F 127 in the CNGC-J could increase the
hydrophilicity of the composition; the increased hydrophilicity could increase the interaction
between cells and material for direct cell viability test [48, 388]. Nevertheless, the MTT Assay in
the research was carried out through extract, and the all cell viabilities recorded represent
reasonable levels of cytocompatibility. The cell viability of CNGCs (Fig 3.21) was compared
with the cell viability of Neurolac at each incubation period, CNGC-D, B, and F had
significantly higher cell viability than the cell viability of Neurolac after 3, 7, and 28 day
incubation period respectively (Section 2.6), and there was no inhibitory effect for the CNGCs
with 20 wt% PLGA. The potential reason might be the wt% of PLGA, which is a marked factor
that it inhibit the ceil viability at lower level (12.5wt %) and enhance cell viability at higher level
(20 wt %). The cell viability of most of the CNGCs were above 100%, which may be not
referred as positive effect [389], since this could results from cell DNA damage in malfunction
lead to uncontrolled proliferation of mutated cell. However, the indirect MTT assay is an
extrapolation to the in vivo situation, further test is required to monitor the active undertaken in
vivo.
This Section has successfully characterised the wet-state, time-dependant mechanical properties
(up to 28 days) of experimental CNGC based on i) a unique, phosphate free ion leachable glass
comprising elements associated with enhanced peripheral nerve regeneration and protection,
alongside ii) a PLGA / F127 polymeric matrix, synthesised as tubular constructs. The data
presented in this paper illustrates that the experimental CNGCs offer comparable mechanical
properties, and cytocompatibility to conventional NGCs and as such offer significant potential
for peripheral nerve repair. Following on from this study, it is now necessary to fully
characterize the ion release profiles arising from each composition of CNGC, and correlate this
data with enhanced biological evaluations.
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3.7
3.7.1
The

Ionic Dissolution Results From CNGCs
Release
release levels for each composition of CNGC are illustrated in Figure 3.22. Si‘^^release

levels (after incubation at 1, 3, 7 and 28 days) for CNGC comprising 20wt% glass (CNGC-B;
CNGC-M and CNGC-D) are shown in Figure 3.22(a), while Si"^^release levels associated with
CNGC comprising 40wt% glass (CNGC-K; CNGC-H and CNHC-L) are shown in Figure
3.22(b). With respect to 20wt% glass CNGCs, it was observed that CNGC-B demonstrated Si"^^
release levels ranging from Ippm (+/-0.028ppm) at 1 day to 5.1 Ippm (+/-0.07ppm) at 28 days;
the highest mean release of Si"^^ of the three CNGCs in this series (between the full range of
incubation periods examined). CNGC-D exhibited Si"^^release levels ranging from 0.76ppm (+/0.04ppm) at 1 day to 2.92ppm (+/-0.137ppm) at 28 days; while CNGC-M demonstrated
release levels ranging from 1.203ppm (+/-0.449ppm) at 1 day to 2.437ppm (+/-0.142ppm) at 28
days; the lowest mean release of Si'^'^of the 3 CNGCs tested in this series (between 3 to 28 day
incubation periods only). In general, CNGC of the series comprising 20wt% glass were observed
to have significant increases in Si"*^ release between each incubation period, with the exception of
CNGC-M (no significant differences were observed between 1 and 3 days, and 3 and 7 days
incubation periods).

•K
♦H
▼L

(a).
Figure 3.22: The

(b).

ion release levels of 6 CNGCs with time dependency (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7 and 28 days incubation periods.
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With respect to 40wt% glass CNGCs, it was observed that CNGC-L demonstrated Si'^^ release
levels ranging from 6.293ppm (+/-0.161ppm) at 1 day to 6.477ppm (+/-0,047ppm) at 28 days;
the highest mean release of Si'^^of the 3 CNGCs in this series (over the full range of incubation
periods studied; reaching a peak after 24h). CNGC-H exhibited Si"^^ release levels ranging from
0.673ppm (+/-0.055ppm) at 1 day to 4.48ppm (+/-0.096ppm) at 28 days; while CNGC-K
demonstrated Si'^'^release levels ranging from 0.217ppm (+/-0.065ppm) at 1 day to (l,14ppm+/0.779ppm) at 28 days; the lowest mean release of Si'^^of the 3 CNGCs tested in this series (over
the full range of incubation periods examined). Indeed, with respect to incubation time, the Si"^^
release levels of CNGC-K significantly increased from 1 day to 3 days, and 3 days to 7 days
before finally plateauing. In general, significant increases in Si"^' release were observed for
CNGC-H between each incubation period; while no significant increase was observed for
CNGC-L between all incubation periods examined.

(a).
Figure 3.23: Student’s t-test results for the

(b).
ion release of the 6 CNGCs (a) CNGCs with 20wt% bioglass, (b)

CNGCs with 40wt% bioglass over 1, 3, 7 and 28 days incubation periods (* P<0.05, ** P<0.005, ***p<0.0005).

The Student’s t-test was used to examine the levels of Si"^"^ release for 20wt% and 40wt% glass
containing CNGCs at equivalent incubation periods (represented in Figures 3.23(a) and 3.23(b),
respectively). For 20wt% glass CNGCs, it was observed that CNGC-B generally releases
significantly more Si'^'^ than either CNGC-M or CNGC-D for each incubation period (the
exceptions being: (i) CNGC-B and CNGC-M releasing similar levels of Si"^^ after 1 days
incubation and (ii) CNGC-B and CNGC-D releasing similar levels of Si'*" after 3 days
incubation). In addition, CNGC-D was observed to release significantly higher amounts of Si'*^
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than CNGC-M at 3 and 28 days incubation. For 40wt% glass CNGCs, it is evident that CNGC-L
releases significantly more Si"^^ than either CNGC-H or CNGC-K for all incubation periods.
However, it is also noted that the Si"'^ release from CNGC-H is significantly higher than the Si"^^
release from CNGC-K at equivalent incubation periods.

3.7.2 Na^ release
The Na^release levels for each composition of CNGC are illustrated in Figure 3.24. Na^release
levels (after incubation at 1, 3, 7 and 28 days) for CNGC comprising 20wt% glass (CNGC-B;
CNGC-M and CNGC-D) are shown in Figure 3.24(a); while Na^ release levels associated with
CNGC comprising 40wt% glass (CNGC-K; CNGC-H and CNHC-L) are shown in Figure
3.24(b). With respect to 20wt% glass CNGCs, it was observed that CNGC-D demonstrated Na^
release levels ranging from 117.6ppm (+/-0.854ppm) at 1 day to 114.6ppm (+/-0.945ppm) at 28
days; the highest mean release of Na^ of the 3 CNGCs in this series. CNGC-B exhibited Na^
release levels ranging from 116.53ppm (+/-2.248ppm) at 1 day to 103.77ppm (+/-0.907ppm) at
28 days; while CNGC-M demonstrated Na^ release levels ranging from 78.76ppm (+/-6.9ppm) at
1 day to 109.2ppm (+/-4.157ppm) at 28 days; the lowest mean release of Na^of the 3 CNGCs
tested in this series (at 1,3 and 7 days incubation periods only). The only significant increase in
the Na^ release for CNGCs comprising 20wt% glass was observed to occur for CNGC-M
between 1 day to 7 days, and 3 days to 28 days.
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(a).
Figure 3.24: The

(b).

ion release levels of 6 CNGCs with time dependency (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7, and 28 days incubation periods.
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With respect to 40wt% glass CNGCs, it was observed that CNGC-H demonstrated Na^ release
levels ranging from 117.57ppm (+/-0.208ppm) at 1 day to 115.03ppm (+/-0.351ppm) at 28 days;
the highest mean release of Na^ of the 3 CNGCs in this series (over the full range incubation
periods studied; reaching a peak after a 24h incubation period). CNGC-K exhibited Na^ release
levels ranging from 93.6ppm (+/-3.33ppm) at 1 day to 50.67ppm (+/-19.54ppm) at 28 days;
while CNGC-L demonstrated Na^ release levels ranging from 29.76ppm (+/-1.316ppm) at 1 day
to (29.46ppm+/-2.93ppm) at 28 days; the lowest mean release of Na^of the 3 CNGCs tested in
this series (over the full range of incubation periods examined). However, with respect to
incubation time, the Na^ release levels of CNGC-L significantly decreases from 1 day to 3 days,
with a subsequent increase from 3 days to 7 days, and no significantly thereafter. Significant
decreases in Na^ release were observed for CNGC-K from 1 day to 7day and from 1 day to 28
days.
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Figure 3.25: Student’s t-test results for the Na^ ion release of 6 CNGCs (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7, and 28 days incubation periods (* P<0.05, ** P<0.005, ***p<0.0005).

The Student’s t-test was used to examine the levels of Na^ release for 20wt% and 40wt% glass
containing CNGCs at equivalent incubation periods (represented in Figures 3.25(a) and 3.25(b),
respectively). For 20wt% glass CNGCs, it was generally observed that Na^ release from CNGCD was significantly higher than that released from CNGC-M for each incubation period (the
exception being after 28 days; for which similar levels of Na^ were released by both
compositions). Additionally, the mean Na^ release from CNGC-D is significantly higher than
release levels observed for CNGC-B after 7 days incubation; with a subsequently more
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pronounced increase in significant difference occurring after a 28 day incubation period. The
only significant difference in Na^ release between CNGC-B and CNGC-M was evident after 1
day incubation; with no subsequent significant difference observed thereafter. For 40wt% glass
CNGCs, it was observed that CNGC-H releases significantly higher levels of Na^ than either
CNGC-K or CNGC-L for each incubation period. It is also noted that the Na^ release from
CNGC-K is significantly higher than that released from CNGC-L after 1, 3 and 7 days
incubation; with no subsequent significant difference observed thereafter.

3.7.3

release

The Ca^^release levels for each composition of CNGC are illustrated in Figure 3.26. Ca^"^release
levels (after incubation at 1, 3, 7 and 28 days) for CNGC comprising 20wt% glass (CNGC-B;
CNGC-M and CNGC-D) are shown in Figure 3.26(a); while Ca^^release levels associated with
CNGC comprising 40wt% glass (CNGC-K; CNGC-H and CNHC-L) are shown in Figure
3.26(b). With respect to 20wt% glass CNGCs, it was observed that CNGC-B demonstrated Ca^^
release levels ranging from 3.12ppm (+/-0.046ppm) at 1 day to 3.277ppm (+/-0.023ppm) at 28
days; the highest mean release of Ca^^of the three CNGCs in this series (over the full range of
incubation periods examined). CNGC-D exhibited Ca^^ release levels ranging from 2.86ppm (+/0.025ppm) at 1 day to 3.15ppm (+/-0.035ppm) at 28 days; while CNGC-M demonstrated Ca^^
release levels ranging from 1.59ppm (+/-0.038ppm) at 1 day to 2.31 ppm (+/-0.059ppm) at 28
days; the lowest mean release of Ca^^of the 3 CNGCs tested in this series (over the full range of
incubation periods examined). In general, CNGC-M and CNGC-D were observed to have
significant increases in Ca^^ release levels between each incubation period, with CNGC-D
demonstrating no significant difference between 3 and 7 day incubation periods.
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Figure 3.26: The Ca^^ ion release levels of 6 CNGCs with time dependency (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7, 28 days incubation periods.

With respect to 40wt% glass CNGC, it was observed that CNGC-K demonstrated Ca^^ release
levels ranging from 3.17ppm (+/-0.056ppm) at 1 day to 3.21 ppm (+/-0.055ppm) at 28 days; the
highest mean release of Ca^^ of the 3 CNGCs in this series (reaching a peak after an initial
incubation period of 1 day). CNGC-H exhibited Ca^^ release levels ranging from 2.43ppm (+/0.072ppm) at 1 day to 2.93ppm (+/-0.023ppm) at 28 days; while CNGC-L demonstrated Na^
release levels ranging from 3.20ppm (+/-0.046ppm) at 1 day to 2.23ppm (+/-0.029ppm) at 28
days; the lowest mean release of Ca^^of the 3 CNGCs tested in this series (over the full range of
incubation periods examined). However, with respect to incubation time, the Ca^^ release levels
of CNGC-H significantly increased over each subsequent incubation period, while the Ca^^
release levels of CNGC-K and CNGC-L demonstrated no significant deference over each of the
incubation periods.
The Student’s t-test was used to examine the levels of Ca^^release for 20wt% and 40wt% glass
containing CNGCs at equivalent incubation periods (represented in Figures 3.27(a) and 3.27(b),
respectively). For 20wt% glass CNGCs: (i) CNGC-D exhibited significantly higher levels of
Ca^"^ release compared to CNGC-B for each incubation period; (ii) CNGC-B demonstrated
significantly higher levels of Ca^"^ release compared to CNGC-M for each incubation period and
(iii) CNGC-B demonstrated significantly higher levels of Ca release compared to CNGC-D for
each incubation period, with the exception of 3 days incubation (where no significant differences
were observed between either composition).
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Figure 3.27: Student’s t-test results for the Ca^^ ion release of 6 CNGCs (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7 and 28 days incubation periods (* P<0.05, ** P<0.005, ***p<0.0005).

For 40wt% glass CNGCs: (i) CNGC-K demonstrated significantly higher levels of Ca^^ release
compared to CNGC-H for each incubation period and (ii) CNGC-L also demonstrated
significantly higher levels of Ca^^ release compared to CNGC-H for each incubation period and
(iii) CNGC-K demonstrated significantly higher levels of Ca^^ release compared to CNGC-L
after a 7 day incubation period, whereby no significant difference was apparent after a longer
incubation period of 28 days.

3.7.4

release

The Zn^^release levels for each composition of CNGC are illustrated in Figure 3.28. Zn^^release
levels (after incubation at 1, 3, 7 and 28 days) for CNGC of the series comprising 20wt% glass
(CNGC-B; CNGC-M and CNGC-D) are shown in Figure 3.28(a); while Zn^^ release levels
associated with CNGC comprising 40wt% glass (CNGC-K; CNGC-H and CNHC-L) are shown
in Figure 3.28(b). With respect to 20wt% glass CNGCs, it was observed that CNGC-D
demonstrated Zn^^ release levels ranging from 51.54ppm (+/-0.584ppm) at 1 day to 47.77ppm
(+/-0.645ppm) at 28 days; the highest mean release of Zn^^of the 3 CNGCs in this series (after
an initial incubation period of 1 day). CNGC-B exhibited Zn release levels ranging from 48.21
ppm (+/-0.67ppm) at 1 day to 47.94ppm (+/-0.29ppm) at 28 days; while CNGC-M demonstrated
Zn^^ release levels ranging from 49.35ppm (+/-0.1.07ppm) at 1 day to 47.34ppm (+/-1.281 ppm)
at 28 days; the lowest mean release of Zn of the 3 CNGCs tested in this series (at the first
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incubation period at 1 day). In general, 20wt% glass CNGCs were observed to have no
significant difference in Zn release at each incubation period, with the exception of CNGC-D
(decreasing significantly from 1 day to 3 days and 1 day to 28 days incubation periods).

(a).

(b).

Figure 3.28: The Zn^^ ion release levels of 6 CNGCs with time dependency (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3,7 and 28 days incubation periods.

With 40wt% glass CNGCs, it was observed that CNGC-K demonstrated Zn^^ release levels
ranging from 44.82 ppm (+/-0.233ppm) at 1 day to 48.37ppm (+/-2.263ppm) at 28 days; the
highest mean release of Zn^^of the three CNGCs in this series (after a final incubation period of
28 days). CNGC-L exhibited Zn^^release levels ranging from 46.57ppm (+/-1.043ppm) at 1 day
to 47.89ppm (+/-0.369ppm) at 28 days; while CNGC-H demonstrated Zn^^ release levels ranging
from 47ppm (+/-0.177ppm) at 1 day to 45.83ppm (+/-0.868ppm) at 28 days; the lowest mean
release of Zn^^ of the three CNGCs in this series (after a final incubation period of 28 days).
Indeed, with respect to incubation time, the Zn^^ release levels of CNGC-K significantly increase
over each incubation periods before plateauing after 7 days incubation. In general, 40wt% glass
CNGCs were observed to have significant increases in Zn^^ release from 1 day to 7 days
incubation periods, and then subsequently plateau.
The Student’s t-test was used to examine the levels of Zn^^ release for 20vv4% and 40wt% glass
containing CNGCs at equivalent incubation periods (represented in Figures 3.29(a) and 3.29(b),
respectively). For 20wt% glass CNGCs, it was generally observed that there was no significant
difference in the level of Zn^^ release from each CNGC over all the incubation periods, (the
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exception of CNGC-D being significantly different (higher) to both CNGC-B and CNGC-M
after 1 day incubation).

Incubation Time (Days)

(a).

(b).

Figure 3.29: Student’s t-test results for the Zn^^ ion release of 6 CNGCs (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7 and 28 days incubation periods (* P<0.05, ** P<0.005, ***p<0.0005).

For 40wt% glass CNGCs, it was observed that CNGC-K released significantly less Zn^^than
either CNGC-H or CNGC-L after Iday incubation. However, after 7 days incubation, CNGC-K
subsequently released significantly higher levels of Zn^^than both CNGC-H and CNGC-L. In
addition, it was also observed that the Zn^^ release from CNGC-L is significantly higher than
CNGC-H after a 28 days incubation period.

3.7.5

and

Ion Release Profile Modeling

The release profiles for each element were modelled using nonlinear regression curve fitting
methodologies; for which Na^ and Zn^^ did not converge to form the desired nonlinear
exponential function. The associated half-life to acquire the highest Si'^^ release levels was
identified for each CNGC using Prism 5.0 software (GraphPad Inc.) as presented in Table 3.14
With respect to CNGC of the series comprising 20wt% glass it was observed that the associated
half-life for each CNGC follows the order of CNGC-B>CNGC-D>CNGC-M (Table 3.14(a)),
such that CNGC-B demonstrated the longest half-time of 4.821 days; CNGC-D exhibited a half
time of 2.689 days; while CNGC-M demonstrated the lowest half-time of 2.02 days. In addition,
the

values obtained were 0.9745, 0.9273, and 0.8352 for CNGC-B, CNGC-D, and CNGC-M,

respectively. With respect to CNGC of the series comprising 40wt% glass it was observed that
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the associated half-life of each CNGC follows the order of CNGC-H>CNGC-K>CNGC-L
(Table 3.14 (b)), such that CNGC-H demonstrated the longest half-time of 4.961 days; CNGC-B
exhibited a half-time of 3.021 days; while CNGC-M demonstrated the lowest half-time of 0.1731
days. In addition, the

values obtained were 0.9906, 0.5514, and 0.1456 for CNGC-H, CNGC-

K, and CNGC-L, respectively.

(b).

(a).

Figure 3.30: The Si'*^ ion release profiles of 6 CNGCs with time dependency (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7 and 28 days incubation periods.

Figure 3

: The Ca^^ ion release profiles of 6 CNGCs with time dependency (a) CNGCs with 20wt% bioglass, (b)
CNGCs with 40wt% bioglass over 1, 3, 7 and 28 days incubation periods.
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Table 3.14: The best fit parameters for non linear one phase association model formed from Si"*" release over 4 time
points (1,3, 7, 28 days)
(a). Nonlinear fit of Si

release from CNGCs content 20% glass

Conduits

t*^ (days)

tau (days)

ymax (ppm)

CNGC-B

4.821

6.956

5.117

0.9745

CNGC-M

2.02

2.915

2.168

0.8352

CNGC-D

2.689

3.879

2.785

0.9273

(b). Nonlinear fit of Si

release from CNGCs content 40% glass

Conduits

t"" (days)

CNGC-K

3.021

4.359~ '

CNGC-H

4.961

7.158

4.556

0.9906

CNGC-L

0.1731

0.2497

6.41

0.1456

tau (days)

ymax (ppm)
'

j

173-

-

0.5514 ’

The associated half-life to acquire the highest Ca^^ release levels was identified for each CNGC
using Prism 5.0 software (GraphPad Inc.) as presented in Table 3.15. With respect to CNGC of
the series comprising 20wt% glass it was observed that the associated half-life of Ca^^ release for
such CNGC follows the order of CNGC-M>CNGC-D>CNGC-B; the inverse order that observed
for Si"^^ release in the same group (Table 3.15 (a)). CNGC-M demonstrated the longest half-time
of 0.5076 days; CNGC-B exhibited a half time of 0.2683 days; while CNGC-D demonstrated the
lowest half-time of 0.1874 days. In addition, the

values obtained were 0.9599, 0.9058, and

0.7062 for CNGC-M, CNGC-D, and CNGC-B respectively. With respect to CNGC of the series
comprising 40wt% glass it was observed that the associated half-life of CNGC-H and CNGC-K
are 0.3332 and 0.1655 respectively (Table 3.15 (b)). The Ca^"^ release of CNGC-L however did
not converge to form a nonlinear exponential function. In addition, the

values obtained were

0.9906, 0.5514, and 0.1456 for CNGC-H, CNGC-K, and CNGC-L, respectively.
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Table 3.15: The best fit parameters for non linear one phase association model formed from Ca^^ release over 4 time
points (1, 3, 7, 28 days)
(a). Nonlinear fit of Ca

release from CNGCs content 20% glass

Conduits

(days)

tau (days)

ymax (ppm)

CNGC-B

0.1874 '

0.27^

3A99

0.7062

CNGC-M

0.5076

0.7323

2.066

0.9599

CNGC-D

0.2683

0.3871

3.089

0.9058

(b). Nonlinear fit of Ca

release from CNGCs content 40% glass

Conduits

t*^ (days)

tau (days)

ymax (ppm)

R*

CNGC-K

0.1655

0.2388

T2l“9

0.1547^

CNGC-H

0.3332

0.4807

2.772

0.9267

CNGC-L

NA

NA

NA

NA

3.7.6 Analysis of the Ion Release Profiles
A requisite component for the biological evaluation of medical devices is to quantify degradation
by-products under simulated physiological conditions. The importance of such analysis increases
significantly when the degradation by-products may establish certain interactions with the local
tissue to support effective regeneration. Consequently, and in the context of the devices
examined in this paper, the aim of this work was to evaluate the Si"^^, Na^, Ca^^, Zn^"^, and Ce'^^
release levels (and profiles where possible) for a group of experimental composites, which have
already demonstrated potential as NGCs.
Table 3.16 summarizes the maximum mean ion release concentration for 20wt% and 40wt%
glass containing CNGCs over all the incubation periods examined. In general it is observed that
maximum ion release levels for detectable elements are in the order (increasing) of Si"^^ <Ca^’^ <

Zn^^ <Na^
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Table 3.16: The maximum mean Si'*^, Na^, Ca^^, and Zn^^ release concentration expressed as Mean±SD, and group
by the glass content of (20wt% and 40wt%)

Element*

CNGCs (20 wt% glass)

CNGCs (40 wt% glass)

Maximum mean +SD (ppm)
CNGC-B

CNGC-M

CNGC-D

Maximum mean ±SD (ppm)
CNGCK

CNGC-H

CNGC-L

Na^

116.53±2.248 109.2±4.157 117.67±2.511 93.66±3.325 119.63±1.159 40.84±4.633

Zn^^

48.63±0.673

49.35±1.070

51.54+0.584

50.45+0.743

48.57+0.868

48.35+0.236

Ca 2+

3.28+0.023

2.31+0.059

3.15+0.035

3.24+0.010

2.93+0.023

3.23+0.029

Si 4+

5.11+0.070

2.44+0.142

2.92+0.137

1.14+0.779

4.48+0.096

6.477+0.047

The 81“^^ release data was suitable for investigation (given the increasing levels of release over
the time period examined) using a one-phase exponential model. It was observed that CNGC-B
had the longest half-life followed by CNGC-D; then CNGC-M in the 20wt% glass group (Table
3.14(a)). With respect to the 40v\4% glass group it is noted from the

data that the validity of

the model becomes compromised; Si"^^ degradation from CNGC-H had a half-life of 3.021 days
(R^ = 0.99, Table 3.14(b)), however the same model yields R^ values of 0.55 and 0.14 for
CNGC-K and CNGC-L respectively; a feature attributable to the enhanced dissolution rates
associated with each composite (Figures 3.22 and 3.30; Table 3.14(b)). Si02 is incorporated into
the compositions to act as the glass network former, and its potential therapeutic value in
peripheral nerve regeneration warrants investigation. The Si'^^ release levels observed for the
composites varied between 0.22ppm and 6.477ppm; whereby at such levels (from a systemic
perspective) Si"^^ release is unlikely to have adverse effects, since Si'^’^ is frequently absorbed
from the diet as orthosilicic acid at levels beyond this threshold. More interestingly the
therapeutic efficacy of Si'^^ release from the conduits is worthy of additional investigation in
respect of soft tissue regeneration. Reffitt et al. [390] have shown that collagen Type I synthesis
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may be increased by orthosilicic acid concentrations between 0.288-0,567 ppm (10 and 20 pM),
whilst Hench [281] recently demonstrated that Si'^^ release may upregulate gene expression for
enhanced tissue repair.
Where controlled release of constituent glass components under physiological condition is
preferred, additions of Na20 are beneficial. Na20 acts a flux during synthesis and adopts a
modifying role in the glass network [201] concurrent to facilitating dissolution [201, 391, 392].
In respect of Na^ release, it was observed that peak release is generally achieved within an initial
24h period, with the exception of CNGC-M. Consequently modeling a release profile is not
possible (the Na^ release at the 4 time points does not supply appropriate information to form
nonlinear exponential regression models. An interesting observation in the Na^ data is that
significant decreases in Na^ release were observed for CNGC-K from 1 day to 7 days and from 1
day to 28 days. While one may intuitively be drawn to conclude interactions between
degradation by-products of the polymer and the glass are a possible mechanism for the observed
reduction, it is necessary to point out that such trends are not observed for CNGC-K and CNGCL (which releases a relatively higher and lower concentration of Na^ respectively, when
compared with CNGC-K (see Figures 3.24 and 3.25). Based on the current data, this observation
is difficult to explain. It has been previously reported that Na20 content in silicate glasses has a
positive effect on cell viability by facilitating enhanced specific surface area [297]. The effect of
Na^ release from glass-ceramics has been published by Li et al. [393]; showing that increased
roughness resulting in degradation may be correlated with improved interfacial bonding and cell
adhesion. Na^ release from CNGCs in this study ranged from 40 to 119 ppm; comparative to
human plasma with Na^ levels of approximately 3200 ppm (142mM) [394]. It can be anticipated
from a systemic standpoint that the Na^ release levels observed are unlikely to lead to any
systemic complications, though localized interactions with living tissue warrant investigation
given the critical role of Na^ in respect of nerve function [395, 396].
The Ca^^ release rate was also investigated through the one-phase exponential model (Figure
3.31 and Table 3.15). CNGC-M had the longest half-life (about a half day), followed by CNGCD, then CNGC-B (for the 20wt% glass group). An interesting observation in respect of the Ca^"^
release profiles arise when compared against previous literature [297]; specifically the half-life
of Ca^^ release for the glass (in solution at pH 7.4) is 2.07 days versus a maximum half-life of 0.5
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days when the same glass is used as a filler in the composites devices. It is reasonable to
conclude that such behavior is due to a combination of features; acidic degradation by-products
from the polymer (which include lactic acid) may act locally to facilitate an acid-base reaction
with the glass (comparable to those reactions in dental restorative materials). Such reactions are
associated with rapid Ca^^ release (on the order of minutes) for glass polyalkenoate cements
[397]. In addition, given that the glass is homogenously distributed in the polymer structure the
effective surface area is maximized for reaction. In synergy, these factors are likely to contribute
to the reduced half-lives of ion release observed, not only for Ca^^ but also for the other elements
investigated. The maximum Ca^^ release is in the range 2.31 ppm to 3.28ppm (Figure 3.26 and
Table 3.16) for the CNGCs examined. Ca^^ regulates motility of the axonal growth cone and the
guidance of growth cone extension [233, 237, 398]. It has been reported that there are grades
affecting Ca^^ ion concentration on the growth cone behavior, with maximal activity occurring at
an optimal level within a permissive range, whereby many calcium-dependent processes also
display a similar dependence on optimal Ca^^ [366]. For example, intracellular Ca^^ levels may
regulate outgrowth by affecting the stability of the peripheral cytoskeleton; such that it has
previously been claimed that the extension of growth cones appear to be greatest at an optimal
Ca^^ level of about 0.008ppm [399]. In addition, pre-synaptic action potentials produce
approximately 0.4008ppm (lOpM) free Ca^^at the calyx of held synapse to give a fast speed of
2+
Ca^^ signaling [400]. Moreover, the mean resting Ca"^^
of olfactory ensheathing cell cultured

alone or with neurons is 1.202 ppm in an external calcium solution for a rat [401]. Tucker et al.
[402] have studied the spatial Ca^^ distribution in hair cells at a concentration of 3.407 ppm,
which could promote extrusion turtle hair cells in the micro-domain of synaptic release sites. The
appropriate Ca^^ concentration for the above application therefore ranges between 0.008ppm to
3.407ppm. Hence, it can be perceived that Ca^^ levels detected within these upper and lower
ranges will have similar beneficial effects. The Ca^^ release concentrations for CNGC reported
herein range from 2.3ppm to 3.32ppm in tissue culture water over al! the incubation periods
examined (Figure 3.26 and 3.27). Hence, Ca^"^ release concentrations from these CNGCs appear
to be in a range, which may be offer beneficial efficacy in respect of peripheral nerve
regeneration.
The Zn^^ release was observed to occur quickly, with levels peaking within an initial 24h period
(consequently, the Zn 2t release levels reported over the 4 incubation periods could not give
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sufficient information to form a nonlinear model). Correlating the Zn^^ release profiles of the
composites versus the glass particulates in isolated form (from previous literature [297, 403]; it is
noted that the half-life for Zn^^ from the glass is 1.4 days at pH=7.4. However, as one would
anticipate; Figure 3.28 and Table 3.16 indicate the half-life for Zn^^ release profiles from the
CNGCs is less than 1 day; a feature, as previously mentioned, likely attributable to localized acid
attack of the glass from early degradation by-products of the polymer. Zinc is present in all body
tissues and fluids. The concentration ofZn^^ in grey matter is about 9.75-13 ppm (0.15-0.2mM),
and 28 ppm in spinal cord. Moreover, human Zn^^ blood plasma levels have been shown to be
approximately 6.4 ppm [404]. Zn^^ levels previously reported to have clinically beneficial effects
on nerve growth were reported in the range of 0.065ppm to 3.27ppm in toad olfactory epithelia,
with higher levels appearing to inhibit neural firing rates; indicating the important nature of
quantification and control of degradation by-product release profiles and levels [404]. Similarly,
research has also demonstrated that Zn^^ may be required for neuroprotection following sublethal ischemia in both in vivo and in vitro models [405]. More recently research has suggested
that about I9.5ppm (300 pM) concentration of Zn^^ is released during neurotransmission, and the
optimal Zn^^ release for muscle cells is about 40 - 50uM (2.615 - 3.27ppm) [297]. In addition,
the antibacterial effects of Zn^^ have been evaluated by broth dilution methods [406], in which
bacterial growth was inhibited in the most concentrated Zn^^ oxide (0.719ppm and 1.046 ppm)
suspension. The Zn^^ concentration between 0.065ppm and 19.5ppm in neuronal cell may
involve some aspects of peripheral nerve regeneration (PNR) function. The Zn^^ release levels in
this study were observed between 45ppm and 51 ppm (Figure 3.18 and 3.19), which is well in the
range for those reported for neurotransmission and antibacterial efficacy. However, Zn^^ release
from the CNGC exceeded the reported optimal ranges, which may produce undesirable cytotoxic
effects [407, 408]. On the other hand, limited literature exists in respect of such ion release local
to regenerating peripheral nerves and requires further examination. In respect of Ce"^^, its
concentration in the tissue culture water was under the minimum detection limits of the ICP
standard solutions and instrument utilized for all the CNGCs; a feature attributable to its low
concentration and structural role in the glass [[409].
The present investigation is not orientated around examining the effects of composition on
property directly; rather its focus is on evaluating levels of dissolution by-products in order to
identify the optimum device compositions. With respect to ion release data from the CNGCs
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prepared in this study, the impact of increased PLGA content (in wt %) may be correlated to
higher ion release levels and a subsequent longer half-life. FI27, on the other hand, while not
previously reported, is considered to impart a significant effect on the degradation rates of such
composite devices, since its inclusion in similar compositions (without glass additions) for PNR
has been reported to control properties pertaining to hydrophilicity, permeability, porosity and
mechanical strength [296, 298, 410].
This Section explores the levels and profiles (where possible) of ionic degradation by-products
from novel composites designed for PNR. However, it is critically important to clarify that the
peripheral nervous system (PNS) is very sensitive to ionic imbalances and such imbalances may
lead to dysfunction (e.g. the functional disturbances of voltage gated calcium channels). On the
other hand, Ca^^ is directly involved in secretion of neurotransmitters and hormones, and plays
an essential role in the development of motor co-ordination and sensory processing [411]. In
particular, Ca^^ influx has a significant effect on the Na^ voltage gate, thus may affect the
voltage potential on the membrane, and hence the ionic concentration in the neuron is very
sensitive to pharmacological augmentation of an endogenous voltage and Ca^^ regulator. PNR is
a complex phenomenon involving interactions between neurons and Schwann cells (SC), where
SC proliferation and myelination processes have been critically linked to appropriate levels of
Zn^^ ions [301, 412]. There may be greater benefit of zinc supplementation for infections in
implantation sites specific to nerve (motor and sensory) recovery. This paper has shown that it is
possible to synthesize novel NGCs based on unique composites that are designed to release
potentially therapeutic elements (and / or regenerative cues) local to the implant site. Such an
approach is a fresh departure from contemporary materials approaches to a significant clinical
problem. Further studies with specific cell lines (e.g. Schwann cells), and polymeric degradation
profiling will comprise the next steps of analysis prior to considering pre-clinical evaluations (e.g.
intracutaneous reactivity) of these novel devices in PNR indications.

3.7.7 Limitations of the Study
As with any scientific study, intrinsic limitations exist which must be acknowledged such that
the impact of the discussed data is as relevant as possible. We would like to address the
limitations; which may arise as a function of our methodology:
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1. The composites evaluated in this work were selected on the basis of mechanical property
evaluation and cell culture data provided for in a previous publication {i.e. the optimum
compositions in the selected design space as per a design of experiments methodology;
based on cytotoxicity, tensile strength and modulus, where selected for this study) a
consequence of this approach meant that limited data on the influence of FI 27 and PLGA
on the degradation behavior of the materials exists.
2. Future work will be required to evaluate and profile the release rates inside a 24h period
to generate earlier profile and degradation data, which was not possible in the present
study.
The use of composite materials is a fresh approach to the challenge of PNR. In line with the
emerging philosophy of having degradation by-products establish key interactions with living
tissues for the purposes of regeneration, we have constructed a composite glass filler which
permits release of ionic components which may facilitate regeneration and protection in the
peripheral nervous system. These devices have previously demonstrated controlled mechanical
properties, and cytocompatibility and the present paper has now quantified and profiled (where
possible) the release of each of its inherent ionic components. Such data will now be leveraged to
select the optimum compositions for specific cell line testing prior to further biological
evaluation.
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4.1

Conclusions

The development of an artificial NGC as an alternative to nerve autografting is a focus of interest
for peripheral nerve repair. An extensive review on the current state of the art devices for
peripheral nerve repair has been carried out, and the criteria for design of optimum NGCs is
proposed. Specifically, such devices should offer: (i) biocompatibility, (ii) biodegradability, (iii)
semi-permeability, and (iv) have a supportive structure with sufficient mechanical properties. In
this study, novel NGC compositions comprising a degradable PLGA / Pluronic FI27 -and a
unique bioactive glass was synthesized and characterized. The conclusions resulting from the
investigation are summarised into sections as follows:
Glass characterisation: Based on this initial study between the experimental data and the
theoretical calculations, it can be assumed that ZnO largely plays a network modifying role in the
Si-Ca-Zn-Na-Ce glass network. Based on the correlation it has been shown that the structure of
the glasses is predominately

and may be controlled (structure and release) by modification of

composition with respect to controlling the Na20:Ce02.
The therapeutic ions from glass: Ca

and Zn

ion released from the designed glass (0.5Si-(x)

Na-0.2Ca-0.13Zn-(0.17-x) Ce) indicate heterogeneous dissolution of the glasses under
physiological pH=7.3, whereby the ion release profiles can be modified by altering the
Na20:Ce02 ratio in the glass composite. The examined Ca^^ and Zn^^ release of the ionic agents
from glass compositions may have potential as therapeutic nerve grafts, but at pH 3 high Zn^^
levels may produce cytotoxic effects.
The cytocompatibility of glass: Cell viability of the three glass compositions were examined in
vitro using the indirect MTT assay (L929 mouse fibroblasts). It was observed that the glasses
can be tailored to provoke no significant cytotoxicity in terms of cell viability. Specifically,
higher Na^ (mol %) enhances the cell viability in the design range. 14% of Na20 contents in the
glass offers the best cell viability (>90%) versus the positive control (tissue culture water). This
preliminary study demonstrates suitable cell viabilities in vitro.
Mechanical properties of PLGA/F127 conduits: The time dependent nature of Young’s
modulus with respect to time and environment for PLGA/F127 NGCs was evaluated. It was
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shown that FI 27 exerts influence on the modulus of PLGA/F127 NGCs; a 5% loading of FI 27 in
such NGCs will yield appropriate mechanical properties for such devices whilst ensuring rapid
adsorption of local fluids with concurrent permeation of nutrients at the implant site.
Design of Expert: The cytotoxicity and initial mechanical properties sixteen CNGCs comprising
PLGA (5, 12.5, 20 wt. %), the polaxomer: Pluronic FI27 (0, 2.5, 5 wt. %) and CNG glass (0, 20,
40 wt. %) were examined. The quadratic and interaction of PLGA and FI27 have strong effect
on the 3 day cell viability results, and become less effective on the 7 and 28 days cell viability,
while the inclusion of glass enhances the 7 and 28 days cell viability as well as the initial
ultimate tensile strength. The desirability / optimization methodology employed was used as a
basis to select preferred compositions (based on cytotoxicity and mechanical properties). The
preferred compositions were noted as being in the range 17.97wt%-19.90wt% PLGA, 0.161.13wt% FI27 and between 5.54 and <20wt% glass.
The Wet-State mechanical properties: The results for the UTS of the six CNGCs (PLGA, 12.5,
20wt %; glass, 0, 20wt %) were in the range of l-71Vlpa, over incubation periods of (1, 3, 7, and
28 days), while the Young’s moduli for each CNGC were in the range 5-204 Mpa. The results
illustrates that the experimental CNGCs offer comparable mechanical properties to commercial
product Neurolac over incubation periods of 1, 3, 7, and 28 days.
The cytocompatibility of CNGCs: The cell viability of the six CNGCs ranged between 90120%, which is also comparable to Neurolac and as such offer significant potential for peripheral
nerve repair.
The therapeutic ions from CNGCs: The Si"*^, Na^, Ca^^’ and Zn^"^ release of glass from six
CNGCs indicated that maximum ion release levels for detectable elements are in the order
(increasing) of Si"^^ <Ca^^ < Zn^^ <Na^, which were ranged between 0.22-6.48ppm, 2.233.24ppm, 48.35-51.54ppm, and 40.84-119.63ppm respectively. Ca^^ and Zn^"^ release
concentrations from these CNGCs appear to be in a range, which may offer beneficial efficacy in
respect of peripheral nerve regeneration.
This research work has shown that it is possible to synthesize novel NGCs based on unique
PLGA/F 127-glass composites. These materials release potentially therapeutic elements (and / or
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regenerative cues) local to the implant site. Such an approach is a fresh departure from
contemporary materials approaches to a significant clinical problem. The present study has also
quantified the mechanical properties and the cytocompatibility of the PLGA/F 127-glass
composition, and profiled (where possible) the release of each of its inherent ionic components.
The

materials examined

have demonstrated

substantial

equivalence or superiority to

conventional devices and have significant potential for further development as synthetic NGCs.

4.2

Future Work

The results documented in this research are significant, however, further evaluation of
biocompatibility and therapeutic efficacy is recommended as follows:
1. An in vitro study with specific cell lines (e.g. Schwann cells) direct contact and indirect
contact for nerve tissue engineering application, and polymeric degradation profiling
should comprise the next stage of analysis. With respect to the cell attachment, the SCs
should be incubated with the compositions for one and three days, and glutaraldehyde,
paraformaldehyde, and sucrose should be used as fixative, follow by sequential
dehydration in graded ethanol. The morphological characteristics of the attached cells
should be determined using SEM. For cell proliferation; 1*10^ cells/cm^ should be
seeded in a 24 well plates left to grow for 1, 3, 5, and 7 days in a humidified atmosphere
of 95% air and 5% CO2. Neurolac could be used as a positive control, and MTT tests
carried after each incubation periods to evaluate the cell viability. The microstructure of
the CNG could be monitored by the SEM after each incubation period concurrent with
preparing the extract for the indirect cell biocompatibility test according to ISO 10993-5.
2. Anti-bacterial assessment of experimental compositions using an indirect method (extract)
in order to assess their antibacterial efficacy in commonly found in vivo conditions would
also be advantageous. Extracts of each CNGC should be produced at concentrations of
3mm/ml, 5mm/ml and 8mm/ml in sterile ISB, and incubated for 1, 3, 7 and 28 days. The
optical density of extracts incubated with Methicillin-resistant Staphylococcus aureus

(MRSA),

Methicillin-sensitive

Staphylococcus

aureus

(MSSA),

Staphylococcus

epidermidis (S. epidermis), and Pseudomonas aeruginosa (P. aeruginosa) would be

191

Chapter 4: Conclusions and Future Work

suitable for such analysis.

Concurrently, the pH of each extract analysed should be

recorded, in order to possibly correlate with any observed antibacterial effects.
3. An in vivo animal trial involving implantation of experimental compositions into a 10 and
15mm sciatic nerve (male Wister rat), comparing to autograft and Neurolac (15 rats per
each group) with a 26 wks follow up would also be an important investigation. After
surgery, all the procedures should be carried out according to the National Guidelines for
Animal Welfare. Thses experiments should determine the in vivo response to the novel
devices contained herein. For Immunohistochemical evaluation and the Histological
evaluation, the rats (n=3) should be sacrificed at predetermined periods (e.g. 4 and 8
weeks post-implantation). Walking Track Analysis, the Electrostimulation Test, may also
yield beneficial results and could be carried out after 4, 8, 15, 21 and 26 wks of
implantation (n=3).
4. The further development of these materials towards preclinical evaluation performed by a
clinician would require characterisation of other physical properties such as porosity,
permeability, and suturing tension etc., as a function of glass composition and PLGA
formulation. The permeability of the CNGC could be measured by placing the CNGC
(with the cross head sealed with the adhesive plaster) in a well of a 48-well tissue culture
cluster. One hundred and twenty ml of ImM model solution containing proteins in PBS,
may be added into the central free space of the conduits. One point two ml PBS should be
added into a well containing one conduit. The diffusion rate of proteins across the conduit
walls can be analyzed using a protein assay kit at different time intervals. The tension
required for suturing and after surgery is also important since the elongation is altered
during surgical procedure. This can be achieved using an animal model; the in vivo visco
elastic properties of peripheral nerve in continuity could be examined in comparison with
the CNGC. The stress-relaxation curves can be plotted at a constant strain. Maximal
relaxation (creep) could be observed at the start of suturing and postsurgical (Ihrs).
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